{"idB": "906709_12_item7_p21_s0", "idA": "906709_11_item7_p0_s2", "sentA": "Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this section as well as factors described in Part I, Item 1A Risk Factors.", "sentB": "We utilize our employee and infrastructure resources across multiple development projects as well as our research programs directed towards identifying drug candidates based on our technology platform.", "type": 1, "words": ["<tag1>", "Factors", "that", "could", "cause", "or", "contribute", "to", "such", "differences", "include,", "but", "are", "not", "limited", "to,", "those", "discussed", "in", "this", "section", "as", "well", "as", "factors", "described", "in", "Part", "I,", "Item", "1A", "Risk", "Factors.", "<tag2>", "We", "utilize", "our", "employee", "and", "infrastructure", "resources", "across", "multiple", "development", "projects", "as", "well", "as", "our", "research", "programs", "directed", "towards", "identifying", "drug", "candidates", "based", "on", "our", "technology", "platform.", "<tag3>"], "wordsA": ["Factors", "that", "could", "cause", "or", "contribute", "to", "such", "differences", "include,", "but", "are", "not", "limited", "to,", "those", "discussed", "in", "this", "section", "as", "well", "as", "factors", "described", "in", "Part", "I,", "Item", "1A", "Risk", "Factors."], "wordsB": ["We", "utilize", "our", "employee", "and", "infrastructure", "resources", "across", "multiple", "development", "projects", "as", "well", "as", "our", "research", "programs", "directed", "towards", "identifying", "drug", "candidates", "based", "on", "our", "technology", "platform."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p39_s2", "idA": "906709_11_item7_p0_s2", "sentA": "Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this section as well as factors described in Part I, Item 1A Risk Factors.", "sentB": "This is further discussed in Note 6 of Item 8.", "type": 1, "words": ["<tag1>", "Factors", "that", "could", "cause", "or", "contribute", "to", "such", "differences", "include,", "but", "are", "not", "limited", "to,", "those", "discussed", "in", "this", "section", "as", "well", "as", "factors", "described", "in", "Part", "I,", "Item", "1A", "Risk", "Factors.", "<tag2>", "This", "is", "further", "discussed", "in", "Note", "6", "of", "Item", "8.", "<tag3>"], "wordsA": ["Factors", "that", "could", "cause", "or", "contribute", "to", "such", "differences", "include,", "but", "are", "not", "limited", "to,", "those", "discussed", "in", "this", "section", "as", "well", "as", "factors", "described", "in", "Part", "I,", "Item", "1A", "Risk", "Factors."], "wordsB": ["This", "is", "further", "discussed", "in", "Note", "6", "of", "Item", "8."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p11_s2", "idA": "906709_11_item7_p10_s0", "sentA": "Historically, we have entered into a number of license and supply contracts under which we manufactured and supplied our proprietary PEGylation reagents on a cost-plus or fixed price basis.", "sentB": "Upfront fees received for license and collaborative agreements are recognized ratably over our expected performance period under the arrangement.", "type": 1, "words": ["<tag1>", "Historically,", "we", "have", "entered", "into", "a", "number", "of", "license", "and", "supply", "contracts", "under", "which", "we", "manufactured", "and", "supplied", "our", "proprietary", "PEGylation", "reagents", "on", "a", "cost-plus", "or", "fixed", "price", "basis.", "<tag2>", "Upfront", "fees", "received", "for", "license", "and", "collaborative", "agreements", "are", "recognized", "ratably", "over", "our", "expected", "performance", "period", "under", "the", "arrangement.", "<tag3>"], "wordsA": ["Historically,", "we", "have", "entered", "into", "a", "number", "of", "license", "and", "supply", "contracts", "under", "which", "we", "manufactured", "and", "supplied", "our", "proprietary", "PEGylation", "reagents", "on", "a", "cost-plus", "or", "fixed", "price", "basis."], "wordsB": ["Upfront", "fees", "received", "for", "license", "and", "collaborative", "agreements", "are", "recognized", "ratably", "over", "our", "expected", "performance", "period", "under", "the", "arrangement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p37_s0", "idA": "906709_11_item7_p10_s2", "sentA": "As a result, whenever possible, we are renegotiating or not seeking renewal of legacy manufacturing supply arrangements that do not include a strategic development or commercialization component.", "sentB": "(1) The above table does not include certain commitments and contingencies which are discussed in Note 7 of Item 8.", "type": 1, "words": ["<tag1>", "As", "a", "result,", "whenever", "possible,", "we", "are", "renegotiating", "or", "not", "seeking", "renewal", "of", "legacy", "manufacturing", "supply", "arrangements", "that", "do", "not", "include", "a", "strategic", "development", "or", "commercialization", "component.", "<tag2>", "(1)", "The", "above", "table", "does", "not", "include", "certain", "commitments", "and", "contingencies", "which", "are", "discussed", "in", "Note", "7", "of", "Item", "8.", "<tag3>"], "wordsA": ["As", "a", "result,", "whenever", "possible,", "we", "are", "renegotiating", "or", "not", "seeking", "renewal", "of", "legacy", "manufacturing", "supply", "arrangements", "that", "do", "not", "include", "a", "strategic", "development", "or", "commercialization", "component."], "wordsB": ["(1)", "The", "above", "table", "does", "not", "include", "certain", "commitments", "and", "contingencies", "which", "are", "discussed", "in", "Note", "7", "of", "Item", "8."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p29_s0", "idA": "906709_11_item7_p10_s4", "sentA": "In addition, in December 2010 we entered into an amended manufacturing and supply agreement with Merck (through its subsidiary Schering) to provide for transfer to an alternative manufacturer and revised economics for an interim supply arrangement until that transition is completed.", "sentB": "General and administrative expenses are associated with administrative staffing, business development, finance, marketing, and legal.", "type": 1, "words": ["<tag1>", "In", "addition,", "in", "December", "2010", "we", "entered", "into", "an", "amended", "manufacturing", "and", "supply", "agreement", "with", "Merck", "(through", "its", "subsidiary", "Schering)", "to", "provide", "for", "transfer", "to", "an", "alternative", "manufacturer", "and", "revised", "economics", "for", "an", "interim", "supply", "arrangement", "until", "that", "transition", "is", "completed.", "<tag2>", "General", "and", "administrative", "expenses", "are", "associated", "with", "administrative", "staffing,", "business", "development,", "finance,", "marketing,", "and", "legal.", "<tag3>"], "wordsA": ["In", "addition,", "in", "December", "2010", "we", "entered", "into", "an", "amended", "manufacturing", "and", "supply", "agreement", "with", "Merck", "(through", "its", "subsidiary", "Schering)", "to", "provide", "for", "transfer", "to", "an", "alternative", "manufacturer", "and", "revised", "economics", "for", "an", "interim", "supply", "arrangement", "until", "that", "transition", "is", "completed."], "wordsB": ["General", "and", "administrative", "expenses", "are", "associated", "with", "administrative", "staffing,", "business", "development,", "finance,", "marketing,", "and", "legal."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p32_s8", "idA": "906709_11_item7_p10_s4", "sentA": "In addition, in December 2010 we entered into an amended manufacturing and supply agreement with Merck (through its subsidiary Schering) to provide for transfer to an alternative manufacturer and revised economics for an interim supply arrangement until that transition is completed.", "sentB": "These letters of credit will expire during 2012 and are secured by investments of similar amounts.", "type": 1, "words": ["<tag1>", "In", "addition,", "in", "December", "2010", "we", "entered", "into", "an", "amended", "manufacturing", "and", "supply", "agreement", "with", "Merck", "(through", "its", "subsidiary", "Schering)", "to", "provide", "for", "transfer", "to", "an", "alternative", "manufacturer", "and", "revised", "economics", "for", "an", "interim", "supply", "arrangement", "until", "that", "transition", "is", "completed.", "<tag2>", "These", "letters", "of", "credit", "will", "expire", "during", "2012", "and", "are", "secured", "by", "investments", "of", "similar", "amounts.", "<tag3>"], "wordsA": ["In", "addition,", "in", "December", "2010", "we", "entered", "into", "an", "amended", "manufacturing", "and", "supply", "agreement", "with", "Merck", "(through", "its", "subsidiary", "Schering)", "to", "provide", "for", "transfer", "to", "an", "alternative", "manufacturer", "and", "revised", "economics", "for", "an", "interim", "supply", "arrangement", "until", "that", "transition", "is", "completed."], "wordsB": ["These", "letters", "of", "credit", "will", "expire", "during", "2012", "and", "are", "secured", "by", "investments", "of", "similar", "amounts."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p40_s0", "idA": "906709_11_item7_p11_s0", "sentA": "At December 31, 2010, we had approximately $315.9 million in cash, cash equivalents, and short-term investments and $240.4 million in indebtedness.", "sentB": "(3) In November 2010, we moved into our Mission Bay Facility, which includes our corporate headquarters and an R D center.", "type": 1, "words": ["<tag1>", "At", "December", "31,", "2010,", "we", "had", "approximately", "$315.9", "million", "in", "cash,", "cash", "equivalents,", "and", "short-term", "investments", "and", "$240.4", "million", "in", "indebtedness.", "<tag2>", "(3)", "In", "November", "2010,", "we", "moved", "into", "our", "Mission", "Bay", "Facility,", "which", "includes", "our", "corporate", "headquarters", "and", "an", "R", "D", "center.", "<tag3>"], "wordsA": ["At", "December", "31,", "2010,", "we", "had", "approximately", "$315.9", "million", "in", "cash,", "cash", "equivalents,", "and", "short-term", "investments", "and", "$240.4", "million", "in", "indebtedness."], "wordsB": ["(3)", "In", "November", "2010,", "we", "moved", "into", "our", "Mission", "Bay", "Facility,", "which", "includes", "our", "corporate", "headquarters", "and", "an", "R", "D", "center."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p13_s7", "idA": "906709_11_item7_p11_s1", "sentA": "On January 24, 2011, we completed a public offering of our common stock with proceeds of approximately $220.4 million.", "sentB": "As noted above, in February 2012, we sold all of our rights to receive future royalty payments on CIMZIA and MIRCERA .", "type": 1, "words": ["<tag1>", "On", "January", "24,", "2011,", "we", "completed", "a", "public", "offering", "of", "our", "common", "stock", "with", "proceeds", "of", "approximately", "$220.4", "million.", "<tag2>", "As", "noted", "above,", "in", "February", "2012,", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "on", "CIMZIA", "and", "MIRCERA", ".", "<tag3>"], "wordsA": ["On", "January", "24,", "2011,", "we", "completed", "a", "public", "offering", "of", "our", "common", "stock", "with", "proceeds", "of", "approximately", "$220.4", "million."], "wordsB": ["As", "noted", "above,", "in", "February", "2012,", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "on", "CIMZIA", "and", "MIRCERA", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p32_s0", "idA": "906709_11_item7_p11_s1", "sentA": "On January 24, 2011, we completed a public offering of our common stock with proceeds of approximately $220.4 million.", "sentB": "As noted above, in February 2012, we sold all of our rights to receive future royalty payments on CIMZIA and MIRCERA .", "type": 1, "words": ["<tag1>", "On", "January", "24,", "2011,", "we", "completed", "a", "public", "offering", "of", "our", "common", "stock", "with", "proceeds", "of", "approximately", "$220.4", "million.", "<tag2>", "As", "noted", "above,", "in", "February", "2012,", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "on", "CIMZIA", "and", "MIRCERA", ".", "<tag3>"], "wordsA": ["On", "January", "24,", "2011,", "we", "completed", "a", "public", "offering", "of", "our", "common", "stock", "with", "proceeds", "of", "approximately", "$220.4", "million."], "wordsB": ["As", "noted", "above,", "in", "February", "2012,", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "on", "CIMZIA", "and", "MIRCERA", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p40_s2", "idA": "906709_11_item7_p11_s1", "sentA": "On January 24, 2011, we completed a public offering of our common stock with proceeds of approximately $220.4 million.", "sentB": "On December 28 2011, we amended the sublease of the Mission Bay Facility to include an additional 24,002 square feet of space.", "type": 1, "words": ["<tag1>", "On", "January", "24,", "2011,", "we", "completed", "a", "public", "offering", "of", "our", "common", "stock", "with", "proceeds", "of", "approximately", "$220.4", "million.", "<tag2>", "On", "December", "28", "2011,", "we", "amended", "the", "sublease", "of", "the", "Mission", "Bay", "Facility", "to", "include", "an", "additional", "24,002", "square", "feet", "of", "space.", "<tag3>"], "wordsA": ["On", "January", "24,", "2011,", "we", "completed", "a", "public", "offering", "of", "our", "common", "stock", "with", "proceeds", "of", "approximately", "$220.4", "million."], "wordsB": ["On", "December", "28", "2011,", "we", "amended", "the", "sublease", "of", "the", "Mission", "Bay", "Facility", "to", "include", "an", "additional", "24,002", "square", "feet", "of", "space."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p12_s0", "idA": "906709_11_item7_p11_s2", "sentA": "Additionally, as part of the public offering, we incurred approximately $0.6 million in legal and accounting fees, filing fees, and other offering expenses.", "sentB": "Management makes its best estimate of the period over which we expect to fulfill our performance obligations.", "type": 1, "words": ["<tag1>", "Additionally,", "as", "part", "of", "the", "public", "offering,", "we", "incurred", "approximately", "$0.6", "million", "in", "legal", "and", "accounting", "fees,", "filing", "fees,", "and", "other", "offering", "expenses.", "<tag2>", "Management", "makes", "its", "best", "estimate", "of", "the", "period", "over", "which", "we", "expect", "to", "fulfill", "our", "performance", "obligations.", "<tag3>"], "wordsA": ["Additionally,", "as", "part", "of", "the", "public", "offering,", "we", "incurred", "approximately", "$0.6", "million", "in", "legal", "and", "accounting", "fees,", "filing", "fees,", "and", "other", "offering", "expenses."], "wordsB": ["Management", "makes", "its", "best", "estimate", "of", "the", "period", "over", "which", "we", "expect", "to", "fulfill", "our", "performance", "obligations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p34_s4", "idA": "906709_11_item7_p11_s2", "sentA": "Additionally, as part of the public offering, we incurred approximately $0.6 million in legal and accounting fees, filing fees, and other offering expenses.", "sentB": "We will evaluate financing alternatives, if any, in light of the then-existing market conditions.", "type": 1, "words": ["<tag1>", "Additionally,", "as", "part", "of", "the", "public", "offering,", "we", "incurred", "approximately", "$0.6", "million", "in", "legal", "and", "accounting", "fees,", "filing", "fees,", "and", "other", "offering", "expenses.", "<tag2>", "We", "will", "evaluate", "financing", "alternatives,", "if", "any,", "in", "light", "of", "the", "then-existing", "market", "conditions.", "<tag3>"], "wordsA": ["Additionally,", "as", "part", "of", "the", "public", "offering,", "we", "incurred", "approximately", "$0.6", "million", "in", "legal", "and", "accounting", "fees,", "filing", "fees,", "and", "other", "offering", "expenses."], "wordsB": ["We", "will", "evaluate", "financing", "alternatives,", "if", "any,", "in", "light", "of", "the", "then-existing", "market", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p10_s6", "idA": "906709_11_item7_p11_s4", "sentA": "We do not have sufficient resources to fund our research and development plans and repay these convertible notes.", "sentB": "If we are not successful in raising additional funds through financing activities in 2012, we may be required to reduce our research and development spending in one or more programs, as well as general and administrative expenses, in order to conserve working capital until additional funding becomes available either from our existing collaborations, new collaboration partnerships or additional fundraising activities.", "type": 1, "words": ["<tag1>", "We", "do", "not", "have", "sufficient", "resources", "to", "fund", "our", "research", "and", "development", "plans", "and", "repay", "these", "convertible", "notes.", "<tag2>", "If", "we", "are", "not", "successful", "in", "raising", "additional", "funds", "through", "financing", "activities", "in", "2012,", "we", "may", "be", "required", "to", "reduce", "our", "research", "and", "development", "spending", "in", "one", "or", "more", "programs,", "as", "well", "as", "general", "and", "administrative", "expenses,", "in", "order", "to", "conserve", "working", "capital", "until", "additional", "funding", "becomes", "available", "either", "from", "our", "existing", "collaborations,", "new", "collaboration", "partnerships", "or", "additional", "fundraising", "activities.", "<tag3>"], "wordsA": ["We", "do", "not", "have", "sufficient", "resources", "to", "fund", "our", "research", "and", "development", "plans", "and", "repay", "these", "convertible", "notes."], "wordsB": ["If", "we", "are", "not", "successful", "in", "raising", "additional", "funds", "through", "financing", "activities", "in", "2012,", "we", "may", "be", "required", "to", "reduce", "our", "research", "and", "development", "spending", "in", "one", "or", "more", "programs,", "as", "well", "as", "general", "and", "administrative", "expenses,", "in", "order", "to", "conserve", "working", "capital", "until", "additional", "funding", "becomes", "available", "either", "from", "our", "existing", "collaborations,", "new", "collaboration", "partnerships", "or", "additional", "fundraising", "activities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p28_s1", "idA": "906709_11_item7_p11_s4", "sentA": "We do not have sufficient resources to fund our research and development plans and repay these convertible notes.", "sentB": "Other than for the BEACON study, due to the uncertainties discussed above, we are unable to determine with any degree of certainty the duration and completion costs of our research and development projects, anticipated completion dates or when and to what extent we will receive cash inflows from a collaboration arrangement or the commercialization of a drug candidate.", "type": 1, "words": ["<tag1>", "We", "do", "not", "have", "sufficient", "resources", "to", "fund", "our", "research", "and", "development", "plans", "and", "repay", "these", "convertible", "notes.", "<tag2>", "Other", "than", "for", "the", "BEACON", "study,", "due", "to", "the", "uncertainties", "discussed", "above,", "we", "are", "unable", "to", "determine", "with", "any", "degree", "of", "certainty", "the", "duration", "and", "completion", "costs", "of", "our", "research", "and", "development", "projects,", "anticipated", "completion", "dates", "or", "when", "and", "to", "what", "extent", "we", "will", "receive", "cash", "inflows", "from", "a", "collaboration", "arrangement", "or", "the", "commercialization", "of", "a", "drug", "candidate.", "<tag3>"], "wordsA": ["We", "do", "not", "have", "sufficient", "resources", "to", "fund", "our", "research", "and", "development", "plans", "and", "repay", "these", "convertible", "notes."], "wordsB": ["Other", "than", "for", "the", "BEACON", "study,", "due", "to", "the", "uncertainties", "discussed", "above,", "we", "are", "unable", "to", "determine", "with", "any", "degree", "of", "certainty", "the", "duration", "and", "completion", "costs", "of", "our", "research", "and", "development", "projects,", "anticipated", "completion", "dates", "or", "when", "and", "to", "what", "extent", "we", "will", "receive", "cash", "inflows", "from", "a", "collaboration", "arrangement", "or", "the", "commercialization", "of", "a", "drug", "candidate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p34_s8", "idA": "906709_11_item7_p11_s4", "sentA": "We do not have sufficient resources to fund our research and development plans and repay these convertible notes.", "sentB": "If we are not successful in raising additional funds through financing activities in 2012, we may be required to reduce our research and development spending in one or more programs, as well as general and administrative expenses, in order to conserve working capital until additional funding becomes available either from our existing collaborations or additional fundraising activities.", "type": 1, "words": ["<tag1>", "We", "do", "not", "have", "sufficient", "resources", "to", "fund", "our", "research", "and", "development", "plans", "and", "repay", "these", "convertible", "notes.", "<tag2>", "If", "we", "are", "not", "successful", "in", "raising", "additional", "funds", "through", "financing", "activities", "in", "2012,", "we", "may", "be", "required", "to", "reduce", "our", "research", "and", "development", "spending", "in", "one", "or", "more", "programs,", "as", "well", "as", "general", "and", "administrative", "expenses,", "in", "order", "to", "conserve", "working", "capital", "until", "additional", "funding", "becomes", "available", "either", "from", "our", "existing", "collaborations", "or", "additional", "fundraising", "activities.", "<tag3>"], "wordsA": ["We", "do", "not", "have", "sufficient", "resources", "to", "fund", "our", "research", "and", "development", "plans", "and", "repay", "these", "convertible", "notes."], "wordsB": ["If", "we", "are", "not", "successful", "in", "raising", "additional", "funds", "through", "financing", "activities", "in", "2012,", "we", "may", "be", "required", "to", "reduce", "our", "research", "and", "development", "spending", "in", "one", "or", "more", "programs,", "as", "well", "as", "general", "and", "administrative", "expenses,", "in", "order", "to", "conserve", "working", "capital", "until", "additional", "funding", "becomes", "available", "either", "from", "our", "existing", "collaborations", "or", "additional", "fundraising", "activities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p32_s2", "idA": "906709_11_item7_p13_s1", "sentA": "While in the past we have received a number of significant payments from license and collaboration agreements and other significant transactions, we do not currently anticipate receiving substantial payments for new transactions in the near future.", "sentB": "While we do not anticipate making any cash payments representing interest, we will impute interest on the transaction and record interest expense at the effective interest rate of approximately 17%.", "type": 1, "words": ["<tag1>", "While", "in", "the", "past", "we", "have", "received", "a", "number", "of", "significant", "payments", "from", "license", "and", "collaboration", "agreements", "and", "other", "significant", "transactions,", "we", "do", "not", "currently", "anticipate", "receiving", "substantial", "payments", "for", "new", "transactions", "in", "the", "near", "future.", "<tag2>", "While", "we", "do", "not", "anticipate", "making", "any", "cash", "payments", "representing", "interest,", "we", "will", "impute", "interest", "on", "the", "transaction", "and", "record", "interest", "expense", "at", "the", "effective", "interest", "rate", "of", "approximately", "17%.", "<tag3>"], "wordsA": ["While", "in", "the", "past", "we", "have", "received", "a", "number", "of", "significant", "payments", "from", "license", "and", "collaboration", "agreements", "and", "other", "significant", "transactions,", "we", "do", "not", "currently", "anticipate", "receiving", "substantial", "payments", "for", "new", "transactions", "in", "the", "near", "future."], "wordsB": ["While", "we", "do", "not", "anticipate", "making", "any", "cash", "payments", "representing", "interest,", "we", "will", "impute", "interest", "on", "the", "transaction", "and", "record", "interest", "expense", "at", "the", "effective", "interest", "rate", "of", "approximately", "17%."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p34_s14", "idA": "906709_11_item7_p13_s5", "sentA": "Even if we or our partners are successful, we may require additional capital to continue to fund our operations and repay our debt obligations as they become due.", "sentB": "However, if the need arose to liquidate such securities before maturity, we may experience losses on liquidation.", "type": 1, "words": ["<tag1>", "Even", "if", "we", "or", "our", "partners", "are", "successful,", "we", "may", "require", "additional", "capital", "to", "continue", "to", "fund", "our", "operations", "and", "repay", "our", "debt", "obligations", "as", "they", "become", "due.", "<tag2>", "However,", "if", "the", "need", "arose", "to", "liquidate", "such", "securities", "before", "maturity,", "we", "may", "experience", "losses", "on", "liquidation.", "<tag3>"], "wordsA": ["Even", "if", "we", "or", "our", "partners", "are", "successful,", "we", "may", "require", "additional", "capital", "to", "continue", "to", "fund", "our", "operations", "and", "repay", "our", "debt", "obligations", "as", "they", "become", "due."], "wordsB": ["However,", "if", "the", "need", "arose", "to", "liquidate", "such", "securities", "before", "maturity,", "we", "may", "experience", "losses", "on", "liquidation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p19_s2", "idA": "906709_11_item7_p15_s0", "sentA": "Total revenue decreased for the year ended December 31, 2009 compared to the year ended December 31, 2008 primarily as a result of the sale of certain of our pulmonary assets to Novartis completed on December 31, 2008 (Novartis Pulmonary Asset Sale) and lower product manufacturing volumes required by our collaboration partners.", "sentB": "As a result of the fixed cost base associated with our manufacturing activities, we expect product gross margin to fluctuate in future periods depending on the level of manufacturing orders from our customers.", "type": 1, "words": ["<tag1>", "Total", "revenue", "decreased", "for", "the", "year", "ended", "December", "31,", "2009", "compared", "to", "the", "year", "ended", "December", "31,", "2008", "primarily", "as", "a", "result", "of", "the", "sale", "of", "certain", "of", "our", "pulmonary", "assets", "to", "Novartis", "completed", "on", "December", "31,", "2008", "(Novartis", "Pulmonary", "Asset", "Sale)", "and", "lower", "product", "manufacturing", "volumes", "required", "by", "our", "collaboration", "partners.", "<tag2>", "As", "a", "result", "of", "the", "fixed", "cost", "base", "associated", "with", "our", "manufacturing", "activities,", "we", "expect", "product", "gross", "margin", "to", "fluctuate", "in", "future", "periods", "depending", "on", "the", "level", "of", "manufacturing", "orders", "from", "our", "customers.", "<tag3>"], "wordsA": ["Total", "revenue", "decreased", "for", "the", "year", "ended", "December", "31,", "2009", "compared", "to", "the", "year", "ended", "December", "31,", "2008", "primarily", "as", "a", "result", "of", "the", "sale", "of", "certain", "of", "our", "pulmonary", "assets", "to", "Novartis", "completed", "on", "December", "31,", "2008", "(Novartis", "Pulmonary", "Asset", "Sale)", "and", "lower", "product", "manufacturing", "volumes", "required", "by", "our", "collaboration", "partners."], "wordsB": ["As", "a", "result", "of", "the", "fixed", "cost", "base", "associated", "with", "our", "manufacturing", "activities,", "we", "expect", "product", "gross", "margin", "to", "fluctuate", "in", "future", "periods", "depending", "on", "the", "level", "of", "manufacturing", "orders", "from", "our", "customers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p30_s1", "idA": "906709_11_item7_p15_s0", "sentA": "Total revenue decreased for the year ended December 31, 2009 compared to the year ended December 31, 2008 primarily as a result of the sale of certain of our pulmonary assets to Novartis completed on December 31, 2008 (Novartis Pulmonary Asset Sale) and lower product manufacturing volumes required by our collaboration partners.", "sentB": "We determined that the carrying value of the San Carlos facility exceeded its fair value based on a discounted cash flow model and an impairment charge of $12.6 million was recognized as a result.", "type": 1, "words": ["<tag1>", "Total", "revenue", "decreased", "for", "the", "year", "ended", "December", "31,", "2009", "compared", "to", "the", "year", "ended", "December", "31,", "2008", "primarily", "as", "a", "result", "of", "the", "sale", "of", "certain", "of", "our", "pulmonary", "assets", "to", "Novartis", "completed", "on", "December", "31,", "2008", "(Novartis", "Pulmonary", "Asset", "Sale)", "and", "lower", "product", "manufacturing", "volumes", "required", "by", "our", "collaboration", "partners.", "<tag2>", "We", "determined", "that", "the", "carrying", "value", "of", "the", "San", "Carlos", "facility", "exceeded", "its", "fair", "value", "based", "on", "a", "discounted", "cash", "flow", "model", "and", "an", "impairment", "charge", "of", "$12.6", "million", "was", "recognized", "as", "a", "result.", "<tag3>"], "wordsA": ["Total", "revenue", "decreased", "for", "the", "year", "ended", "December", "31,", "2009", "compared", "to", "the", "year", "ended", "December", "31,", "2008", "primarily", "as", "a", "result", "of", "the", "sale", "of", "certain", "of", "our", "pulmonary", "assets", "to", "Novartis", "completed", "on", "December", "31,", "2008", "(Novartis", "Pulmonary", "Asset", "Sale)", "and", "lower", "product", "manufacturing", "volumes", "required", "by", "our", "collaboration", "partners."], "wordsB": ["We", "determined", "that", "the", "carrying", "value", "of", "the", "San", "Carlos", "facility", "exceeded", "its", "fair", "value", "based", "on", "a", "discounted", "cash", "flow", "model", "and", "an", "impairment", "charge", "of", "$12.6", "million", "was", "recognized", "as", "a", "result."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p39_s0", "idA": "906709_11_item7_p15_s0", "sentA": "Total revenue decreased for the year ended December 31, 2009 compared to the year ended December 31, 2008 primarily as a result of the sale of certain of our pulmonary assets to Novartis completed on December 31, 2008 (Novartis Pulmonary Asset Sale) and lower product manufacturing volumes required by our collaboration partners.", "sentB": "result of the relocation of all of our California functions, including our corporate headquarters and an R D center, to our Mission Bay Facility.", "type": 1, "words": ["<tag1>", "Total", "revenue", "decreased", "for", "the", "year", "ended", "December", "31,", "2009", "compared", "to", "the", "year", "ended", "December", "31,", "2008", "primarily", "as", "a", "result", "of", "the", "sale", "of", "certain", "of", "our", "pulmonary", "assets", "to", "Novartis", "completed", "on", "December", "31,", "2008", "(Novartis", "Pulmonary", "Asset", "Sale)", "and", "lower", "product", "manufacturing", "volumes", "required", "by", "our", "collaboration", "partners.", "<tag2>", "result", "of", "the", "relocation", "of", "all", "of", "our", "California", "functions,", "including", "our", "corporate", "headquarters", "and", "an", "R", "D", "center,", "to", "our", "Mission", "Bay", "Facility.", "<tag3>"], "wordsA": ["Total", "revenue", "decreased", "for", "the", "year", "ended", "December", "31,", "2009", "compared", "to", "the", "year", "ended", "December", "31,", "2008", "primarily", "as", "a", "result", "of", "the", "sale", "of", "certain", "of", "our", "pulmonary", "assets", "to", "Novartis", "completed", "on", "December", "31,", "2008", "(Novartis", "Pulmonary", "Asset", "Sale)", "and", "lower", "product", "manufacturing", "volumes", "required", "by", "our", "collaboration", "partners."], "wordsB": ["result", "of", "the", "relocation", "of", "all", "of", "our", "California", "functions,", "including", "our", "corporate", "headquarters", "and", "an", "R", "D", "center,", "to", "our", "Mission", "Bay", "Facility."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p23_s0", "idA": "906709_11_item7_p15_s1", "sentA": "In connection with the Novartis Pulmonary Asset Sale, our collaboration agreement with Novartis for TIP was terminated and our collaboration agreement with Bayer Schering Pharma AG for Cipro Inhale was assigned to Novartis.", "sentB": "(3) Partnered with Bayer Healthcare LLC in August 2007.", "type": 1, "words": ["<tag1>", "In", "connection", "with", "the", "Novartis", "Pulmonary", "Asset", "Sale,", "our", "collaboration", "agreement", "with", "Novartis", "for", "TIP", "was", "terminated", "and", "our", "collaboration", "agreement", "with", "Bayer", "Schering", "Pharma", "AG", "for", "Cipro", "Inhale", "was", "assigned", "to", "Novartis.", "<tag2>", "(3)", "Partnered", "with", "Bayer", "Healthcare", "LLC", "in", "August", "2007.", "<tag3>"], "wordsA": ["In", "connection", "with", "the", "Novartis", "Pulmonary", "Asset", "Sale,", "our", "collaboration", "agreement", "with", "Novartis", "for", "TIP", "was", "terminated", "and", "our", "collaboration", "agreement", "with", "Bayer", "Schering", "Pharma", "AG", "for", "Cipro", "Inhale", "was", "assigned", "to", "Novartis."], "wordsB": ["(3)", "Partnered", "with", "Bayer", "Healthcare", "LLC", "in", "August", "2007."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p20_s4", "idA": "906709_11_item7_p17_s0", "sentA": "The decrease in product sales and royalties for the year ended December 31, 2010 compared to the year ended December 31, 2009 is attributable to decreased product sales of $2.7 million partially offset by increased royalty revenue of $2.1 million.", "sentB": "The increase also includes a $3.8 million increase in non-cash stock-based compensation expense due to our higher stock price and increased headcount, a $3.1 million increase to facilities and equipment costs primarily due to the completion of our India research facility and to the move to our Mission Bay Facility, and a $2.7 million increase in supplies, including clinical trial materials.", "type": 1, "words": ["<tag1>", "The", "decrease", "in", "product", "sales", "and", "royalties", "for", "the", "year", "ended", "December", "31,", "2010", "compared", "to", "the", "year", "ended", "December", "31,", "2009", "is", "attributable", "to", "decreased", "product", "sales", "of", "$2.7", "million", "partially", "offset", "by", "increased", "royalty", "revenue", "of", "$2.1", "million.", "<tag2>", "The", "increase", "also", "includes", "a", "$3.8", "million", "increase", "in", "non-cash", "stock-based", "compensation", "expense", "due", "to", "our", "higher", "stock", "price", "and", "increased", "headcount,", "a", "$3.1", "million", "increase", "to", "facilities", "and", "equipment", "costs", "primarily", "due", "to", "the", "completion", "of", "our", "India", "research", "facility", "and", "to", "the", "move", "to", "our", "Mission", "Bay", "Facility,", "and", "a", "$2.7", "million", "increase", "in", "supplies,", "including", "clinical", "trial", "materials.", "<tag3>"], "wordsA": ["The", "decrease", "in", "product", "sales", "and", "royalties", "for", "the", "year", "ended", "December", "31,", "2010", "compared", "to", "the", "year", "ended", "December", "31,", "2009", "is", "attributable", "to", "decreased", "product", "sales", "of", "$2.7", "million", "partially", "offset", "by", "increased", "royalty", "revenue", "of", "$2.1", "million."], "wordsB": ["The", "increase", "also", "includes", "a", "$3.8", "million", "increase", "in", "non-cash", "stock-based", "compensation", "expense", "due", "to", "our", "higher", "stock", "price", "and", "increased", "headcount,", "a", "$3.1", "million", "increase", "to", "facilities", "and", "equipment", "costs", "primarily", "due", "to", "the", "completion", "of", "our", "India", "research", "facility", "and", "to", "the", "move", "to", "our", "Mission", "Bay", "Facility,", "and", "a", "$2.7", "million", "increase", "in", "supplies,", "including", "clinical", "trial", "materials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p3_s0", "idA": "906709_11_item7_p17_s1", "sentA": "The timing of shipments is based on the demand and requirements of our collaboration partners and is not ratable throughout the year.", "sentB": "Following the commercial launch of NKTR-118, we are entitled to significant and escalating double-digit royalties varying by country of sale and based on the level of annual net sales.", "type": 1, "words": ["<tag1>", "The", "timing", "of", "shipments", "is", "based", "on", "the", "demand", "and", "requirements", "of", "our", "collaboration", "partners", "and", "is", "not", "ratable", "throughout", "the", "year.", "<tag2>", "Following", "the", "commercial", "launch", "of", "NKTR-118,", "we", "are", "entitled", "to", "significant", "and", "escalating", "double-digit", "royalties", "varying", "by", "country", "of", "sale", "and", "based", "on", "the", "level", "of", "annual", "net", "sales.", "<tag3>"], "wordsA": ["The", "timing", "of", "shipments", "is", "based", "on", "the", "demand", "and", "requirements", "of", "our", "collaboration", "partners", "and", "is", "not", "ratable", "throughout", "the", "year."], "wordsB": ["Following", "the", "commercial", "launch", "of", "NKTR-118,", "we", "are", "entitled", "to", "significant", "and", "escalating", "double-digit", "royalties", "varying", "by", "country", "of", "sale", "and", "based", "on", "the", "level", "of", "annual", "net", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p38_s0", "idA": "906709_11_item7_p19_s0", "sentA": "Lower product demand from our collaboration partners resulted in decreased product sales of approximately $7.5 million for the year ended December 31, 2009 compared to the year ended December 31, 2008.", "sentB": "(2) These amounts primarily result from capital lease obligations arising from our office space lease at 201 Industrial Road in San Carlos, California.", "type": 1, "words": ["<tag1>", "Lower", "product", "demand", "from", "our", "collaboration", "partners", "resulted", "in", "decreased", "product", "sales", "of", "approximately", "$7.5", "million", "for", "the", "year", "ended", "December", "31,", "2009", "compared", "to", "the", "year", "ended", "December", "31,", "2008.", "<tag2>", "(2)", "These", "amounts", "primarily", "result", "from", "capital", "lease", "obligations", "arising", "from", "our", "office", "space", "lease", "at", "201", "Industrial", "Road", "in", "San", "Carlos,", "California.", "<tag3>"], "wordsA": ["Lower", "product", "demand", "from", "our", "collaboration", "partners", "resulted", "in", "decreased", "product", "sales", "of", "approximately", "$7.5", "million", "for", "the", "year", "ended", "December", "31,", "2009", "compared", "to", "the", "year", "ended", "December", "31,", "2008."], "wordsB": ["(2)", "These", "amounts", "primarily", "result", "from", "capital", "lease", "obligations", "arising", "from", "our", "office", "space", "lease", "at", "201", "Industrial", "Road", "in", "San", "Carlos,", "California."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p26_s1", "idA": "906709_11_item7_p1_s0", "sentA": "We are a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize our PEGylation and advanced polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients.", "sentB": "We then conduct clinical studies for our drug candidates that take several years to complete.", "type": 1, "words": ["<tag1>", "We", "are", "a", "clinical-stage", "biopharmaceutical", "company", "developing", "a", "pipeline", "of", "drug", "candidates", "that", "utilize", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms,", "which", "are", "designed", "to", "improve", "the", "benefits", "of", "drugs", "for", "patients.", "<tag2>", "We", "then", "conduct", "clinical", "studies", "for", "our", "drug", "candidates", "that", "take", "several", "years", "to", "complete.", "<tag3>"], "wordsA": ["We", "are", "a", "clinical-stage", "biopharmaceutical", "company", "developing", "a", "pipeline", "of", "drug", "candidates", "that", "utilize", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms,", "which", "are", "designed", "to", "improve", "the", "benefits", "of", "drugs", "for", "patients."], "wordsB": ["We", "then", "conduct", "clinical", "studies", "for", "our", "drug", "candidates", "that", "take", "several", "years", "to", "complete."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p1_s4", "idA": "906709_11_item7_p1_s1", "sentA": "Our current proprietary product pipeline is comprised of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology.", "sentB": "Our most advanced proprietary product candidate, NKTR-118, is a peripheral opioid antagonist that is currently being evaluated for the treatment of opioid-induced constipation.", "type": 1, "words": ["<tag1>", "Our", "current", "proprietary", "product", "pipeline", "is", "comprised", "of", "drug", "candidates", "across", "a", "number", "of", "therapeutic", "areas,", "including", "oncology,", "pain,", "anti-infectives,", "anti-viral", "and", "immunology.", "<tag2>", "Our", "most", "advanced", "proprietary", "product", "candidate,", "NKTR-118,", "is", "a", "peripheral", "opioid", "antagonist", "that", "is", "currently", "being", "evaluated", "for", "the", "treatment", "of", "opioid-induced", "constipation.", "<tag3>"], "wordsA": ["Our", "current", "proprietary", "product", "pipeline", "is", "comprised", "of", "drug", "candidates", "across", "a", "number", "of", "therapeutic", "areas,", "including", "oncology,", "pain,", "anti-infectives,", "anti-viral", "and", "immunology."], "wordsB": ["Our", "most", "advanced", "proprietary", "product", "candidate,", "NKTR-118,", "is", "a", "peripheral", "opioid", "antagonist", "that", "is", "currently", "being", "evaluated", "for", "the", "treatment", "of", "opioid-induced", "constipation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p20_s1", "idA": "906709_11_item7_p1_s2", "sentA": "Our research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates.", "sentB": "Research and development expense also includes certain overhead allocations consisting of various support and facilities related costs.", "type": 1, "words": ["<tag1>", "Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "potential", "biologic", "drug", "candidates.", "<tag2>", "Research", "and", "development", "expense", "also", "includes", "certain", "overhead", "allocations", "consisting", "of", "various", "support", "and", "facilities", "related", "costs.", "<tag3>"], "wordsA": ["Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "potential", "biologic", "drug", "candidates."], "wordsB": ["Research", "and", "development", "expense", "also", "includes", "certain", "overhead", "allocations", "consisting", "of", "various", "support", "and", "facilities", "related", "costs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p21_s1", "idA": "906709_11_item7_p1_s2", "sentA": "Our research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates.", "sentB": "The following table shows expenses incurred for preclinical study support, contract manufacturing for clinical supplies, clinical and regulatory services provided by third parties and direct materials costs for each of our drug candidates.", "type": 1, "words": ["<tag1>", "Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "potential", "biologic", "drug", "candidates.", "<tag2>", "The", "following", "table", "shows", "expenses", "incurred", "for", "preclinical", "study", "support,", "contract", "manufacturing", "for", "clinical", "supplies,", "clinical", "and", "regulatory", "services", "provided", "by", "third", "parties", "and", "direct", "materials", "costs", "for", "each", "of", "our", "drug", "candidates.", "<tag3>"], "wordsA": ["Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "potential", "biologic", "drug", "candidates."], "wordsB": ["The", "following", "table", "shows", "expenses", "incurred", "for", "preclinical", "study", "support,", "contract", "manufacturing", "for", "clinical", "supplies,", "clinical", "and", "regulatory", "services", "provided", "by", "third", "parties", "and", "direct", "materials", "costs", "for", "each", "of", "our", "drug", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p21_s2", "idA": "906709_11_item7_p1_s2", "sentA": "Our research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates.", "sentB": "The table also presents other costs and overhead consisting of personnel, facilities and other indirect costs (in thousands):", "type": 1, "words": ["<tag1>", "Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "potential", "biologic", "drug", "candidates.", "<tag2>", "The", "table", "also", "presents", "other", "costs", "and", "overhead", "consisting", "of", "personnel,", "facilities", "and", "other", "indirect", "costs", "(in", "thousands):", "<tag3>"], "wordsA": ["Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "potential", "biologic", "drug", "candidates."], "wordsB": ["The", "table", "also", "presents", "other", "costs", "and", "overhead", "consisting", "of", "personnel,", "facilities", "and", "other", "indirect", "costs", "(in", "thousands):"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p40_s3", "idA": "906709_11_item7_p21_s1", "sentA": "Under the AstraZeneca license agreement and related technology transfer agreement, we recognized $101.4 million and $23.6 million of the $125.0 million upfront payment and $6.5 million and $1.5 million of contract research and other revenue for the years ended December 31, 2010 and 2009, respectively.", "sentB": "Under the terms of the amendment, beginning January 1, 2012, we will begin making lease payments for this additional space of $40,000 per month until May 31, 2013.", "type": 1, "words": ["<tag1>", "Under", "the", "AstraZeneca", "license", "agreement", "and", "related", "technology", "transfer", "agreement,", "we", "recognized", "$101.4", "million", "and", "$23.6", "million", "of", "the", "$125.0", "million", "upfront", "payment", "and", "$6.5", "million", "and", "$1.5", "million", "of", "contract", "research", "and", "other", "revenue", "for", "the", "years", "ended", "December", "31,", "2010", "and", "2009,", "respectively.", "<tag2>", "Under", "the", "terms", "of", "the", "amendment,", "beginning", "January", "1,", "2012,", "we", "will", "begin", "making", "lease", "payments", "for", "this", "additional", "space", "of", "$40,000", "per", "month", "until", "May", "31,", "2013.", "<tag3>"], "wordsA": ["Under", "the", "AstraZeneca", "license", "agreement", "and", "related", "technology", "transfer", "agreement,", "we", "recognized", "$101.4", "million", "and", "$23.6", "million", "of", "the", "$125.0", "million", "upfront", "payment", "and", "$6.5", "million", "and", "$1.5", "million", "of", "contract", "research", "and", "other", "revenue", "for", "the", "years", "ended", "December", "31,", "2010", "and", "2009,", "respectively."], "wordsB": ["Under", "the", "terms", "of", "the", "amendment,", "beginning", "January", "1,", "2012,", "we", "will", "begin", "making", "lease", "payments", "for", "this", "additional", "space", "of", "$40,000", "per", "month", "until", "May", "31,", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p24_s0", "idA": "906709_11_item7_p22_s2", "sentA": "This decrease is partially off-set by $25.1 million in revenue recognized related to our agreement with AstraZeneca for NKTR-118 and NKTR-119.", "sentB": "(4) Partnered with AstraZeneca in 2009.", "type": 1, "words": ["<tag1>", "This", "decrease", "is", "partially", "off-set", "by", "$25.1", "million", "in", "revenue", "recognized", "related", "to", "our", "agreement", "with", "AstraZeneca", "for", "NKTR-118", "and", "NKTR-119.", "<tag2>", "(4)", "Partnered", "with", "AstraZeneca", "in", "2009.", "<tag3>"], "wordsA": ["This", "decrease", "is", "partially", "off-set", "by", "$25.1", "million", "in", "revenue", "recognized", "related", "to", "our", "agreement", "with", "AstraZeneca", "for", "NKTR-118", "and", "NKTR-119."], "wordsB": ["(4)", "Partnered", "with", "AstraZeneca", "in", "2009."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p24_s1", "idA": "906709_11_item7_p22_s2", "sentA": "This decrease is partially off-set by $25.1 million in revenue recognized related to our agreement with AstraZeneca for NKTR-118 and NKTR-119.", "sentB": "In general, all development costs incurred by us after partnering with AstraZeneca are reimbursed by AstraZeneca.", "type": 1, "words": ["<tag1>", "This", "decrease", "is", "partially", "off-set", "by", "$25.1", "million", "in", "revenue", "recognized", "related", "to", "our", "agreement", "with", "AstraZeneca", "for", "NKTR-118", "and", "NKTR-119.", "<tag2>", "In", "general,", "all", "development", "costs", "incurred", "by", "us", "after", "partnering", "with", "AstraZeneca", "are", "reimbursed", "by", "AstraZeneca.", "<tag3>"], "wordsA": ["This", "decrease", "is", "partially", "off-set", "by", "$25.1", "million", "in", "revenue", "recognized", "related", "to", "our", "agreement", "with", "AstraZeneca", "for", "NKTR-118", "and", "NKTR-119."], "wordsB": ["In", "general,", "all", "development", "costs", "incurred", "by", "us", "after", "partnering", "with", "AstraZeneca", "are", "reimbursed", "by", "AstraZeneca."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p24_s9", "idA": "906709_11_item7_p23_s0", "sentA": "We expect license, collaboration and other revenue to substantially decrease in 2011 due to the complete recognition as of December 31, 2010 of the upfront payment we received under the AstraZeneca license agreement.", "sentB": "Although we are still in the early stages of the BEACON study, we estimate that the total third party and direct material costs over the life of the BEACON study will range from approximately $110.0 million to $120.0 million, of which $14.0 million was paid as of December 31, 2011, and that it will be completed around the end of 2014.", "type": 1, "words": ["<tag1>", "We", "expect", "license,", "collaboration", "and", "other", "revenue", "to", "substantially", "decrease", "in", "2011", "due", "to", "the", "complete", "recognition", "as", "of", "December", "31,", "2010", "of", "the", "upfront", "payment", "we", "received", "under", "the", "AstraZeneca", "license", "agreement.", "<tag2>", "Although", "we", "are", "still", "in", "the", "early", "stages", "of", "the", "BEACON", "study,", "we", "estimate", "that", "the", "total", "third", "party", "and", "direct", "material", "costs", "over", "the", "life", "of", "the", "BEACON", "study", "will", "range", "from", "approximately", "$110.0", "million", "to", "$120.0", "million,", "of", "which", "$14.0", "million", "was", "paid", "as", "of", "December", "31,", "2011,", "and", "that", "it", "will", "be", "completed", "around", "the", "end", "of", "2014.", "<tag3>"], "wordsA": ["We", "expect", "license,", "collaboration", "and", "other", "revenue", "to", "substantially", "decrease", "in", "2011", "due", "to", "the", "complete", "recognition", "as", "of", "December", "31,", "2010", "of", "the", "upfront", "payment", "we", "received", "under", "the", "AstraZeneca", "license", "agreement."], "wordsB": ["Although", "we", "are", "still", "in", "the", "early", "stages", "of", "the", "BEACON", "study,", "we", "estimate", "that", "the", "total", "third", "party", "and", "direct", "material", "costs", "over", "the", "life", "of", "the", "BEACON", "study", "will", "range", "from", "approximately", "$110.0", "million", "to", "$120.0", "million,", "of", "which", "$14.0", "million", "was", "paid", "as", "of", "December", "31,", "2011,", "and", "that", "it", "will", "be", "completed", "around", "the", "end", "of", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p29_s2", "idA": "906709_11_item7_p23_s0", "sentA": "We expect license, collaboration and other revenue to substantially decrease in 2011 due to the complete recognition as of December 31, 2010 of the upfront payment we received under the AstraZeneca license agreement.", "sentB": "In addition, general and administrative expense increased due to personnel-related costs, support and facilities-related costs, and other administrative costs.", "type": 1, "words": ["<tag1>", "We", "expect", "license,", "collaboration", "and", "other", "revenue", "to", "substantially", "decrease", "in", "2011", "due", "to", "the", "complete", "recognition", "as", "of", "December", "31,", "2010", "of", "the", "upfront", "payment", "we", "received", "under", "the", "AstraZeneca", "license", "agreement.", "<tag2>", "In", "addition,", "general", "and", "administrative", "expense", "increased", "due", "to", "personnel-related", "costs,", "support", "and", "facilities-related", "costs,", "and", "other", "administrative", "costs.", "<tag3>"], "wordsA": ["We", "expect", "license,", "collaboration", "and", "other", "revenue", "to", "substantially", "decrease", "in", "2011", "due", "to", "the", "complete", "recognition", "as", "of", "December", "31,", "2010", "of", "the", "upfront", "payment", "we", "received", "under", "the", "AstraZeneca", "license", "agreement."], "wordsB": ["In", "addition,", "general", "and", "administrative", "expense", "increased", "due", "to", "personnel-related", "costs,", "support", "and", "facilities-related", "costs,", "and", "other", "administrative", "costs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p5_s0", "idA": "906709_11_item7_p4_s2", "sentA": "In 2010, we expanded the Phase 2 clinical trial by 50 patients in platinum resistant/refractory ovarian cancer patients and on March 1, 2011, we announced that we intended to further expand this study by up to 60 additional patients.", "sentB": "clinical study was completed in mid-2010 and we further expanded this study to enroll up to 110 additional women with platinum-resistant ovarian cancer who had progressed after prior treatment with Doxil (doxorubicin HCl liposome injection).", "type": 1, "words": ["<tag1>", "In", "2010,", "we", "expanded", "the", "Phase", "2", "clinical", "trial", "by", "50", "patients", "in", "platinum", "resistant/refractory", "ovarian", "cancer", "patients", "and", "on", "March", "1,", "2011,", "we", "announced", "that", "we", "intended", "to", "further", "expand", "this", "study", "by", "up", "to", "60", "additional", "patients.", "<tag2>", "clinical", "study", "was", "completed", "in", "mid-2010", "and", "we", "further", "expanded", "this", "study", "to", "enroll", "up", "to", "110", "additional", "women", "with", "platinum-resistant", "ovarian", "cancer", "who", "had", "progressed", "after", "prior", "treatment", "with", "Doxil", "(doxorubicin", "HCl", "liposome", "injection).", "<tag3>"], "wordsA": ["In", "2010,", "we", "expanded", "the", "Phase", "2", "clinical", "trial", "by", "50", "patients", "in", "platinum", "resistant/refractory", "ovarian", "cancer", "patients", "and", "on", "March", "1,", "2011,", "we", "announced", "that", "we", "intended", "to", "further", "expand", "this", "study", "by", "up", "to", "60", "additional", "patients."], "wordsB": ["clinical", "study", "was", "completed", "in", "mid-2010", "and", "we", "further", "expanded", "this", "study", "to", "enroll", "up", "to", "110", "additional", "women", "with", "platinum-resistant", "ovarian", "cancer", "who", "had", "progressed", "after", "prior", "treatment", "with", "Doxil", "(doxorubicin", "HCl", "liposome", "injection)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p20_s0", "idA": "906709_11_item7_p4_s4", "sentA": "The Phase 2 clinical study in metastatic colorectal cancer patients is still enrolling.", "sentB": "Research and development expense consists primarily of personnel costs, including salaries, benefits, and stock-based compensation, clinical study costs, direct costs of outside research, materials, supplies, licenses and fees.", "type": 1, "words": ["<tag1>", "The", "Phase", "2", "clinical", "study", "in", "metastatic", "colorectal", "cancer", "patients", "is", "still", "enrolling.", "<tag2>", "Research", "and", "development", "expense", "consists", "primarily", "of", "personnel", "costs,", "including", "salaries,", "benefits,", "and", "stock-based", "compensation,", "clinical", "study", "costs,", "direct", "costs", "of", "outside", "research,", "materials,", "supplies,", "licenses", "and", "fees.", "<tag3>"], "wordsA": ["The", "Phase", "2", "clinical", "study", "in", "metastatic", "colorectal", "cancer", "patients", "is", "still", "enrolling."], "wordsB": ["Research", "and", "development", "expense", "consists", "primarily", "of", "personnel", "costs,", "including", "salaries,", "benefits,", "and", "stock-based", "compensation,", "clinical", "study", "costs,", "direct", "costs", "of", "outside", "research,", "materials,", "supplies,", "licenses", "and", "fees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p34_s12", "idA": "906709_11_item7_p4_s5", "sentA": "Enrollment in the colorectal cancer study has been challenging due to the fact that the comparator arm of this study, single-agent irinotecan, is not the standard of care for second line metastatic colorectal therapy in the United States or Europe.", "sentB": "Due to the potential for continued uncertainty in the credit markets in 2012, we may experience reduced liquidity with respect to some of our investments in marketable securities.", "type": 1, "words": ["<tag1>", "Enrollment", "in", "the", "colorectal", "cancer", "study", "has", "been", "challenging", "due", "to", "the", "fact", "that", "the", "comparator", "arm", "of", "this", "study,", "single-agent", "irinotecan,", "is", "not", "the", "standard", "of", "care", "for", "second", "line", "metastatic", "colorectal", "therapy", "in", "the", "United", "States", "or", "Europe.", "<tag2>", "Due", "to", "the", "potential", "for", "continued", "uncertainty", "in", "the", "credit", "markets", "in", "2012,", "we", "may", "experience", "reduced", "liquidity", "with", "respect", "to", "some", "of", "our", "investments", "in", "marketable", "securities.", "<tag3>"], "wordsA": ["Enrollment", "in", "the", "colorectal", "cancer", "study", "has", "been", "challenging", "due", "to", "the", "fact", "that", "the", "comparator", "arm", "of", "this", "study,", "single-agent", "irinotecan,", "is", "not", "the", "standard", "of", "care", "for", "second", "line", "metastatic", "colorectal", "therapy", "in", "the", "United", "States", "or", "Europe."], "wordsB": ["Due", "to", "the", "potential", "for", "continued", "uncertainty", "in", "the", "credit", "markets", "in", "2012,", "we", "may", "experience", "reduced", "liquidity", "with", "respect", "to", "some", "of", "our", "investments", "in", "marketable", "securities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p2_s2", "idA": "906709_11_item7_p5_s0", "sentA": "In December 2010, we announced that we were planning to take NKTR-102 into Phase 3 clinical development prior to seeking a collaboration partner.", "sentB": "This Phase 3 clinical program is designed to investigate the safety and efficacy of NKTR-118 as a medicine to relieve opioid-induced constipation, a common side effect of prescription opioids when used for chronic pain management.", "type": 1, "words": ["<tag1>", "In", "December", "2010,", "we", "announced", "that", "we", "were", "planning", "to", "take", "NKTR-102", "into", "Phase", "3", "clinical", "development", "prior", "to", "seeking", "a", "collaboration", "partner.", "<tag2>", "This", "Phase", "3", "clinical", "program", "is", "designed", "to", "investigate", "the", "safety", "and", "efficacy", "of", "NKTR-118", "as", "a", "medicine", "to", "relieve", "opioid-induced", "constipation,", "a", "common", "side", "effect", "of", "prescription", "opioids", "when", "used", "for", "chronic", "pain", "management.", "<tag3>"], "wordsA": ["In", "December", "2010,", "we", "announced", "that", "we", "were", "planning", "to", "take", "NKTR-102", "into", "Phase", "3", "clinical", "development", "prior", "to", "seeking", "a", "collaboration", "partner."], "wordsB": ["This", "Phase", "3", "clinical", "program", "is", "designed", "to", "investigate", "the", "safety", "and", "efficacy", "of", "NKTR-118", "as", "a", "medicine", "to", "relieve", "opioid-induced", "constipation,", "a", "common", "side", "effect", "of", "prescription", "opioids", "when", "used", "for", "chronic", "pain", "management."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p5_s7", "idA": "906709_11_item7_p5_s0", "sentA": "In December 2010, we announced that we were planning to take NKTR-102 into Phase 3 clinical development prior to seeking a collaboration partner.", "sentB": "The program is significantly behind schedule due to our plan with Bayer to finalize the design of the nebulizer device for commercial manufacturing prior to initiating Phase 3 clinical development, with the objective of commencing Phase 3 clinical trials as soon as possible following completion of this work.", "type": 1, "words": ["<tag1>", "In", "December", "2010,", "we", "announced", "that", "we", "were", "planning", "to", "take", "NKTR-102", "into", "Phase", "3", "clinical", "development", "prior", "to", "seeking", "a", "collaboration", "partner.", "<tag2>", "The", "program", "is", "significantly", "behind", "schedule", "due", "to", "our", "plan", "with", "Bayer", "to", "finalize", "the", "design", "of", "the", "nebulizer", "device", "for", "commercial", "manufacturing", "prior", "to", "initiating", "Phase", "3", "clinical", "development,", "with", "the", "objective", "of", "commencing", "Phase", "3", "clinical", "trials", "as", "soon", "as", "possible", "following", "completion", "of", "this", "work.", "<tag3>"], "wordsA": ["In", "December", "2010,", "we", "announced", "that", "we", "were", "planning", "to", "take", "NKTR-102", "into", "Phase", "3", "clinical", "development", "prior", "to", "seeking", "a", "collaboration", "partner."], "wordsB": ["The", "program", "is", "significantly", "behind", "schedule", "due", "to", "our", "plan", "with", "Bayer", "to", "finalize", "the", "design", "of", "the", "nebulizer", "device", "for", "commercial", "manufacturing", "prior", "to", "initiating", "Phase", "3", "clinical", "development,", "with", "the", "objective", "of", "commencing", "Phase", "3", "clinical", "trials", "as", "soon", "as", "possible", "following", "completion", "of", "this", "work."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p5_s3", "idA": "906709_11_item7_p5_s1", "sentA": "We are currently planning a comparative Phase 3 clinical study for NKTR-102 in metastatic breast cancer and plan to start this study in late 2011.", "sentB": "We are currently in the process of compiling and performing verification procedures on certain top-line results (i.e. objective tumor response rate) from the patients enrolled to date.", "type": 1, "words": ["<tag1>", "We", "are", "currently", "planning", "a", "comparative", "Phase", "3", "clinical", "study", "for", "NKTR-102", "in", "metastatic", "breast", "cancer", "and", "plan", "to", "start", "this", "study", "in", "late", "2011.", "<tag2>", "We", "are", "currently", "in", "the", "process", "of", "compiling", "and", "performing", "verification", "procedures", "on", "certain", "top-line", "results", "(i.e.", "objective", "tumor", "response", "rate)", "from", "the", "patients", "enrolled", "to", "date.", "<tag3>"], "wordsA": ["We", "are", "currently", "planning", "a", "comparative", "Phase", "3", "clinical", "study", "for", "NKTR-102", "in", "metastatic", "breast", "cancer", "and", "plan", "to", "start", "this", "study", "in", "late", "2011."], "wordsB": ["We", "are", "currently", "in", "the", "process", "of", "compiling", "and", "performing", "verification", "procedures", "on", "certain", "top-line", "results", "(i.e.", "objective", "tumor", "response", "rate)", "from", "the", "patients", "enrolled", "to", "date."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p27_s0", "idA": "906709_11_item7_p5_s3", "sentA": "The size, scope and timing of our investment in a comparative Phase 3 clinical study in platinum resistant/refractory ovarian cancer will depend upon a number of important variables including our evaluation of the expanded Phase 2 study results, discussions with health authorities and key opinion leaders, evolving regulatory standards and requirements, and the estimated cost of these studies.", "sentB": "the costs and timing of, and the ability to secure, approvals from government health authorities.", "type": 1, "words": ["<tag1>", "The", "size,", "scope", "and", "timing", "of", "our", "investment", "in", "a", "comparative", "Phase", "3", "clinical", "study", "in", "platinum", "resistant/refractory", "ovarian", "cancer", "will", "depend", "upon", "a", "number", "of", "important", "variables", "including", "our", "evaluation", "of", "the", "expanded", "Phase", "2", "study", "results,", "discussions", "with", "health", "authorities", "and", "key", "opinion", "leaders,", "evolving", "regulatory", "standards", "and", "requirements,", "and", "the", "estimated", "cost", "of", "these", "studies.", "<tag2>", "the", "costs", "and", "timing", "of,", "and", "the", "ability", "to", "secure,", "approvals", "from", "government", "health", "authorities.", "<tag3>"], "wordsA": ["The", "size,", "scope", "and", "timing", "of", "our", "investment", "in", "a", "comparative", "Phase", "3", "clinical", "study", "in", "platinum", "resistant/refractory", "ovarian", "cancer", "will", "depend", "upon", "a", "number", "of", "important", "variables", "including", "our", "evaluation", "of", "the", "expanded", "Phase", "2", "study", "results,", "discussions", "with", "health", "authorities", "and", "key", "opinion", "leaders,", "evolving", "regulatory", "standards", "and", "requirements,", "and", "the", "estimated", "cost", "of", "these", "studies."], "wordsB": ["the", "costs", "and", "timing", "of,", "and", "the", "ability", "to", "secure,", "approvals", "from", "government", "health", "authorities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p34_s13", "idA": "906709_11_item7_p5_s4", "sentA": "We anticipate our Phase 3 development plans for NKTR-102 to require substantial investment over the next several years.", "sentB": "These investments are generally held to maturity, which is less than two years.", "type": 1, "words": ["<tag1>", "We", "anticipate", "our", "Phase", "3", "development", "plans", "for", "NKTR-102", "to", "require", "substantial", "investment", "over", "the", "next", "several", "years.", "<tag2>", "These", "investments", "are", "generally", "held", "to", "maturity,", "which", "is", "less", "than", "two", "years.", "<tag3>"], "wordsA": ["We", "anticipate", "our", "Phase", "3", "development", "plans", "for", "NKTR-102", "to", "require", "substantial", "investment", "over", "the", "next", "several", "years."], "wordsB": ["These", "investments", "are", "generally", "held", "to", "maturity,", "which", "is", "less", "than", "two", "years."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p13_s8", "idA": "906709_11_item7_p6_s0", "sentA": "Our focus on research and clinical development requires substantial investments that continue to increase as we advance each drug candidate through each phase of the development cycle.", "sentB": "However, although any future CIMZIA and MIRCERA royalties will go directly to the purchaser of these royalty interests, as this transaction will be recorded as a liability that amortizes over the life of the estimated royalty payment period, we will continue to recognize the royalties as revenue, which we expect to increase in 2012.", "type": 1, "words": ["<tag1>", "Our", "focus", "on", "research", "and", "clinical", "development", "requires", "substantial", "investments", "that", "continue", "to", "increase", "as", "we", "advance", "each", "drug", "candidate", "through", "each", "phase", "of", "the", "development", "cycle.", "<tag2>", "However,", "although", "any", "future", "CIMZIA", "and", "MIRCERA", "royalties", "will", "go", "directly", "to", "the", "purchaser", "of", "these", "royalty", "interests,", "as", "this", "transaction", "will", "be", "recorded", "as", "a", "liability", "that", "amortizes", "over", "the", "life", "of", "the", "estimated", "royalty", "payment", "period,", "we", "will", "continue", "to", "recognize", "the", "royalties", "as", "revenue,", "which", "we", "expect", "to", "increase", "in", "2012.", "<tag3>"], "wordsA": ["Our", "focus", "on", "research", "and", "clinical", "development", "requires", "substantial", "investments", "that", "continue", "to", "increase", "as", "we", "advance", "each", "drug", "candidate", "through", "each", "phase", "of", "the", "development", "cycle."], "wordsB": ["However,", "although", "any", "future", "CIMZIA", "and", "MIRCERA", "royalties", "will", "go", "directly", "to", "the", "purchaser", "of", "these", "royalty", "interests,", "as", "this", "transaction", "will", "be", "recorded", "as", "a", "liability", "that", "amortizes", "over", "the", "life", "of", "the", "estimated", "royalty", "payment", "period,", "we", "will", "continue", "to", "recognize", "the", "royalties", "as", "revenue,", "which", "we", "expect", "to", "increase", "in", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p27_s2", "idA": "906709_11_item7_p6_s0", "sentA": "Our focus on research and clinical development requires substantial investments that continue to increase as we advance each drug candidate through each phase of the development cycle.", "sentB": "In these situations, the clinical development program and process for a drug candidate and the estimated completion date will largely be under the control of that third party and not under our control.", "type": 1, "words": ["<tag1>", "Our", "focus", "on", "research", "and", "clinical", "development", "requires", "substantial", "investments", "that", "continue", "to", "increase", "as", "we", "advance", "each", "drug", "candidate", "through", "each", "phase", "of", "the", "development", "cycle.", "<tag2>", "In", "these", "situations,", "the", "clinical", "development", "program", "and", "process", "for", "a", "drug", "candidate", "and", "the", "estimated", "completion", "date", "will", "largely", "be", "under", "the", "control", "of", "that", "third", "party", "and", "not", "under", "our", "control.", "<tag3>"], "wordsA": ["Our", "focus", "on", "research", "and", "clinical", "development", "requires", "substantial", "investments", "that", "continue", "to", "increase", "as", "we", "advance", "each", "drug", "candidate", "through", "each", "phase", "of", "the", "development", "cycle."], "wordsB": ["In", "these", "situations,", "the", "clinical", "development", "program", "and", "process", "for", "a", "drug", "candidate", "and", "the", "estimated", "completion", "date", "will", "largely", "be", "under", "the", "control", "of", "that", "third", "party", "and", "not", "under", "our", "control."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p29_s3", "idA": "906709_11_item7_p6_s0", "sentA": "Our focus on research and clinical development requires substantial investments that continue to increase as we advance each drug candidate through each phase of the development cycle.", "sentB": "In 2012, after excluding the impact of the 2011 commercial litigation settlement, we expect general and administrative expenses to increase modestly compared to 2011.", "type": 1, "words": ["<tag1>", "Our", "focus", "on", "research", "and", "clinical", "development", "requires", "substantial", "investments", "that", "continue", "to", "increase", "as", "we", "advance", "each", "drug", "candidate", "through", "each", "phase", "of", "the", "development", "cycle.", "<tag2>", "In", "2012,", "after", "excluding", "the", "impact", "of", "the", "2011", "commercial", "litigation", "settlement,", "we", "expect", "general", "and", "administrative", "expenses", "to", "increase", "modestly", "compared", "to", "2011.", "<tag3>"], "wordsA": ["Our", "focus", "on", "research", "and", "clinical", "development", "requires", "substantial", "investments", "that", "continue", "to", "increase", "as", "we", "advance", "each", "drug", "candidate", "through", "each", "phase", "of", "the", "development", "cycle."], "wordsB": ["In", "2012,", "after", "excluding", "the", "impact", "of", "the", "2011", "commercial", "litigation", "settlement,", "we", "expect", "general", "and", "administrative", "expenses", "to", "increase", "modestly", "compared", "to", "2011."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p32_s1", "idA": "906709_11_item7_p6_s1", "sentA": "In addition to advancing our proprietary programs that are currently in clinical development, we are committed to continuing to make significant investments to advance new opportunities from our earlier stage research discovery pipeline.", "sentB": "Although we are required to make payments to the purchaser of these rights only in certain situations, this transaction will be recorded as a liability.", "type": 1, "words": ["<tag1>", "In", "addition", "to", "advancing", "our", "proprietary", "programs", "that", "are", "currently", "in", "clinical", "development,", "we", "are", "committed", "to", "continuing", "to", "make", "significant", "investments", "to", "advance", "new", "opportunities", "from", "our", "earlier", "stage", "research", "discovery", "pipeline.", "<tag2>", "Although", "we", "are", "required", "to", "make", "payments", "to", "the", "purchaser", "of", "these", "rights", "only", "in", "certain", "situations,", "this", "transaction", "will", "be", "recorded", "as", "a", "liability.", "<tag3>"], "wordsA": ["In", "addition", "to", "advancing", "our", "proprietary", "programs", "that", "are", "currently", "in", "clinical", "development,", "we", "are", "committed", "to", "continuing", "to", "make", "significant", "investments", "to", "advance", "new", "opportunities", "from", "our", "earlier", "stage", "research", "discovery", "pipeline."], "wordsB": ["Although", "we", "are", "required", "to", "make", "payments", "to", "the", "purchaser", "of", "these", "rights", "only", "in", "certain", "situations,", "this", "transaction", "will", "be", "recorded", "as", "a", "liability."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p11_s1", "idA": "906709_11_item7_p7_s0", "sentA": "drug research and development is an inherently uncertain process and there is a high risk of failure at every stage prior to approval and the timing and outcome of clinical trial results is extremely difficult to predict.", "sentB": "Revenue is recognized when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured.", "type": 1, "words": ["<tag1>", "drug", "research", "and", "development", "is", "an", "inherently", "uncertain", "process", "and", "there", "is", "a", "high", "risk", "of", "failure", "at", "every", "stage", "prior", "to", "approval", "and", "the", "timing", "and", "outcome", "of", "clinical", "trial", "results", "is", "extremely", "difficult", "to", "predict.", "<tag2>", "Revenue", "is", "recognized", "when", "there", "is", "persuasive", "evidence", "that", "an", "arrangement", "exists,", "delivery", "has", "occurred,", "the", "price", "is", "fixed", "or", "determinable,", "and", "collection", "is", "reasonably", "assured.", "<tag3>"], "wordsA": ["drug", "research", "and", "development", "is", "an", "inherently", "uncertain", "process", "and", "there", "is", "a", "high", "risk", "of", "failure", "at", "every", "stage", "prior", "to", "approval", "and", "the", "timing", "and", "outcome", "of", "clinical", "trial", "results", "is", "extremely", "difficult", "to", "predict."], "wordsB": ["Revenue", "is", "recognized", "when", "there", "is", "persuasive", "evidence", "that", "an", "arrangement", "exists,", "delivery", "has", "occurred,", "the", "price", "is", "fixed", "or", "determinable,", "and", "collection", "is", "reasonably", "assured."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p24_s10", "idA": "906709_11_item7_p8_s0", "sentA": "We have a number of existing license and collaboration agreements with third parties in which we have an economic interest and could have a material impact on our business, results of operations and financial condition.", "sentB": "We are unable to estimate the dates or costs to complete the clinical development efforts for the ovarian and colorectal cancer indications in which we are studying NKTR-102.", "type": 1, "words": ["<tag1>", "We", "have", "a", "number", "of", "existing", "license", "and", "collaboration", "agreements", "with", "third", "parties", "in", "which", "we", "have", "an", "economic", "interest", "and", "could", "have", "a", "material", "impact", "on", "our", "business,", "results", "of", "operations", "and", "financial", "condition.", "<tag2>", "We", "are", "unable", "to", "estimate", "the", "dates", "or", "costs", "to", "complete", "the", "clinical", "development", "efforts", "for", "the", "ovarian", "and", "colorectal", "cancer", "indications", "in", "which", "we", "are", "studying", "NKTR-102.", "<tag3>"], "wordsA": ["We", "have", "a", "number", "of", "existing", "license", "and", "collaboration", "agreements", "with", "third", "parties", "in", "which", "we", "have", "an", "economic", "interest", "and", "could", "have", "a", "material", "impact", "on", "our", "business,", "results", "of", "operations", "and", "financial", "condition."], "wordsB": ["We", "are", "unable", "to", "estimate", "the", "dates", "or", "costs", "to", "complete", "the", "clinical", "development", "efforts", "for", "the", "ovarian", "and", "colorectal", "cancer", "indications", "in", "which", "we", "are", "studying", "NKTR-102."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p34_s3", "idA": "906709_11_item7_p9_s0", "sentA": "among other of our collaboration agreements, will together have a material impact on our business, financial results and cash position.", "sentB": "We may also seek from time to time to purchase or retire our outstanding convertible notes through cash purchases and/or exchanges for other of our securities in open market transactions, privately negotiated transactions and/or a tender offer, if we can do so on attractive terms.", "type": 1, "words": ["<tag1>", "among", "other", "of", "our", "collaboration", "agreements,", "will", "together", "have", "a", "material", "impact", "on", "our", "business,", "financial", "results", "and", "cash", "position.", "<tag2>", "We", "may", "also", "seek", "from", "time", "to", "time", "to", "purchase", "or", "retire", "our", "outstanding", "convertible", "notes", "through", "cash", "purchases", "and/or", "exchanges", "for", "other", "of", "our", "securities", "in", "open", "market", "transactions,", "privately", "negotiated", "transactions", "and/or", "a", "tender", "offer,", "if", "we", "can", "do", "so", "on", "attractive", "terms.", "<tag3>"], "wordsA": ["among", "other", "of", "our", "collaboration", "agreements,", "will", "together", "have", "a", "material", "impact", "on", "our", "business,", "financial", "results", "and", "cash", "position."], "wordsB": ["We", "may", "also", "seek", "from", "time", "to", "time", "to", "purchase", "or", "retire", "our", "outstanding", "convertible", "notes", "through", "cash", "purchases", "and/or", "exchanges", "for", "other", "of", "our", "securities", "in", "open", "market", "transactions,", "privately", "negotiated", "transactions", "and/or", "a", "tender", "offer,", "if", "we", "can", "do", "so", "on", "attractive", "terms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item7_p2_s4", "idA": "906709_11_item7_p9_s1", "sentA": "Because drug development and commercialization is subject to numerous risks and uncertainties, there is a substantial risk that our future revenue from one or more of these agreements will be less than we project in our business plans.", "sentB": "If the KODIAC study is successful and AstraZeneca files for regulatory approval with the FDA and the European Medicines Agency (EMA), Nektar will be entitled to $95.0 million of these milestones.", "type": 1, "words": ["<tag1>", "Because", "drug", "development", "and", "commercialization", "is", "subject", "to", "numerous", "risks", "and", "uncertainties,", "there", "is", "a", "substantial", "risk", "that", "our", "future", "revenue", "from", "one", "or", "more", "of", "these", "agreements", "will", "be", "less", "than", "we", "project", "in", "our", "business", "plans.", "<tag2>", "If", "the", "KODIAC", "study", "is", "successful", "and", "AstraZeneca", "files", "for", "regulatory", "approval", "with", "the", "FDA", "and", "the", "European", "Medicines", "Agency", "(EMA),", "Nektar", "will", "be", "entitled", "to", "$95.0", "million", "of", "these", "milestones.", "<tag3>"], "wordsA": ["Because", "drug", "development", "and", "commercialization", "is", "subject", "to", "numerous", "risks", "and", "uncertainties,", "there", "is", "a", "substantial", "risk", "that", "our", "future", "revenue", "from", "one", "or", "more", "of", "these", "agreements", "will", "be", "less", "than", "we", "project", "in", "our", "business", "plans."], "wordsB": ["If", "the", "KODIAC", "study", "is", "successful", "and", "AstraZeneca", "files", "for", "regulatory", "approval", "with", "the", "FDA", "and", "the", "European", "Medicines", "Agency", "(EMA),", "Nektar", "will", "be", "entitled", "to", "$95.0", "million", "of", "these", "milestones."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p62_s5", "idA": "906709_12_item7_p10_s0", "sentA": "As discussed above, the success of the KODIAC study is critical to providing cash to fund our operations and there can be no assurance as to the outcome of this study.", "sentB": "Since we apply significant judgment in arriving at the ESPs, any material changes would significantly affect the allocation of the total consideration to the different elements of a multiple element arrangement.", "type": 1, "words": ["<tag1>", "As", "discussed", "above,", "the", "success", "of", "the", "KODIAC", "study", "is", "critical", "to", "providing", "cash", "to", "fund", "our", "operations", "and", "there", "can", "be", "no", "assurance", "as", "to", "the", "outcome", "of", "this", "study.", "<tag2>", "Since", "we", "apply", "significant", "judgment", "in", "arriving", "at", "the", "ESPs,", "any", "material", "changes", "would", "significantly", "affect", "the", "allocation", "of", "the", "total", "consideration", "to", "the", "different", "elements", "of", "a", "multiple", "element", "arrangement.", "<tag3>"], "wordsA": ["As", "discussed", "above,", "the", "success", "of", "the", "KODIAC", "study", "is", "critical", "to", "providing", "cash", "to", "fund", "our", "operations", "and", "there", "can", "be", "no", "assurance", "as", "to", "the", "outcome", "of", "this", "study."], "wordsB": ["Since", "we", "apply", "significant", "judgment", "in", "arriving", "at", "the", "ESPs,", "any", "material", "changes", "would", "significantly", "affect", "the", "allocation", "of", "the", "total", "consideration", "to", "the", "different", "elements", "of", "a", "multiple", "element", "arrangement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p62_s2", "idA": "906709_12_item7_p12_s0", "sentA": "Management makes its best estimate of the period over which we expect to fulfill our performance obligations.", "sentB": "Under this guidance, at the inception of each new multiple-element arrangement or the material modification of an existing multiple-element arrangement, we allocate arrangement consideration to all units of accounting based on the relative selling price method, generally based on our best estimate of selling price (ESP).", "type": 1, "words": ["<tag1>", "Management", "makes", "its", "best", "estimate", "of", "the", "period", "over", "which", "we", "expect", "to", "fulfill", "our", "performance", "obligations.", "<tag2>", "Under", "this", "guidance,", "at", "the", "inception", "of", "each", "new", "multiple-element", "arrangement", "or", "the", "material", "modification", "of", "an", "existing", "multiple-element", "arrangement,", "we", "allocate", "arrangement", "consideration", "to", "all", "units", "of", "accounting", "based", "on", "the", "relative", "selling", "price", "method,", "generally", "based", "on", "our", "best", "estimate", "of", "selling", "price", "(ESP).", "<tag3>"], "wordsA": ["Management", "makes", "its", "best", "estimate", "of", "the", "period", "over", "which", "we", "expect", "to", "fulfill", "our", "performance", "obligations."], "wordsB": ["Under", "this", "guidance,", "at", "the", "inception", "of", "each", "new", "multiple-element", "arrangement", "or", "the", "material", "modification", "of", "an", "existing", "multiple-element", "arrangement,", "we", "allocate", "arrangement", "consideration", "to", "all", "units", "of", "accounting", "based", "on", "the", "relative", "selling", "price", "method,", "generally", "based", "on", "our", "best", "estimate", "of", "selling", "price", "(ESP)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p61_s4", "idA": "906709_12_item7_p12_s1", "sentA": "Given the uncertainties in research and development collaborations, significant judgment is required by management to determine the performance periods.", "sentB": "Our original estimates are periodically evaluated to determine if circumstances have caused the estimates to change and if so, amortization of revenue is adjusted prospectively.", "type": 1, "words": ["<tag1>", "Given", "the", "uncertainties", "in", "research", "and", "development", "collaborations,", "significant", "judgment", "is", "required", "by", "management", "to", "determine", "the", "performance", "periods.", "<tag2>", "Our", "original", "estimates", "are", "periodically", "evaluated", "to", "determine", "if", "circumstances", "have", "caused", "the", "estimates", "to", "change", "and", "if", "so,", "amortization", "of", "revenue", "is", "adjusted", "prospectively.", "<tag3>"], "wordsA": ["Given", "the", "uncertainties", "in", "research", "and", "development", "collaborations,", "significant", "judgment", "is", "required", "by", "management", "to", "determine", "the", "performance", "periods."], "wordsB": ["Our", "original", "estimates", "are", "periodically", "evaluated", "to", "determine", "if", "circumstances", "have", "caused", "the", "estimates", "to", "change", "and", "if", "so,", "amortization", "of", "revenue", "is", "adjusted", "prospectively."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p66_s0", "idA": "906709_12_item7_p12_s1", "sentA": "Given the uncertainties in research and development collaborations, significant judgment is required by management to determine the performance periods.", "sentB": "Stock-Based Compensation We use the Black-Scholes option valuation model for each respective grant to determine the estimated fair value of stock options on the date of grant (grant date fair value) and common stock purchased under the ESPP.", "type": 1, "words": ["<tag1>", "Given", "the", "uncertainties", "in", "research", "and", "development", "collaborations,", "significant", "judgment", "is", "required", "by", "management", "to", "determine", "the", "performance", "periods.", "<tag2>", "Stock-Based", "Compensation", "We", "use", "the", "Black-Scholes", "option", "valuation", "model", "for", "each", "respective", "grant", "to", "determine", "the", "estimated", "fair", "value", "of", "stock", "options", "on", "the", "date", "of", "grant", "(grant", "date", "fair", "value)", "and", "common", "stock", "purchased", "under", "the", "ESPP.", "<tag3>"], "wordsA": ["Given", "the", "uncertainties", "in", "research", "and", "development", "collaborations,", "significant", "judgment", "is", "required", "by", "management", "to", "determine", "the", "performance", "periods."], "wordsB": ["Stock-Based", "Compensation", "We", "use", "the", "Black-Scholes", "option", "valuation", "model", "for", "each", "respective", "grant", "to", "determine", "the", "estimated", "fair", "value", "of", "stock", "options", "on", "the", "date", "of", "grant", "(grant", "date", "fair", "value)", "and", "common", "stock", "purchased", "under", "the", "ESPP."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p61_s2", "idA": "906709_12_item7_p13_s0", "sentA": "Product sales Product sales include cost-plus and fixed price manufacturing and supply agreements with our collaboration partners.", "sentB": "Our performance obligations for these agreements may include technology transfer assistance and/or back-up manufacturing and supply services for a specified period of time; therefore, the time estimated to complete the performance obligations related to licenses is either specified or is much shorter than the collaboration agreements.", "type": 1, "words": ["<tag1>", "Product", "sales", "Product", "sales", "include", "cost-plus", "and", "fixed", "price", "manufacturing", "and", "supply", "agreements", "with", "our", "collaboration", "partners.", "<tag2>", "Our", "performance", "obligations", "for", "these", "agreements", "may", "include", "technology", "transfer", "assistance", "and/or", "back-up", "manufacturing", "and", "supply", "services", "for", "a", "specified", "period", "of", "time;", "therefore,", "the", "time", "estimated", "to", "complete", "the", "performance", "obligations", "related", "to", "licenses", "is", "either", "specified", "or", "is", "much", "shorter", "than", "the", "collaboration", "agreements.", "<tag3>"], "wordsA": ["Product", "sales", "Product", "sales", "include", "cost-plus", "and", "fixed", "price", "manufacturing", "and", "supply", "agreements", "with", "our", "collaboration", "partners."], "wordsB": ["Our", "performance", "obligations", "for", "these", "agreements", "may", "include", "technology", "transfer", "assistance", "and/or", "back-up", "manufacturing", "and", "supply", "services", "for", "a", "specified", "period", "of", "time;", "therefore,", "the", "time", "estimated", "to", "complete", "the", "performance", "obligations", "related", "to", "licenses", "is", "either", "specified", "or", "is", "much", "shorter", "than", "the", "collaboration", "agreements."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p53_s0", "idA": "906709_12_item7_p13_s11", "sentA": "License, collaboration and other revenue for the year ended December 31, 2011 decreased compared to the year ended December 31, 2010 primarily due to the complete recognition as of December 31, 2010 of the $125.0 million upfront payment received in the fourth quarter of 2009 from AstraZeneca in connection with the NKTR-118 and NKTR-119 global license agreement.", "sentB": "(4) Substantially all of this amount was subject to open purchase orders as of December 31, 2012 that were issued under existing contracts.", "type": 1, "words": ["<tag1>", "License,", "collaboration", "and", "other", "revenue", "for", "the", "year", "ended", "December", "31,", "2011", "decreased", "compared", "to", "the", "year", "ended", "December", "31,", "2010", "primarily", "due", "to", "the", "complete", "recognition", "as", "of", "December", "31,", "2010", "of", "the", "$125.0", "million", "upfront", "payment", "received", "in", "the", "fourth", "quarter", "of", "2009", "from", "AstraZeneca", "in", "connection", "with", "the", "NKTR-118", "and", "NKTR-119", "global", "license", "agreement.", "<tag2>", "(4)", "Substantially", "all", "of", "this", "amount", "was", "subject", "to", "open", "purchase", "orders", "as", "of", "December", "31,", "2012", "that", "were", "issued", "under", "existing", "contracts.", "<tag3>"], "wordsA": ["License,", "collaboration", "and", "other", "revenue", "for", "the", "year", "ended", "December", "31,", "2011", "decreased", "compared", "to", "the", "year", "ended", "December", "31,", "2010", "primarily", "due", "to", "the", "complete", "recognition", "as", "of", "December", "31,", "2010", "of", "the", "$125.0", "million", "upfront", "payment", "received", "in", "the", "fourth", "quarter", "of", "2009", "from", "AstraZeneca", "in", "connection", "with", "the", "NKTR-118", "and", "NKTR-119", "global", "license", "agreement."], "wordsB": ["(4)", "Substantially", "all", "of", "this", "amount", "was", "subject", "to", "open", "purchase", "orders", "as", "of", "December", "31,", "2012", "that", "were", "issued", "under", "existing", "contracts."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p67_s0", "idA": "906709_12_item7_p13_s3", "sentA": "We expect product sales to increase in 2012 compared with 2011.", "sentB": "The Black-Scholes option pricing model requires the input of highly subjective assumptions.", "type": 1, "words": ["<tag1>", "We", "expect", "product", "sales", "to", "increase", "in", "2012", "compared", "with", "2011.", "<tag2>", "The", "Black-Scholes", "option", "pricing", "model", "requires", "the", "input", "of", "highly", "subjective", "assumptions.", "<tag3>"], "wordsA": ["We", "expect", "product", "sales", "to", "increase", "in", "2012", "compared", "with", "2011."], "wordsB": ["The", "Black-Scholes", "option", "pricing", "model", "requires", "the", "input", "of", "highly", "subjective", "assumptions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p72_s1", "idA": "906709_12_item7_p13_s3", "sentA": "We expect product sales to increase in 2012 compared with 2011.", "sentB": "We elected to present OCI in two separate consecutive statements.", "type": 1, "words": ["<tag1>", "We", "expect", "product", "sales", "to", "increase", "in", "2012", "compared", "with", "2011.", "<tag2>", "We", "elected", "to", "present", "OCI", "in", "two", "separate", "consecutive", "statements.", "<tag3>"], "wordsA": ["We", "expect", "product", "sales", "to", "increase", "in", "2012", "compared", "with", "2011."], "wordsB": ["We", "elected", "to", "present", "OCI", "in", "two", "separate", "consecutive", "statements."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p47_s9", "idA": "906709_12_item7_p14_s1", "sentA": "Under the AstraZeneca license agreement and related technology transfer agreement, we recognized $101.4 million and $23.6 million of the $125.0 million upfront payment and $6.5 million and $1.5 million of contract research and other revenue for the years ended December 31, 2010 and 2009, respectively.", "sentB": "In addition, $25.0 million of the proceeds from the senior secured notes issuance is required to be maintained in a restricted account until July 1, 2015.", "type": 1, "words": ["<tag1>", "Under", "the", "AstraZeneca", "license", "agreement", "and", "related", "technology", "transfer", "agreement,", "we", "recognized", "$101.4", "million", "and", "$23.6", "million", "of", "the", "$125.0", "million", "upfront", "payment", "and", "$6.5", "million", "and", "$1.5", "million", "of", "contract", "research", "and", "other", "revenue", "for", "the", "years", "ended", "December", "31,", "2010", "and", "2009,", "respectively.", "<tag2>", "In", "addition,", "$25.0", "million", "of", "the", "proceeds", "from", "the", "senior", "secured", "notes", "issuance", "is", "required", "to", "be", "maintained", "in", "a", "restricted", "account", "until", "July", "1,", "2015.", "<tag3>"], "wordsA": ["Under", "the", "AstraZeneca", "license", "agreement", "and", "related", "technology", "transfer", "agreement,", "we", "recognized", "$101.4", "million", "and", "$23.6", "million", "of", "the", "$125.0", "million", "upfront", "payment", "and", "$6.5", "million", "and", "$1.5", "million", "of", "contract", "research", "and", "other", "revenue", "for", "the", "years", "ended", "December", "31,", "2010", "and", "2009,", "respectively."], "wordsB": ["In", "addition,", "$25.0", "million", "of", "the", "proceeds", "from", "the", "senior", "secured", "notes", "issuance", "is", "required", "to", "be", "maintained", "in", "a", "restricted", "account", "until", "July", "1,", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p17_s7", "idA": "906709_12_item7_p15_s0", "sentA": "The timing and future success of our drug development programs and those of our collaboration partners are subject to a number of risks and uncertainties.", "sentB": "The availability and terms of financing alternatives and any future significant payments from existing or new collaborations all depend on the positive outcome of ongoing or planned clinical studies, whether we or our partners are successful in obtaining health authority approvals in major markets, and if approved, the commercial success of these drugs.", "type": 1, "words": ["<tag1>", "The", "timing", "and", "future", "success", "of", "our", "drug", "development", "programs", "and", "those", "of", "our", "collaboration", "partners", "are", "subject", "to", "a", "number", "of", "risks", "and", "uncertainties.", "<tag2>", "The", "availability", "and", "terms", "of", "financing", "alternatives", "and", "any", "future", "significant", "payments", "from", "existing", "or", "new", "collaborations", "all", "depend", "on", "the", "positive", "outcome", "of", "ongoing", "or", "planned", "clinical", "studies,", "whether", "we", "or", "our", "partners", "are", "successful", "in", "obtaining", "health", "authority", "approvals", "in", "major", "markets,", "and", "if", "approved,", "the", "commercial", "success", "of", "these", "drugs.", "<tag3>"], "wordsA": ["The", "timing", "and", "future", "success", "of", "our", "drug", "development", "programs", "and", "those", "of", "our", "collaboration", "partners", "are", "subject", "to", "a", "number", "of", "risks", "and", "uncertainties."], "wordsB": ["The", "availability", "and", "terms", "of", "financing", "alternatives", "and", "any", "future", "significant", "payments", "from", "existing", "or", "new", "collaborations", "all", "depend", "on", "the", "positive", "outcome", "of", "ongoing", "or", "planned", "clinical", "studies,", "whether", "we", "or", "our", "partners", "are", "successful", "in", "obtaining", "health", "authority", "approvals", "in", "major", "markets,", "and", "if", "approved,", "the", "commercial", "success", "of", "these", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p44_s3", "idA": "906709_12_item7_p15_s0", "sentA": "The timing and future success of our drug development programs and those of our collaboration partners are subject to a number of risks and uncertainties.", "sentB": "The availability and terms of financing alternatives and any future significant payments from existing or new collaborations all depend on the positive outcome of ongoing or planned clinical studies, whether we or our partners are successful in obtaining health authority approvals in major markets, and if approved, the commercial success of these drugs.", "type": 1, "words": ["<tag1>", "The", "timing", "and", "future", "success", "of", "our", "drug", "development", "programs", "and", "those", "of", "our", "collaboration", "partners", "are", "subject", "to", "a", "number", "of", "risks", "and", "uncertainties.", "<tag2>", "The", "availability", "and", "terms", "of", "financing", "alternatives", "and", "any", "future", "significant", "payments", "from", "existing", "or", "new", "collaborations", "all", "depend", "on", "the", "positive", "outcome", "of", "ongoing", "or", "planned", "clinical", "studies,", "whether", "we", "or", "our", "partners", "are", "successful", "in", "obtaining", "health", "authority", "approvals", "in", "major", "markets,", "and", "if", "approved,", "the", "commercial", "success", "of", "these", "drugs.", "<tag3>"], "wordsA": ["The", "timing", "and", "future", "success", "of", "our", "drug", "development", "programs", "and", "those", "of", "our", "collaboration", "partners", "are", "subject", "to", "a", "number", "of", "risks", "and", "uncertainties."], "wordsB": ["The", "availability", "and", "terms", "of", "financing", "alternatives", "and", "any", "future", "significant", "payments", "from", "existing", "or", "new", "collaborations", "all", "depend", "on", "the", "positive", "outcome", "of", "ongoing", "or", "planned", "clinical", "studies,", "whether", "we", "or", "our", "partners", "are", "successful", "in", "obtaining", "health", "authority", "approvals", "in", "major", "markets,", "and", "if", "approved,", "the", "commercial", "success", "of", "these", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p60_s0", "idA": "906709_12_item7_p15_s0", "sentA": "The timing and future success of our drug development programs and those of our collaboration partners are subject to a number of risks and uncertainties.", "sentB": "Given the statistical probability of drug development success in the bio-pharmaceutical industry, drug development programs have only a 5% to 10% probability of reaching commercial success.", "type": 1, "words": ["<tag1>", "The", "timing", "and", "future", "success", "of", "our", "drug", "development", "programs", "and", "those", "of", "our", "collaboration", "partners", "are", "subject", "to", "a", "number", "of", "risks", "and", "uncertainties.", "<tag2>", "Given", "the", "statistical", "probability", "of", "drug", "development", "success", "in", "the", "bio-pharmaceutical", "industry,", "drug", "development", "programs", "have", "only", "a", "5%", "to", "10%", "probability", "of", "reaching", "commercial", "success.", "<tag3>"], "wordsA": ["The", "timing", "and", "future", "success", "of", "our", "drug", "development", "programs", "and", "those", "of", "our", "collaboration", "partners", "are", "subject", "to", "a", "number", "of", "risks", "and", "uncertainties."], "wordsB": ["Given", "the", "statistical", "probability", "of", "drug", "development", "success", "in", "the", "bio-pharmaceutical", "industry,", "drug", "development", "programs", "have", "only", "a", "5%", "to", "10%", "probability", "of", "reaching", "commercial", "success."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p17_s9", "idA": "906709_12_item7_p15_s1", "sentA": "See Part I, Item 1A Risk Factors for discussion of the risks associated with the complex nature of our collaboration agreements.", "sentB": "AstraZeneca has indicated that it plans to submit regulatory filings for naloxegol subject to subject to AstraZeneca s final preparation of the registration package and a pre-NDA meeting with the FDA.", "type": 1, "words": ["<tag1>", "See", "Part", "I,", "Item", "1A", "Risk", "Factors", "for", "discussion", "of", "the", "risks", "associated", "with", "the", "complex", "nature", "of", "our", "collaboration", "agreements.", "<tag2>", "AstraZeneca", "has", "indicated", "that", "it", "plans", "to", "submit", "regulatory", "filings", "for", "naloxegol", "subject", "to", "subject", "to", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA.", "<tag3>"], "wordsA": ["See", "Part", "I,", "Item", "1A", "Risk", "Factors", "for", "discussion", "of", "the", "risks", "associated", "with", "the", "complex", "nature", "of", "our", "collaboration", "agreements."], "wordsB": ["AstraZeneca", "has", "indicated", "that", "it", "plans", "to", "submit", "regulatory", "filings", "for", "naloxegol", "subject", "to", "subject", "to", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p44_s5", "idA": "906709_12_item7_p15_s1", "sentA": "See Part I, Item 1A Risk Factors for discussion of the risks associated with the complex nature of our collaboration agreements.", "sentB": "AstraZeneca has indicated that it plans to submit regulatory filings for naloxegol subject to AstraZeneca s preparation of the NDA submission package and a pre-NDA meeting with the FDA.", "type": 1, "words": ["<tag1>", "See", "Part", "I,", "Item", "1A", "Risk", "Factors", "for", "discussion", "of", "the", "risks", "associated", "with", "the", "complex", "nature", "of", "our", "collaboration", "agreements.", "<tag2>", "AstraZeneca", "has", "indicated", "that", "it", "plans", "to", "submit", "regulatory", "filings", "for", "naloxegol", "subject", "to", "AstraZeneca", "s", "preparation", "of", "the", "NDA", "submission", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA.", "<tag3>"], "wordsA": ["See", "Part", "I,", "Item", "1A", "Risk", "Factors", "for", "discussion", "of", "the", "risks", "associated", "with", "the", "complex", "nature", "of", "our", "collaboration", "agreements."], "wordsB": ["AstraZeneca", "has", "indicated", "that", "it", "plans", "to", "submit", "regulatory", "filings", "for", "naloxegol", "subject", "to", "AstraZeneca", "s", "preparation", "of", "the", "NDA", "submission", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p62_s4", "idA": "906709_12_item7_p15_s1", "sentA": "See Part I, Item 1A Risk Factors for discussion of the risks associated with the complex nature of our collaboration agreements.", "sentB": "We determine ESP for the elements in our collaboration arrangements by considering multiple factors including, but not limited to, technical complexity of the performance obligation and similarity of elements to those performed under previous arrangements.", "type": 1, "words": ["<tag1>", "See", "Part", "I,", "Item", "1A", "Risk", "Factors", "for", "discussion", "of", "the", "risks", "associated", "with", "the", "complex", "nature", "of", "our", "collaboration", "agreements.", "<tag2>", "We", "determine", "ESP", "for", "the", "elements", "in", "our", "collaboration", "arrangements", "by", "considering", "multiple", "factors", "including,", "but", "not", "limited", "to,", "technical", "complexity", "of", "the", "performance", "obligation", "and", "similarity", "of", "elements", "to", "those", "performed", "under", "previous", "arrangements.", "<tag3>"], "wordsA": ["See", "Part", "I,", "Item", "1A", "Risk", "Factors", "for", "discussion", "of", "the", "risks", "associated", "with", "the", "complex", "nature", "of", "our", "collaboration", "agreements."], "wordsB": ["We", "determine", "ESP", "for", "the", "elements", "in", "our", "collaboration", "arrangements", "by", "considering", "multiple", "factors", "including,", "but", "not", "limited", "to,", "technical", "complexity", "of", "the", "performance", "obligation", "and", "similarity", "of", "elements", "to", "those", "performed", "under", "previous", "arrangements."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p69_s4", "idA": "906709_12_item7_p1_s1", "sentA": "Additionally, we may utilize established pharmacologic targets to engineer a new drug candidate relying on a combination of the known properties of these targets and our proprietary polymer chemistry technology and expertise.", "sentB": "We will periodically assess the expected royalty payments to RPI from UCB and Roche using a combination of historical results and forecasts from market data sources.", "type": 1, "words": ["<tag1>", "Additionally,", "we", "may", "utilize", "established", "pharmacologic", "targets", "to", "engineer", "a", "new", "drug", "candidate", "relying", "on", "a", "combination", "of", "the", "known", "properties", "of", "these", "targets", "and", "our", "proprietary", "polymer", "chemistry", "technology", "and", "expertise.", "<tag2>", "We", "will", "periodically", "assess", "the", "expected", "royalty", "payments", "to", "RPI", "from", "UCB", "and", "Roche", "using", "a", "combination", "of", "historical", "results", "and", "forecasts", "from", "market", "data", "sources.", "<tag3>"], "wordsA": ["Additionally,", "we", "may", "utilize", "established", "pharmacologic", "targets", "to", "engineer", "a", "new", "drug", "candidate", "relying", "on", "a", "combination", "of", "the", "known", "properties", "of", "these", "targets", "and", "our", "proprietary", "polymer", "chemistry", "technology", "and", "expertise."], "wordsB": ["We", "will", "periodically", "assess", "the", "expected", "royalty", "payments", "to", "RPI", "from", "UCB", "and", "Roche", "using", "a", "combination", "of", "historical", "results", "and", "forecasts", "from", "market", "data", "sources."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p32_s11", "idA": "906709_12_item7_p24_s10", "sentA": "We are unable to estimate the dates or costs to complete the clinical development efforts for the ovarian and colorectal cancer indications in which we are studying NKTR-102.", "sentB": "We are also actively advancing the preclinical development work for NKTR-171 and NKTR-214 in preparation for entering clinical development in the 2013-2014 timeframe.", "type": 1, "words": ["<tag1>", "We", "are", "unable", "to", "estimate", "the", "dates", "or", "costs", "to", "complete", "the", "clinical", "development", "efforts", "for", "the", "ovarian", "and", "colorectal", "cancer", "indications", "in", "which", "we", "are", "studying", "NKTR-102.", "<tag2>", "We", "are", "also", "actively", "advancing", "the", "preclinical", "development", "work", "for", "NKTR-171", "and", "NKTR-214", "in", "preparation", "for", "entering", "clinical", "development", "in", "the", "2013-2014", "timeframe.", "<tag3>"], "wordsA": ["We", "are", "unable", "to", "estimate", "the", "dates", "or", "costs", "to", "complete", "the", "clinical", "development", "efforts", "for", "the", "ovarian", "and", "colorectal", "cancer", "indications", "in", "which", "we", "are", "studying", "NKTR-102."], "wordsB": ["We", "are", "also", "actively", "advancing", "the", "preclinical", "development", "work", "for", "NKTR-171", "and", "NKTR-214", "in", "preparation", "for", "entering", "clinical", "development", "in", "the", "2013-2014", "timeframe."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p59_s1", "idA": "906709_12_item7_p24_s9", "sentA": "Although we are still in the early stages of the BEACON study, we estimate that the total third party and direct material costs over the life of the BEACON study will range from approximately $110.0 million to $120.0 million, of which $14.0 million was paid as of December 31, 2011, and that it will be completed around the end of 2014.", "sentB": "For these, the shortest reasonable period is the end of the development period (estimated to be 4 to 6 years) and the longest period is the contractual life of the agreement, which is generally 10-12 years from the first commercial sale.", "type": 1, "words": ["<tag1>", "Although", "we", "are", "still", "in", "the", "early", "stages", "of", "the", "BEACON", "study,", "we", "estimate", "that", "the", "total", "third", "party", "and", "direct", "material", "costs", "over", "the", "life", "of", "the", "BEACON", "study", "will", "range", "from", "approximately", "$110.0", "million", "to", "$120.0", "million,", "of", "which", "$14.0", "million", "was", "paid", "as", "of", "December", "31,", "2011,", "and", "that", "it", "will", "be", "completed", "around", "the", "end", "of", "2014.", "<tag2>", "For", "these,", "the", "shortest", "reasonable", "period", "is", "the", "end", "of", "the", "development", "period", "(estimated", "to", "be", "4", "to", "6", "years)", "and", "the", "longest", "period", "is", "the", "contractual", "life", "of", "the", "agreement,", "which", "is", "generally", "10-12", "years", "from", "the", "first", "commercial", "sale.", "<tag3>"], "wordsA": ["Although", "we", "are", "still", "in", "the", "early", "stages", "of", "the", "BEACON", "study,", "we", "estimate", "that", "the", "total", "third", "party", "and", "direct", "material", "costs", "over", "the", "life", "of", "the", "BEACON", "study", "will", "range", "from", "approximately", "$110.0", "million", "to", "$120.0", "million,", "of", "which", "$14.0", "million", "was", "paid", "as", "of", "December", "31,", "2011,", "and", "that", "it", "will", "be", "completed", "around", "the", "end", "of", "2014."], "wordsB": ["For", "these,", "the", "shortest", "reasonable", "period", "is", "the", "end", "of", "the", "development", "period", "(estimated", "to", "be", "4", "to", "6", "years)", "and", "the", "longest", "period", "is", "the", "contractual", "life", "of", "the", "agreement,", "which", "is", "generally", "10-12", "years", "from", "the", "first", "commercial", "sale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p53_s9", "idA": "906709_12_item7_p25_s4", "sentA": "We do not expect to have any significant future research and development costs associated with NKTR-118 and NKTR-119 as AstraZeneca is responsible for all further development and commercialization costs for these drug candidates.", "sentB": "We do not utilize off-balance sheet financing arrangements as a source of liquidity or financing.", "type": 1, "words": ["<tag1>", "We", "do", "not", "expect", "to", "have", "any", "significant", "future", "research", "and", "development", "costs", "associated", "with", "NKTR-118", "and", "NKTR-119", "as", "AstraZeneca", "is", "responsible", "for", "all", "further", "development", "and", "commercialization", "costs", "for", "these", "drug", "candidates.", "<tag2>", "We", "do", "not", "utilize", "off-balance", "sheet", "financing", "arrangements", "as", "a", "source", "of", "liquidity", "or", "financing.", "<tag3>"], "wordsA": ["We", "do", "not", "expect", "to", "have", "any", "significant", "future", "research", "and", "development", "costs", "associated", "with", "NKTR-118", "and", "NKTR-119", "as", "AstraZeneca", "is", "responsible", "for", "all", "further", "development", "and", "commercialization", "costs", "for", "these", "drug", "candidates."], "wordsB": ["We", "do", "not", "utilize", "off-balance", "sheet", "financing", "arrangements", "as", "a", "source", "of", "liquidity", "or", "financing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p53_s1", "idA": "906709_12_item7_p26_s1", "sentA": "We then conduct clinical studies for our drug candidates that take several years to complete.", "sentB": "This amount does not represent any minimum contract termination liabilities for our existing contracts.", "type": 1, "words": ["<tag1>", "We", "then", "conduct", "clinical", "studies", "for", "our", "drug", "candidates", "that", "take", "several", "years", "to", "complete.", "<tag2>", "This", "amount", "does", "not", "represent", "any", "minimum", "contract", "termination", "liabilities", "for", "our", "existing", "contracts.", "<tag3>"], "wordsA": ["We", "then", "conduct", "clinical", "studies", "for", "our", "drug", "candidates", "that", "take", "several", "years", "to", "complete."], "wordsB": ["This", "amount", "does", "not", "represent", "any", "minimum", "contract", "termination", "liabilities", "for", "our", "existing", "contracts."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p53_s6", "idA": "906709_12_item7_p26_s2", "sentA": "The cost and time required to complete clinical trials may vary significantly over the life of a clinical development program as a result of a variety of factors, including but not limited to:", "sentB": "Our ability to meet our ongoing operating expenses and repay our outstanding indebtedness is dependent upon our and our partners ability to successfully complete clinical development of, obtain regulatory approvals for and successfully commercialize new drugs.", "type": 1, "words": ["<tag1>", "The", "cost", "and", "time", "required", "to", "complete", "clinical", "trials", "may", "vary", "significantly", "over", "the", "life", "of", "a", "clinical", "development", "program", "as", "a", "result", "of", "a", "variety", "of", "factors,", "including", "but", "not", "limited", "to:", "<tag2>", "Our", "ability", "to", "meet", "our", "ongoing", "operating", "expenses", "and", "repay", "our", "outstanding", "indebtedness", "is", "dependent", "upon", "our", "and", "our", "partners", "ability", "to", "successfully", "complete", "clinical", "development", "of,", "obtain", "regulatory", "approvals", "for", "and", "successfully", "commercialize", "new", "drugs.", "<tag3>"], "wordsA": ["The", "cost", "and", "time", "required", "to", "complete", "clinical", "trials", "may", "vary", "significantly", "over", "the", "life", "of", "a", "clinical", "development", "program", "as", "a", "result", "of", "a", "variety", "of", "factors,", "including", "but", "not", "limited", "to:"], "wordsB": ["Our", "ability", "to", "meet", "our", "ongoing", "operating", "expenses", "and", "repay", "our", "outstanding", "indebtedness", "is", "dependent", "upon", "our", "and", "our", "partners", "ability", "to", "successfully", "complete", "clinical", "development", "of,", "obtain", "regulatory", "approvals", "for", "and", "successfully", "commercialize", "new", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p5_s0", "idA": "906709_12_item7_p2_s1", "sentA": "On March 15, 2011, AstraZeneca announced enrollment of the first patient in Phase 3 clinical studies for NKTR-118 that AstraZeneca calls the KODIAC study.", "sentB": "On November 12, 2012, AstraZeneca announced positive top-line results from two Phase 3 efficacy and safety clinical trials and from a safety extension trial (KODIAC-04, -05, and -07).", "type": 1, "words": ["<tag1>", "On", "March", "15,", "2011,", "AstraZeneca", "announced", "enrollment", "of", "the", "first", "patient", "in", "Phase", "3", "clinical", "studies", "for", "NKTR-118", "that", "AstraZeneca", "calls", "the", "KODIAC", "study.", "<tag2>", "On", "November", "12,", "2012,", "AstraZeneca", "announced", "positive", "top-line", "results", "from", "two", "Phase", "3", "efficacy", "and", "safety", "clinical", "trials", "and", "from", "a", "safety", "extension", "trial", "(KODIAC-04,", "-05,", "and", "-07).", "<tag3>"], "wordsA": ["On", "March", "15,", "2011,", "AstraZeneca", "announced", "enrollment", "of", "the", "first", "patient", "in", "Phase", "3", "clinical", "studies", "for", "NKTR-118", "that", "AstraZeneca", "calls", "the", "KODIAC", "study."], "wordsB": ["On", "November", "12,", "2012,", "AstraZeneca", "announced", "positive", "top-line", "results", "from", "two", "Phase", "3", "efficacy", "and", "safety", "clinical", "trials", "and", "from", "a", "safety", "extension", "trial", "(KODIAC-04,", "-05,", "and", "-07)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p64_s1", "idA": "906709_12_item7_p2_s4", "sentA": "If the KODIAC study is successful and AstraZeneca files for regulatory approval with the FDA and the European Medicines Agency (EMA), Nektar will be entitled to $95.0 million of these milestones.", "sentB": "If the actual timing of these phases varies from the estimate, we will adjust the accrual prospectively.", "type": 1, "words": ["<tag1>", "If", "the", "KODIAC", "study", "is", "successful", "and", "AstraZeneca", "files", "for", "regulatory", "approval", "with", "the", "FDA", "and", "the", "European", "Medicines", "Agency", "(EMA),", "Nektar", "will", "be", "entitled", "to", "$95.0", "million", "of", "these", "milestones.", "<tag2>", "If", "the", "actual", "timing", "of", "these", "phases", "varies", "from", "the", "estimate,", "we", "will", "adjust", "the", "accrual", "prospectively.", "<tag3>"], "wordsA": ["If", "the", "KODIAC", "study", "is", "successful", "and", "AstraZeneca", "files", "for", "regulatory", "approval", "with", "the", "FDA", "and", "the", "European", "Medicines", "Agency", "(EMA),", "Nektar", "will", "be", "entitled", "to", "$95.0", "million", "of", "these", "milestones."], "wordsB": ["If", "the", "actual", "timing", "of", "these", "phases", "varies", "from", "the", "estimate,", "we", "will", "adjust", "the", "accrual", "prospectively."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p67_s2", "idA": "906709_12_item7_p30_s1", "sentA": "We determined that the carrying value of the San Carlos facility exceeded its fair value based on a discounted cash flow model and an impairment charge of $12.6 million was recognized as a result.", "sentB": "In addition, management continually assesses the assumptions and methodologies used to calculate the estimated fair value of stock-based compensation.", "type": 1, "words": ["<tag1>", "We", "determined", "that", "the", "carrying", "value", "of", "the", "San", "Carlos", "facility", "exceeded", "its", "fair", "value", "based", "on", "a", "discounted", "cash", "flow", "model", "and", "an", "impairment", "charge", "of", "$12.6", "million", "was", "recognized", "as", "a", "result.", "<tag2>", "In", "addition,", "management", "continually", "assesses", "the", "assumptions", "and", "methodologies", "used", "to", "calculate", "the", "estimated", "fair", "value", "of", "stock-based", "compensation.", "<tag3>"], "wordsA": ["We", "determined", "that", "the", "carrying", "value", "of", "the", "San", "Carlos", "facility", "exceeded", "its", "fair", "value", "based", "on", "a", "discounted", "cash", "flow", "model", "and", "an", "impairment", "charge", "of", "$12.6", "million", "was", "recognized", "as", "a", "result."], "wordsB": ["In", "addition,", "management", "continually", "assesses", "the", "assumptions", "and", "methodologies", "used", "to", "calculate", "the", "estimated", "fair", "value", "of", "stock-based", "compensation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p61_s3", "idA": "906709_12_item7_p34_s12", "sentA": "Due to the potential for continued uncertainty in the credit markets in 2012, we may experience reduced liquidity with respect to some of our investments in marketable securities.", "sentB": "We may experience delays in the execution of technology transfer plans, which may result in a longer amortization period for applicable agreements.", "type": 1, "words": ["<tag1>", "Due", "to", "the", "potential", "for", "continued", "uncertainty", "in", "the", "credit", "markets", "in", "2012,", "we", "may", "experience", "reduced", "liquidity", "with", "respect", "to", "some", "of", "our", "investments", "in", "marketable", "securities.", "<tag2>", "We", "may", "experience", "delays", "in", "the", "execution", "of", "technology", "transfer", "plans,", "which", "may", "result", "in", "a", "longer", "amortization", "period", "for", "applicable", "agreements.", "<tag3>"], "wordsA": ["Due", "to", "the", "potential", "for", "continued", "uncertainty", "in", "the", "credit", "markets", "in", "2012,", "we", "may", "experience", "reduced", "liquidity", "with", "respect", "to", "some", "of", "our", "investments", "in", "marketable", "securities."], "wordsB": ["We", "may", "experience", "delays", "in", "the", "execution", "of", "technology", "transfer", "plans,", "which", "may", "result", "in", "a", "longer", "amortization", "period", "for", "applicable", "agreements."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p72_s0", "idA": "906709_12_item7_p34_s12", "sentA": "Due to the potential for continued uncertainty in the credit markets in 2012, we may experience reduced liquidity with respect to some of our investments in marketable securities.", "sentB": "Recent Accounting Pronouncements On January 1, 2012, we were required to adopt new accounting guidance related to the presentation of comprehensive income that prohibits the presentation of other comprehensive income (OCI) in the statement of stockholders equity and instead, provides the option of presenting OCI in a continuous statement of comprehensive income or as two separate consecutive statements.", "type": 1, "words": ["<tag1>", "Due", "to", "the", "potential", "for", "continued", "uncertainty", "in", "the", "credit", "markets", "in", "2012,", "we", "may", "experience", "reduced", "liquidity", "with", "respect", "to", "some", "of", "our", "investments", "in", "marketable", "securities.", "<tag2>", "Recent", "Accounting", "Pronouncements", "On", "January", "1,", "2012,", "we", "were", "required", "to", "adopt", "new", "accounting", "guidance", "related", "to", "the", "presentation", "of", "comprehensive", "income", "that", "prohibits", "the", "presentation", "of", "other", "comprehensive", "income", "(OCI)", "in", "the", "statement", "of", "stockholders", "equity", "and", "instead,", "provides", "the", "option", "of", "presenting", "OCI", "in", "a", "continuous", "statement", "of", "comprehensive", "income", "or", "as", "two", "separate", "consecutive", "statements.", "<tag3>"], "wordsA": ["Due", "to", "the", "potential", "for", "continued", "uncertainty", "in", "the", "credit", "markets", "in", "2012,", "we", "may", "experience", "reduced", "liquidity", "with", "respect", "to", "some", "of", "our", "investments", "in", "marketable", "securities."], "wordsB": ["Recent", "Accounting", "Pronouncements", "On", "January", "1,", "2012,", "we", "were", "required", "to", "adopt", "new", "accounting", "guidance", "related", "to", "the", "presentation", "of", "comprehensive", "income", "that", "prohibits", "the", "presentation", "of", "other", "comprehensive", "income", "(OCI)", "in", "the", "statement", "of", "stockholders", "equity", "and", "instead,", "provides", "the", "option", "of", "presenting", "OCI", "in", "a", "continuous", "statement", "of", "comprehensive", "income", "or", "as", "two", "separate", "consecutive", "statements."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p54_s2", "idA": "906709_12_item7_p34_s4", "sentA": "We will evaluate financing alternatives, if any, in light of the then-existing market conditions.", "sentB": "Actual results may differ from those estimates under different assumptions or conditions.", "type": 1, "words": ["<tag1>", "We", "will", "evaluate", "financing", "alternatives,", "if", "any,", "in", "light", "of", "the", "then-existing", "market", "conditions.", "<tag2>", "Actual", "results", "may", "differ", "from", "those", "estimates", "under", "different", "assumptions", "or", "conditions.", "<tag3>"], "wordsA": ["We", "will", "evaluate", "financing", "alternatives,", "if", "any,", "in", "light", "of", "the", "then-existing", "market", "conditions."], "wordsB": ["Actual", "results", "may", "differ", "from", "those", "estimates", "under", "different", "assumptions", "or", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p54_s1", "idA": "906709_12_item7_p34_s5", "sentA": "Where we believe it is in the best interests of the company and our stockholders, we are pursuing financing alternatives that are not dilutive to the ownership of our common stock security holders.", "sentB": "We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources, and evaluate our estimates on an ongoing basis.", "type": 1, "words": ["<tag1>", "Where", "we", "believe", "it", "is", "in", "the", "best", "interests", "of", "the", "company", "and", "our", "stockholders,", "we", "are", "pursuing", "financing", "alternatives", "that", "are", "not", "dilutive", "to", "the", "ownership", "of", "our", "common", "stock", "security", "holders.", "<tag2>", "We", "base", "our", "estimates", "on", "historical", "experience", "and", "on", "various", "other", "assumptions", "that", "we", "believe", "to", "be", "reasonable", "under", "the", "circumstances,", "the", "results", "of", "which", "form", "our", "basis", "for", "making", "judgments", "about", "the", "carrying", "value", "of", "assets", "and", "liabilities", "that", "are", "not", "readily", "apparent", "from", "other", "sources,", "and", "evaluate", "our", "estimates", "on", "an", "ongoing", "basis.", "<tag3>"], "wordsA": ["Where", "we", "believe", "it", "is", "in", "the", "best", "interests", "of", "the", "company", "and", "our", "stockholders,", "we", "are", "pursuing", "financing", "alternatives", "that", "are", "not", "dilutive", "to", "the", "ownership", "of", "our", "common", "stock", "security", "holders."], "wordsB": ["We", "base", "our", "estimates", "on", "historical", "experience", "and", "on", "various", "other", "assumptions", "that", "we", "believe", "to", "be", "reasonable", "under", "the", "circumstances,", "the", "results", "of", "which", "form", "our", "basis", "for", "making", "judgments", "about", "the", "carrying", "value", "of", "assets", "and", "liabilities", "that", "are", "not", "readily", "apparent", "from", "other", "sources,", "and", "evaluate", "our", "estimates", "on", "an", "ongoing", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p37_s0", "idA": "906709_12_item7_p34_s8", "sentA": "If we are not successful in raising additional funds through financing activities in 2012, we may be required to reduce our research and development spending in one or more programs, as well as general and administrative expenses, in order to conserve working capital until additional funding becomes available either from our existing collaborations or additional fundraising activities.", "sentB": "In an effort to reduce ongoing operating costs and improve our organizational structure, efficiency and productivity, in March 2012, we announced a plan to consolidate our U.S.-based research activities at our existing San Francisco location and to cease the use of and offer for sale one of our buildings located in Huntsville, Alabama that was dedicated to research activities.", "type": 1, "words": ["<tag1>", "If", "we", "are", "not", "successful", "in", "raising", "additional", "funds", "through", "financing", "activities", "in", "2012,", "we", "may", "be", "required", "to", "reduce", "our", "research", "and", "development", "spending", "in", "one", "or", "more", "programs,", "as", "well", "as", "general", "and", "administrative", "expenses,", "in", "order", "to", "conserve", "working", "capital", "until", "additional", "funding", "becomes", "available", "either", "from", "our", "existing", "collaborations", "or", "additional", "fundraising", "activities.", "<tag2>", "In", "an", "effort", "to", "reduce", "ongoing", "operating", "costs", "and", "improve", "our", "organizational", "structure,", "efficiency", "and", "productivity,", "in", "March", "2012,", "we", "announced", "a", "plan", "to", "consolidate", "our", "U.S.-based", "research", "activities", "at", "our", "existing", "San", "Francisco", "location", "and", "to", "cease", "the", "use", "of", "and", "offer", "for", "sale", "one", "of", "our", "buildings", "located", "in", "Huntsville,", "Alabama", "that", "was", "dedicated", "to", "research", "activities.", "<tag3>"], "wordsA": ["If", "we", "are", "not", "successful", "in", "raising", "additional", "funds", "through", "financing", "activities", "in", "2012,", "we", "may", "be", "required", "to", "reduce", "our", "research", "and", "development", "spending", "in", "one", "or", "more", "programs,", "as", "well", "as", "general", "and", "administrative", "expenses,", "in", "order", "to", "conserve", "working", "capital", "until", "additional", "funding", "becomes", "available", "either", "from", "our", "existing", "collaborations", "or", "additional", "fundraising", "activities."], "wordsB": ["In", "an", "effort", "to", "reduce", "ongoing", "operating", "costs", "and", "improve", "our", "organizational", "structure,", "efficiency", "and", "productivity,", "in", "March", "2012,", "we", "announced", "a", "plan", "to", "consolidate", "our", "U.S.-based", "research", "activities", "at", "our", "existing", "San", "Francisco", "location", "and", "to", "cease", "the", "use", "of", "and", "offer", "for", "sale", "one", "of", "our", "buildings", "located", "in", "Huntsville,", "Alabama", "that", "was", "dedicated", "to", "research", "activities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p17_s5", "idA": "906709_12_item7_p34_s9", "sentA": "Our substantial debt, the market price of our common stock, and the general economic and equity market climate, among other factors, could substantially weaken our financial condition and could reduce or eliminate our ability to obtain short-term and long-term financing alternatives.", "sentB": "Our current business plan is also subject to significant uncertainties and risks as a result of, among other factors, expenses being higher than anticipated, unplanned expenses, cash receipts being lower than anticipated, and the need to satisfy contingent liabilities including litigation matters and indemnification obligations.", "type": 1, "words": ["<tag1>", "Our", "substantial", "debt,", "the", "market", "price", "of", "our", "common", "stock,", "and", "the", "general", "economic", "and", "equity", "market", "climate,", "among", "other", "factors,", "could", "substantially", "weaken", "our", "financial", "condition", "and", "could", "reduce", "or", "eliminate", "our", "ability", "to", "obtain", "short-term", "and", "long-term", "financing", "alternatives.", "<tag2>", "Our", "current", "business", "plan", "is", "also", "subject", "to", "significant", "uncertainties", "and", "risks", "as", "a", "result", "of,", "among", "other", "factors,", "expenses", "being", "higher", "than", "anticipated,", "unplanned", "expenses,", "cash", "receipts", "being", "lower", "than", "anticipated,", "and", "the", "need", "to", "satisfy", "contingent", "liabilities", "including", "litigation", "matters", "and", "indemnification", "obligations.", "<tag3>"], "wordsA": ["Our", "substantial", "debt,", "the", "market", "price", "of", "our", "common", "stock,", "and", "the", "general", "economic", "and", "equity", "market", "climate,", "among", "other", "factors,", "could", "substantially", "weaken", "our", "financial", "condition", "and", "could", "reduce", "or", "eliminate", "our", "ability", "to", "obtain", "short-term", "and", "long-term", "financing", "alternatives."], "wordsB": ["Our", "current", "business", "plan", "is", "also", "subject", "to", "significant", "uncertainties", "and", "risks", "as", "a", "result", "of,", "among", "other", "factors,", "expenses", "being", "higher", "than", "anticipated,", "unplanned", "expenses,", "cash", "receipts", "being", "lower", "than", "anticipated,", "and", "the", "need", "to", "satisfy", "contingent", "liabilities", "including", "litigation", "matters", "and", "indemnification", "obligations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p44_s1", "idA": "906709_12_item7_p34_s9", "sentA": "Our substantial debt, the market price of our common stock, and the general economic and equity market climate, among other factors, could substantially weaken our financial condition and could reduce or eliminate our ability to obtain short-term and long-term financing alternatives.", "sentB": "Our current business plan is also subject to significant uncertainties and risks as a result of, among other factors, expenses being higher than anticipated, unplanned expenses, cash receipts being lower than anticipated, and the need to satisfy contingent liabilities including litigation matters and indemnification obligations.", "type": 1, "words": ["<tag1>", "Our", "substantial", "debt,", "the", "market", "price", "of", "our", "common", "stock,", "and", "the", "general", "economic", "and", "equity", "market", "climate,", "among", "other", "factors,", "could", "substantially", "weaken", "our", "financial", "condition", "and", "could", "reduce", "or", "eliminate", "our", "ability", "to", "obtain", "short-term", "and", "long-term", "financing", "alternatives.", "<tag2>", "Our", "current", "business", "plan", "is", "also", "subject", "to", "significant", "uncertainties", "and", "risks", "as", "a", "result", "of,", "among", "other", "factors,", "expenses", "being", "higher", "than", "anticipated,", "unplanned", "expenses,", "cash", "receipts", "being", "lower", "than", "anticipated,", "and", "the", "need", "to", "satisfy", "contingent", "liabilities", "including", "litigation", "matters", "and", "indemnification", "obligations.", "<tag3>"], "wordsA": ["Our", "substantial", "debt,", "the", "market", "price", "of", "our", "common", "stock,", "and", "the", "general", "economic", "and", "equity", "market", "climate,", "among", "other", "factors,", "could", "substantially", "weaken", "our", "financial", "condition", "and", "could", "reduce", "or", "eliminate", "our", "ability", "to", "obtain", "short-term", "and", "long-term", "financing", "alternatives."], "wordsB": ["Our", "current", "business", "plan", "is", "also", "subject", "to", "significant", "uncertainties", "and", "risks", "as", "a", "result", "of,", "among", "other", "factors,", "expenses", "being", "higher", "than", "anticipated,", "unplanned", "expenses,", "cash", "receipts", "being", "lower", "than", "anticipated,", "and", "the", "need", "to", "satisfy", "contingent", "liabilities", "including", "litigation", "matters", "and", "indemnification", "obligations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p62_s0", "idA": "906709_12_item7_p36_s2", "sentA": "On January 24, 2011, we completed a public offering of our common stock with gross proceeds of approximately $220.4 million.", "sentB": "On January 1, 2011, we adopted on a prospective basis Accounting Standards Update (ASU) 2009-13, which amends the criteria to identify separate units of accounting within Subtopic 605-25, Revenue Recognition-Multiple-Element Arrangements.", "type": 1, "words": ["<tag1>", "On", "January", "24,", "2011,", "we", "completed", "a", "public", "offering", "of", "our", "common", "stock", "with", "gross", "proceeds", "of", "approximately", "$220.4", "million.", "<tag2>", "On", "January", "1,", "2011,", "we", "adopted", "on", "a", "prospective", "basis", "Accounting", "Standards", "Update", "(ASU)", "2009-13,", "which", "amends", "the", "criteria", "to", "identify", "separate", "units", "of", "accounting", "within", "Subtopic", "605-25,", "Revenue", "Recognition-Multiple-Element", "Arrangements.", "<tag3>"], "wordsA": ["On", "January", "24,", "2011,", "we", "completed", "a", "public", "offering", "of", "our", "common", "stock", "with", "gross", "proceeds", "of", "approximately", "$220.4", "million."], "wordsB": ["On", "January", "1,", "2011,", "we", "adopted", "on", "a", "prospective", "basis", "Accounting", "Standards", "Update", "(ASU)", "2009-13,", "which", "amends", "the", "criteria", "to", "identify", "separate", "units", "of", "accounting", "within", "Subtopic", "605-25,", "Revenue", "Recognition-Multiple-Element", "Arrangements."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p69_s5", "idA": "906709_12_item7_p3_s1", "sentA": "Therefore, the results from the KODIAC study, the timing and outcome of approval review of NKTR-118 by the FDA and EMA, the timing of the commercial launch of NKTR-118 (if approved), and the level of NKTR-118 sales, will have a significant impact on our financial condition and future business prospects.", "sentB": "To the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different than our original estimates, we will prospectively adjust the amortization of the Royalty Obligation.", "type": 1, "words": ["<tag1>", "Therefore,", "the", "results", "from", "the", "KODIAC", "study,", "the", "timing", "and", "outcome", "of", "approval", "review", "of", "NKTR-118", "by", "the", "FDA", "and", "EMA,", "the", "timing", "of", "the", "commercial", "launch", "of", "NKTR-118", "(if", "approved),", "and", "the", "level", "of", "NKTR-118", "sales,", "will", "have", "a", "significant", "impact", "on", "our", "financial", "condition", "and", "future", "business", "prospects.", "<tag2>", "To", "the", "extent", "such", "payments", "are", "greater", "or", "less", "than", "our", "initial", "estimates", "or", "the", "timing", "of", "such", "payments", "is", "materially", "different", "than", "our", "original", "estimates,", "we", "will", "prospectively", "adjust", "the", "amortization", "of", "the", "Royalty", "Obligation.", "<tag3>"], "wordsA": ["Therefore,", "the", "results", "from", "the", "KODIAC", "study,", "the", "timing", "and", "outcome", "of", "approval", "review", "of", "NKTR-118", "by", "the", "FDA", "and", "EMA,", "the", "timing", "of", "the", "commercial", "launch", "of", "NKTR-118", "(if", "approved),", "and", "the", "level", "of", "NKTR-118", "sales,", "will", "have", "a", "significant", "impact", "on", "our", "financial", "condition", "and", "future", "business", "prospects."], "wordsB": ["To", "the", "extent", "such", "payments", "are", "greater", "or", "less", "than", "our", "initial", "estimates", "or", "the", "timing", "of", "such", "payments", "is", "materially", "different", "than", "our", "original", "estimates,", "we", "will", "prospectively", "adjust", "the", "amortization", "of", "the", "Royalty", "Obligation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p11_s0", "idA": "906709_12_item7_p4_s0", "sentA": "Our second most advanced drug candidate, NKTR-102, is a next-generation topoisomerase I inhibitor, currently being evaluated as a single-agent therapy in a Phase 3 open-label, randomized, multicenter clinical study in patients with metastatic breast cancer.", "sentB": "The first drug candidate in this collaboration, BAX 855, is a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein which has completed Phase 1 clinical development in patients with hemophilia A.", "type": 1, "words": ["<tag1>", "Our", "second", "most", "advanced", "drug", "candidate,", "NKTR-102,", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "as", "a", "single-agent", "therapy", "in", "a", "Phase", "3", "open-label,", "randomized,", "multicenter", "clinical", "study", "in", "patients", "with", "metastatic", "breast", "cancer.", "<tag2>", "The", "first", "drug", "candidate", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein", "which", "has", "completed", "Phase", "1", "clinical", "development", "in", "patients", "with", "hemophilia", "A.", "<tag3>"], "wordsA": ["Our", "second", "most", "advanced", "drug", "candidate,", "NKTR-102,", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "as", "a", "single-agent", "therapy", "in", "a", "Phase", "3", "open-label,", "randomized,", "multicenter", "clinical", "study", "in", "patients", "with", "metastatic", "breast", "cancer."], "wordsB": ["The", "first", "drug", "candidate", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein", "which", "has", "completed", "Phase", "1", "clinical", "development", "in", "patients", "with", "hemophilia", "A."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p65_s1", "idA": "906709_12_item7_p4_s3", "sentA": "The BEACON study will require a substantial investment over the next three years.", "sentB": "In addition, certain time-based costs are expensed ratably over the treatment phase.", "type": 1, "words": ["<tag1>", "The", "BEACON", "study", "will", "require", "a", "substantial", "investment", "over", "the", "next", "three", "years.", "<tag2>", "In", "addition,", "certain", "time-based", "costs", "are", "expensed", "ratably", "over", "the", "treatment", "phase.", "<tag3>"], "wordsA": ["The", "BEACON", "study", "will", "require", "a", "substantial", "investment", "over", "the", "next", "three", "years."], "wordsB": ["In", "addition,", "certain", "time-based", "costs", "are", "expensed", "ratably", "over", "the", "treatment", "phase."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p54_s0", "idA": "906709_12_item7_p5_s8", "sentA": "We expect to continue to make significant investments over the next two years in establishing manufacturing capability for the nebulizer device necessary to support the Phase 3 clinical study of this drug candidate and, if such study is successful and the drug candidate is approved by government health authorities, the commercial supply of the nebulizer device.", "sentB": "The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.", "type": 1, "words": ["<tag1>", "We", "expect", "to", "continue", "to", "make", "significant", "investments", "over", "the", "next", "two", "years", "in", "establishing", "manufacturing", "capability", "for", "the", "nebulizer", "device", "necessary", "to", "support", "the", "Phase", "3", "clinical", "study", "of", "this", "drug", "candidate", "and,", "if", "such", "study", "is", "successful", "and", "the", "drug", "candidate", "is", "approved", "by", "government", "health", "authorities,", "the", "commercial", "supply", "of", "the", "nebulizer", "device.", "<tag2>", "The", "preparation", "of", "financial", "statements", "in", "conformity", "with", "U.S.", "Generally", "Accepted", "Accounting", "Principles", "(GAAP)", "requires", "management", "to", "make", "estimates", "and", "assumptions", "that", "affect", "the", "reported", "amounts", "of", "assets", "and", "liabilities", "and", "disclosure", "of", "contingent", "assets", "and", "liabilities", "at", "the", "date", "of", "the", "financial", "statements", "and", "the", "reported", "amounts", "of", "revenues", "and", "expenses", "during", "the", "reporting", "period.", "<tag3>"], "wordsA": ["We", "expect", "to", "continue", "to", "make", "significant", "investments", "over", "the", "next", "two", "years", "in", "establishing", "manufacturing", "capability", "for", "the", "nebulizer", "device", "necessary", "to", "support", "the", "Phase", "3", "clinical", "study", "of", "this", "drug", "candidate", "and,", "if", "such", "study", "is", "successful", "and", "the", "drug", "candidate", "is", "approved", "by", "government", "health", "authorities,", "the", "commercial", "supply", "of", "the", "nebulizer", "device."], "wordsB": ["The", "preparation", "of", "financial", "statements", "in", "conformity", "with", "U.S.", "Generally", "Accepted", "Accounting", "Principles", "(GAAP)", "requires", "management", "to", "make", "estimates", "and", "assumptions", "that", "affect", "the", "reported", "amounts", "of", "assets", "and", "liabilities", "and", "disclosure", "of", "contingent", "assets", "and", "liabilities", "at", "the", "date", "of", "the", "financial", "statements", "and", "the", "reported", "amounts", "of", "revenues", "and", "expenses", "during", "the", "reporting", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item7_p56_s0", "idA": "906709_12_item7_p9_s0", "sentA": "Historically, we have financed our operations primarily through cash from licensing, collaboration and manufacturing agreements and public and private placements of debt and equity securities.", "sentB": "We defer income under contractual agreements when we have further obligations that indicate that a separate earnings process has not been completed.", "type": 1, "words": ["<tag1>", "Historically,", "we", "have", "financed", "our", "operations", "primarily", "through", "cash", "from", "licensing,", "collaboration", "and", "manufacturing", "agreements", "and", "public", "and", "private", "placements", "of", "debt", "and", "equity", "securities.", "<tag2>", "We", "defer", "income", "under", "contractual", "agreements", "when", "we", "have", "further", "obligations", "that", "indicate", "that", "a", "separate", "earnings", "process", "has", "not", "been", "completed.", "<tag3>"], "wordsA": ["Historically,", "we", "have", "financed", "our", "operations", "primarily", "through", "cash", "from", "licensing,", "collaboration", "and", "manufacturing", "agreements", "and", "public", "and", "private", "placements", "of", "debt", "and", "equity", "securities."], "wordsB": ["We", "defer", "income", "under", "contractual", "agreements", "when", "we", "have", "further", "obligations", "that", "indicate", "that", "a", "separate", "earnings", "process", "has", "not", "been", "completed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item7_p6_s2", "idA": "906709_13_item7_p21_s11", "sentA": "In the event regulatory approval filings for naloxegol are submitted by AstraZeneca and accepted by the FDA and by the EMA, we would be entitled to $95.0 million in milestone payments.", "sentB": "On September 25, 2013, the EMA notified AstraZeneca that it had accepted for review the naloxegol regulatory approval application filed by AstraZeneca in August 2013.", "type": 1, "words": ["<tag1>", "In", "the", "event", "regulatory", "approval", "filings", "for", "naloxegol", "are", "submitted", "by", "AstraZeneca", "and", "accepted", "by", "the", "FDA", "and", "by", "the", "EMA,", "we", "would", "be", "entitled", "to", "$95.0", "million", "in", "milestone", "payments.", "<tag2>", "On", "September", "25,", "2013,", "the", "EMA", "notified", "AstraZeneca", "that", "it", "had", "accepted", "for", "review", "the", "naloxegol", "regulatory", "approval", "application", "filed", "by", "AstraZeneca", "in", "August", "2013.", "<tag3>"], "wordsA": ["In", "the", "event", "regulatory", "approval", "filings", "for", "naloxegol", "are", "submitted", "by", "AstraZeneca", "and", "accepted", "by", "the", "FDA", "and", "by", "the", "EMA,", "we", "would", "be", "entitled", "to", "$95.0", "million", "in", "milestone", "payments."], "wordsB": ["On", "September", "25,", "2013,", "the", "EMA", "notified", "AstraZeneca", "that", "it", "had", "accepted", "for", "review", "the", "naloxegol", "regulatory", "approval", "application", "filed", "by", "AstraZeneca", "in", "August", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item7_p7_s1", "idA": "906709_13_item7_p21_s11", "sentA": "In the event regulatory approval filings for naloxegol are submitted by AstraZeneca and accepted by the FDA and by the EMA, we would be entitled to $95.0 million in milestone payments.", "sentB": "On September 16, 2013, AstraZeneca filed an NDA with the FDA for naloxegol, which was accepted for review by the FDA on November 16, 2013, resulting in a $70.0 million milestone payment to Nektar from AstraZeneca in November 2013.", "type": 1, "words": ["<tag1>", "In", "the", "event", "regulatory", "approval", "filings", "for", "naloxegol", "are", "submitted", "by", "AstraZeneca", "and", "accepted", "by", "the", "FDA", "and", "by", "the", "EMA,", "we", "would", "be", "entitled", "to", "$95.0", "million", "in", "milestone", "payments.", "<tag2>", "On", "September", "16,", "2013,", "AstraZeneca", "filed", "an", "NDA", "with", "the", "FDA", "for", "naloxegol,", "which", "was", "accepted", "for", "review", "by", "the", "FDA", "on", "November", "16,", "2013,", "resulting", "in", "a", "$70.0", "million", "milestone", "payment", "to", "Nektar", "from", "AstraZeneca", "in", "November", "2013.", "<tag3>"], "wordsA": ["In", "the", "event", "regulatory", "approval", "filings", "for", "naloxegol", "are", "submitted", "by", "AstraZeneca", "and", "accepted", "by", "the", "FDA", "and", "by", "the", "EMA,", "we", "would", "be", "entitled", "to", "$95.0", "million", "in", "milestone", "payments."], "wordsB": ["On", "September", "16,", "2013,", "AstraZeneca", "filed", "an", "NDA", "with", "the", "FDA", "for", "naloxegol,", "which", "was", "accepted", "for", "review", "by", "the", "FDA", "on", "November", "16,", "2013,", "resulting", "in", "a", "$70.0", "million", "milestone", "payment", "to", "Nektar", "from", "AstraZeneca", "in", "November", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item7_p10_s8", "idA": "906709_13_item7_p24_s0", "sentA": "Cost of goods sold increased during the year ended December 31, 2012 compared to the year ended December 31, 2011 primarily due to the $10.5 million increase in product sales in 2012.", "sentB": "However, patients who were randomized to the placebo arm did not show the expected increase in pain scores observed in similar enriched enrollment, randomized withdrawal studies.", "type": 1, "words": ["<tag1>", "Cost", "of", "goods", "sold", "increased", "during", "the", "year", "ended", "December", "31,", "2012", "compared", "to", "the", "year", "ended", "December", "31,", "2011", "primarily", "due", "to", "the", "$10.5", "million", "increase", "in", "product", "sales", "in", "2012.", "<tag2>", "However,", "patients", "who", "were", "randomized", "to", "the", "placebo", "arm", "did", "not", "show", "the", "expected", "increase", "in", "pain", "scores", "observed", "in", "similar", "enriched", "enrollment,", "randomized", "withdrawal", "studies.", "<tag3>"], "wordsA": ["Cost", "of", "goods", "sold", "increased", "during", "the", "year", "ended", "December", "31,", "2012", "compared", "to", "the", "year", "ended", "December", "31,", "2011", "primarily", "due", "to", "the", "$10.5", "million", "increase", "in", "product", "sales", "in", "2012."], "wordsB": ["However,", "patients", "who", "were", "randomized", "to", "the", "placebo", "arm", "did", "not", "show", "the", "expected", "increase", "in", "pain", "scores", "observed", "in", "similar", "enriched", "enrollment,", "randomized", "withdrawal", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item7_p10_s7", "idA": "906709_13_item7_p29_s0", "sentA": "In addition, during the year ended December 31, 2011, we made $11.2 million of prepayments to certain vendors in our BEACON study.", "sentB": "In this study, NKTR-181 performed as expected as an opioid analgesic throughout the study.", "type": 1, "words": ["<tag1>", "In", "addition,", "during", "the", "year", "ended", "December", "31,", "2011,", "we", "made", "$11.2", "million", "of", "prepayments", "to", "certain", "vendors", "in", "our", "BEACON", "study.", "<tag2>", "In", "this", "study,", "NKTR-181", "performed", "as", "expected", "as", "an", "opioid", "analgesic", "throughout", "the", "study.", "<tag3>"], "wordsA": ["In", "addition,", "during", "the", "year", "ended", "December", "31,", "2011,", "we", "made", "$11.2", "million", "of", "prepayments", "to", "certain", "vendors", "in", "our", "BEACON", "study."], "wordsB": ["In", "this", "study,", "NKTR-181", "performed", "as", "expected", "as", "an", "opioid", "analgesic", "throughout", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item7_p14_s2", "idA": "906709_13_item7_p32_s1", "sentA": "We plan to continue to advance etirinotecan pegol in the Phase 3 BEACON study for metastatic breast cancer for which we expect patient enrollment to continue throughout 2013 and the clinical study to continue through 2014.", "sentB": "On November 13, 2013, Baxter announced that it had completed enrollment of 146 patients in the PROLONG-ATE clinical study.", "type": 1, "words": ["<tag1>", "We", "plan", "to", "continue", "to", "advance", "etirinotecan", "pegol", "in", "the", "Phase", "3", "BEACON", "study", "for", "metastatic", "breast", "cancer", "for", "which", "we", "expect", "patient", "enrollment", "to", "continue", "throughout", "2013", "and", "the", "clinical", "study", "to", "continue", "through", "2014.", "<tag2>", "On", "November", "13,", "2013,", "Baxter", "announced", "that", "it", "had", "completed", "enrollment", "of", "146", "patients", "in", "the", "PROLONG-ATE", "clinical", "study.", "<tag3>"], "wordsA": ["We", "plan", "to", "continue", "to", "advance", "etirinotecan", "pegol", "in", "the", "Phase", "3", "BEACON", "study", "for", "metastatic", "breast", "cancer", "for", "which", "we", "expect", "patient", "enrollment", "to", "continue", "throughout", "2013", "and", "the", "clinical", "study", "to", "continue", "through", "2014."], "wordsB": ["On", "November", "13,", "2013,", "Baxter", "announced", "that", "it", "had", "completed", "enrollment", "of", "146", "patients", "in", "the", "PROLONG-ATE", "clinical", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item7_p10_s4", "idA": "906709_13_item7_p32_s9", "sentA": "Further, if the Phase 2 clinical results are successful, we plan to begin preparations for the commencement of Phase 3 clinical studies for NKTR-181.", "sentB": "Of the 295 patients that entered the study, only 9 (3%) patients did not achieve meaningful pain relief with NKTR-181.", "type": 1, "words": ["<tag1>", "Further,", "if", "the", "Phase", "2", "clinical", "results", "are", "successful,", "we", "plan", "to", "begin", "preparations", "for", "the", "commencement", "of", "Phase", "3", "clinical", "studies", "for", "NKTR-181.", "<tag2>", "Of", "the", "295", "patients", "that", "entered", "the", "study,", "only", "9", "(3%)", "patients", "did", "not", "achieve", "meaningful", "pain", "relief", "with", "NKTR-181.", "<tag3>"], "wordsA": ["Further,", "if", "the", "Phase", "2", "clinical", "results", "are", "successful,", "we", "plan", "to", "begin", "preparations", "for", "the", "commencement", "of", "Phase", "3", "clinical", "studies", "for", "NKTR-181."], "wordsB": ["Of", "the", "295", "patients", "that", "entered", "the", "study,", "only", "9", "(3%)", "patients", "did", "not", "achieve", "meaningful", "pain", "relief", "with", "NKTR-181."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item7_p7_s2", "idA": "906709_13_item7_p40_s5", "sentA": "On February 24, 2012, we sold all of our rights to receive future royalty payments on CIMZIA and MIRCERA in exchange for $124.0 million.", "sentB": "If the FDA does not require a future clinical trial or other significant studies to assess the cardiovascular safety ( CV Safety Study ) of naloxegol prior to an approval decision, AstraZeneca is obligated to pay us an additional $35.0 million.", "type": 1, "words": ["<tag1>", "On", "February", "24,", "2012,", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "on", "CIMZIA", "and", "MIRCERA", "in", "exchange", "for", "$124.0", "million.", "<tag2>", "If", "the", "FDA", "does", "not", "require", "a", "future", "clinical", "trial", "or", "other", "significant", "studies", "to", "assess", "the", "cardiovascular", "safety", "(", "CV", "Safety", "Study", ")", "of", "naloxegol", "prior", "to", "an", "approval", "decision,", "AstraZeneca", "is", "obligated", "to", "pay", "us", "an", "additional", "$35.0", "million.", "<tag3>"], "wordsA": ["On", "February", "24,", "2012,", "we", "sold", "all", "of", "our", "rights", "to", "receive", "future", "royalty", "payments", "on", "CIMZIA", "and", "MIRCERA", "in", "exchange", "for", "$124.0", "million."], "wordsB": ["If", "the", "FDA", "does", "not", "require", "a", "future", "clinical", "trial", "or", "other", "significant", "studies", "to", "assess", "the", "cardiovascular", "safety", "(", "CV", "Safety", "Study", ")", "of", "naloxegol", "prior", "to", "an", "approval", "decision,", "AstraZeneca", "is", "obligated", "to", "pay", "us", "an", "additional", "$35.0", "million."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item7_p7_s5", "idA": "906709_13_item7_p5_s3", "sentA": "In the event regulatory approval filings are submitted by AstraZeneca and accepted by the U.S. Food and Drug Administration (FDA) and by the European Medicines Agency (EMA), we would be entitled to receive $95.0 million in milestone payments.", "sentB": "If AstraZeneca elects to terminate the license agreement only with respect to its rights in the U.S., then such repayment amount would be funded through a 50% reduction of non-U.S. royalty amounts otherwise payable to us until the aggregate amount of such royalty reduction equals the total principal amount of $70.0 million plus accumulated interest at 4.5% compounded annually.", "type": 1, "words": ["<tag1>", "In", "the", "event", "regulatory", "approval", "filings", "are", "submitted", "by", "AstraZeneca", "and", "accepted", "by", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "and", "by", "the", "European", "Medicines", "Agency", "(EMA),", "we", "would", "be", "entitled", "to", "receive", "$95.0", "million", "in", "milestone", "payments.", "<tag2>", "If", "AstraZeneca", "elects", "to", "terminate", "the", "license", "agreement", "only", "with", "respect", "to", "its", "rights", "in", "the", "U.S.,", "then", "such", "repayment", "amount", "would", "be", "funded", "through", "a", "50%", "reduction", "of", "non-U.S.", "royalty", "amounts", "otherwise", "payable", "to", "us", "until", "the", "aggregate", "amount", "of", "such", "royalty", "reduction", "equals", "the", "total", "principal", "amount", "of", "$70.0", "million", "plus", "accumulated", "interest", "at", "4.5%", "compounded", "annually.", "<tag3>"], "wordsA": ["In", "the", "event", "regulatory", "approval", "filings", "are", "submitted", "by", "AstraZeneca", "and", "accepted", "by", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "and", "by", "the", "European", "Medicines", "Agency", "(EMA),", "we", "would", "be", "entitled", "to", "receive", "$95.0", "million", "in", "milestone", "payments."], "wordsB": ["If", "AstraZeneca", "elects", "to", "terminate", "the", "license", "agreement", "only", "with", "respect", "to", "its", "rights", "in", "the", "U.S.,", "then", "such", "repayment", "amount", "would", "be", "funded", "through", "a", "50%", "reduction", "of", "non-U.S.", "royalty", "amounts", "otherwise", "payable", "to", "us", "until", "the", "aggregate", "amount", "of", "such", "royalty", "reduction", "equals", "the", "total", "principal", "amount", "of", "$70.0", "million", "plus", "accumulated", "interest", "at", "4.5%", "compounded", "annually."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item7_p10_s6", "idA": "906709_13_item7_p64_s0", "sentA": "estimated duration of the start-up and reporting phases.", "sentB": "A total of 213 patients achieved an average 40% reduction in pain and entered the randomized phase of the study.", "type": 1, "words": ["<tag1>", "estimated", "duration", "of", "the", "start-up", "and", "reporting", "phases.", "<tag2>", "A", "total", "of", "213", "patients", "achieved", "an", "average", "40%", "reduction", "in", "pain", "and", "entered", "the", "randomized", "phase", "of", "the", "study.", "<tag3>"], "wordsA": ["estimated", "duration", "of", "the", "start-up", "and", "reporting", "phases."], "wordsB": ["A", "total", "of", "213", "patients", "achieved", "an", "average", "40%", "reduction", "in", "pain", "and", "entered", "the", "randomized", "phase", "of", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item7_p64_s0", "idA": "906709_13_item7_p72_s0", "sentA": "Recent Accounting Pronouncements On January 1, 2012, we were required to adopt new accounting guidance related to the presentation of comprehensive income that prohibits the presentation of other comprehensive income (OCI) in the statement of stockholders equity and instead, provides the option of presenting OCI in a continuous statement of comprehensive income or as two separate consecutive statements.", "sentB": "In July 2013, the Financial Accounting Standards Board issued a new accounting standard that will require the presentation of certain unrecognized tax benefits as a reduction to deferred tax assets rather than as a liability when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists.", "type": 1, "words": ["<tag1>", "Recent", "Accounting", "Pronouncements", "On", "January", "1,", "2012,", "we", "were", "required", "to", "adopt", "new", "accounting", "guidance", "related", "to", "the", "presentation", "of", "comprehensive", "income", "that", "prohibits", "the", "presentation", "of", "other", "comprehensive", "income", "(OCI)", "in", "the", "statement", "of", "stockholders", "equity", "and", "instead,", "provides", "the", "option", "of", "presenting", "OCI", "in", "a", "continuous", "statement", "of", "comprehensive", "income", "or", "as", "two", "separate", "consecutive", "statements.", "<tag2>", "In", "July", "2013,", "the", "Financial", "Accounting", "Standards", "Board", "issued", "a", "new", "accounting", "standard", "that", "will", "require", "the", "presentation", "of", "certain", "unrecognized", "tax", "benefits", "as", "a", "reduction", "to", "deferred", "tax", "assets", "rather", "than", "as", "a", "liability", "when", "a", "net", "operating", "loss", "carryforward,", "a", "similar", "tax", "loss,", "or", "a", "tax", "credit", "carryforward", "exists.", "<tag3>"], "wordsA": ["Recent", "Accounting", "Pronouncements", "On", "January", "1,", "2012,", "we", "were", "required", "to", "adopt", "new", "accounting", "guidance", "related", "to", "the", "presentation", "of", "comprehensive", "income", "that", "prohibits", "the", "presentation", "of", "other", "comprehensive", "income", "(OCI)", "in", "the", "statement", "of", "stockholders", "equity", "and", "instead,", "provides", "the", "option", "of", "presenting", "OCI", "in", "a", "continuous", "statement", "of", "comprehensive", "income", "or", "as", "two", "separate", "consecutive", "statements."], "wordsB": ["In", "July", "2013,", "the", "Financial", "Accounting", "Standards", "Board", "issued", "a", "new", "accounting", "standard", "that", "will", "require", "the", "presentation", "of", "certain", "unrecognized", "tax", "benefits", "as", "a", "reduction", "to", "deferred", "tax", "assets", "rather", "than", "as", "a", "liability", "when", "a", "net", "operating", "loss", "carryforward,", "a", "similar", "tax", "loss,", "or", "a", "tax", "credit", "carryforward", "exists."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item7_p9_s1", "idA": "906709_13_item7_p9_s3", "sentA": "The Phase 3 clinical program is expected to be initiated by Bayer in March 2013.", "sentB": "The molecule has been designed to have a slow rate of entry into the brain, which is expected to reduce the attractiveness of the molecule as a target of abuse and reduce other serious central nervous system-related side effects, such as sedation and respiratory depression, which are commonly associated with standard opioid therapies.", "type": 1, "words": ["<tag1>", "The", "Phase", "3", "clinical", "program", "is", "expected", "to", "be", "initiated", "by", "Bayer", "in", "March", "2013.", "<tag2>", "The", "molecule", "has", "been", "designed", "to", "have", "a", "slow", "rate", "of", "entry", "into", "the", "brain,", "which", "is", "expected", "to", "reduce", "the", "attractiveness", "of", "the", "molecule", "as", "a", "target", "of", "abuse", "and", "reduce", "other", "serious", "central", "nervous", "system-related", "side", "effects,", "such", "as", "sedation", "and", "respiratory", "depression,", "which", "are", "commonly", "associated", "with", "standard", "opioid", "therapies.", "<tag3>"], "wordsA": ["The", "Phase", "3", "clinical", "program", "is", "expected", "to", "be", "initiated", "by", "Bayer", "in", "March", "2013."], "wordsB": ["The", "molecule", "has", "been", "designed", "to", "have", "a", "slow", "rate", "of", "entry", "into", "the", "brain,", "which", "is", "expected", "to", "reduce", "the", "attractiveness", "of", "the", "molecule", "as", "a", "target", "of", "abuse", "and", "reduce", "other", "serious", "central", "nervous", "system-related", "side", "effects,", "such", "as", "sedation", "and", "respiratory", "depression,", "which", "are", "commonly", "associated", "with", "standard", "opioid", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p10_s3", "idA": "906709_14_item7_p10_s8", "sentA": "However, patients who were randomized to the placebo arm did not show the expected increase in pain scores observed in similar enriched enrollment, randomized withdrawal studies.", "sentB": "Baxter reported that the results demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding episodes and routine prophylaxis for patients who were 12 years or older.", "type": 1, "words": ["<tag1>", "However,", "patients", "who", "were", "randomized", "to", "the", "placebo", "arm", "did", "not", "show", "the", "expected", "increase", "in", "pain", "scores", "observed", "in", "similar", "enriched", "enrollment,", "randomized", "withdrawal", "studies.", "<tag2>", "Baxter", "reported", "that", "the", "results", "demonstrated", "that", "BAX", "855", "met", "its", "primary", "endpoint", "in", "the", "control", "and", "prevention", "of", "bleeding", "episodes", "and", "routine", "prophylaxis", "for", "patients", "who", "were", "12", "years", "or", "older.", "<tag3>"], "wordsA": ["However,", "patients", "who", "were", "randomized", "to", "the", "placebo", "arm", "did", "not", "show", "the", "expected", "increase", "in", "pain", "scores", "observed", "in", "similar", "enriched", "enrollment,", "randomized", "withdrawal", "studies."], "wordsB": ["Baxter", "reported", "that", "the", "results", "demonstrated", "that", "BAX", "855", "met", "its", "primary", "endpoint", "in", "the", "control", "and", "prevention", "of", "bleeding", "episodes", "and", "routine", "prophylaxis", "for", "patients", "who", "were", "12", "years", "or", "older."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p8_s11", "idA": "906709_14_item7_p11_s0", "sentA": "lack of a placebo rebound caused the Phase 2 study to miss the primary endpoint, which was the average change in a patient s pain score from baseline to the end of the double-blind, randomized treatment period.", "sentB": "The primary endpoint will be change in weekly pain score in the double-blind randomized period relative to the baseline pain score and the key secondary endpoints will include percentage of responders ( 30% reduction in pain score) and patient impression of change.", "type": 1, "words": ["<tag1>", "lack", "of", "a", "placebo", "rebound", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint,", "which", "was", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period.", "<tag2>", "The", "primary", "endpoint", "will", "be", "change", "in", "weekly", "pain", "score", "in", "the", "double-blind", "randomized", "period", "relative", "to", "the", "baseline", "pain", "score", "and", "the", "key", "secondary", "endpoints", "will", "include", "percentage", "of", "responders", "(", "30%", "reduction", "in", "pain", "score)", "and", "patient", "impression", "of", "change.", "<tag3>"], "wordsA": ["lack", "of", "a", "placebo", "rebound", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint,", "which", "was", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period."], "wordsB": ["The", "primary", "endpoint", "will", "be", "change", "in", "weekly", "pain", "score", "in", "the", "double-blind", "randomized", "period", "relative", "to", "the", "baseline", "pain", "score", "and", "the", "key", "secondary", "endpoints", "will", "include", "percentage", "of", "responders", "(", "30%", "reduction", "in", "pain", "score)", "and", "patient", "impression", "of", "change."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p11_s7", "idA": "906709_14_item7_p15_s0", "sentA": "If BAX 855 is approved by health authorities and is successfully commercialized by Baxter, this will represent a substantial royalty revenue opportunity for us, subject to significant risks and uncertainties relating to the outcome of the ongoing Phase 3 clinical study, the health authority regulatory review process, and if approved, subsequent commercial success.", "sentB": "These programs represent a significant future economic opportunity for us.", "type": 1, "words": ["<tag1>", "If", "BAX", "855", "is", "approved", "by", "health", "authorities", "and", "is", "successfully", "commercialized", "by", "Baxter,", "this", "will", "represent", "a", "substantial", "royalty", "revenue", "opportunity", "for", "us,", "subject", "to", "significant", "risks", "and", "uncertainties", "relating", "to", "the", "outcome", "of", "the", "ongoing", "Phase", "3", "clinical", "study,", "the", "health", "authority", "regulatory", "review", "process,", "and", "if", "approved,", "subsequent", "commercial", "success.", "<tag2>", "These", "programs", "represent", "a", "significant", "future", "economic", "opportunity", "for", "us.", "<tag3>"], "wordsA": ["If", "BAX", "855", "is", "approved", "by", "health", "authorities", "and", "is", "successfully", "commercialized", "by", "Baxter,", "this", "will", "represent", "a", "substantial", "royalty", "revenue", "opportunity", "for", "us,", "subject", "to", "significant", "risks", "and", "uncertainties", "relating", "to", "the", "outcome", "of", "the", "ongoing", "Phase", "3", "clinical", "study,", "the", "health", "authority", "regulatory", "review", "process,", "and", "if", "approved,", "subsequent", "commercial", "success."], "wordsB": ["These", "programs", "represent", "a", "significant", "future", "economic", "opportunity", "for", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p11_s13", "idA": "906709_14_item7_p23_s3", "sentA": "License, collaboration and other revenue for the year ended December 31, 2012 decreased compared to the year ended December 31, 2011 primarily due to the recognition in 2011 of a $5.0 million license fee from an agreement signed in September 2011.", "sentB": "NKTR-214 is engineered to selectively activate IL-2 receptors on cytotoxic T cells that kill tumor cells, with relatively low affinity for IL-2 receptors on regulatory T cells that dampen the immune response to tumors.", "type": 1, "words": ["<tag1>", "License,", "collaboration", "and", "other", "revenue", "for", "the", "year", "ended", "December", "31,", "2012", "decreased", "compared", "to", "the", "year", "ended", "December", "31,", "2011", "primarily", "due", "to", "the", "recognition", "in", "2011", "of", "a", "$5.0", "million", "license", "fee", "from", "an", "agreement", "signed", "in", "September", "2011.", "<tag2>", "NKTR-214", "is", "engineered", "to", "selectively", "activate", "IL-2", "receptors", "on", "cytotoxic", "T", "cells", "that", "kill", "tumor", "cells,", "with", "relatively", "low", "affinity", "for", "IL-2", "receptors", "on", "regulatory", "T", "cells", "that", "dampen", "the", "immune", "response", "to", "tumors.", "<tag3>"], "wordsA": ["License,", "collaboration", "and", "other", "revenue", "for", "the", "year", "ended", "December", "31,", "2012", "decreased", "compared", "to", "the", "year", "ended", "December", "31,", "2011", "primarily", "due", "to", "the", "recognition", "in", "2011", "of", "a", "$5.0", "million", "license", "fee", "from", "an", "agreement", "signed", "in", "September", "2011."], "wordsB": ["NKTR-214", "is", "engineered", "to", "selectively", "activate", "IL-2", "receptors", "on", "cytotoxic", "T", "cells", "that", "kill", "tumor", "cells,", "with", "relatively", "low", "affinity", "for", "IL-2", "receptors", "on", "regulatory", "T", "cells", "that", "dampen", "the", "immune", "response", "to", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p62_s0", "idA": "906709_14_item7_p25_s0", "sentA": "Revenue by geography Revenue by geographic area is based on locations of our partners.", "sentB": "Foreign Currency Risk The majority of our revenue, expense, and capital purchasing activities are transacted in U.S. dollars.", "type": 1, "words": ["<tag1>", "Revenue", "by", "geography", "Revenue", "by", "geographic", "area", "is", "based", "on", "locations", "of", "our", "partners.", "<tag2>", "Foreign", "Currency", "Risk", "The", "majority", "of", "our", "revenue,", "expense,", "and", "capital", "purchasing", "activities", "are", "transacted", "in", "U.S.", "dollars.", "<tag3>"], "wordsA": ["Revenue", "by", "geography", "Revenue", "by", "geographic", "area", "is", "based", "on", "locations", "of", "our", "partners."], "wordsB": ["Foreign", "Currency", "Risk", "The", "majority", "of", "our", "revenue,", "expense,", "and", "capital", "purchasing", "activities", "are", "transacted", "in", "U.S.", "dollars."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p8_s10", "idA": "906709_14_item7_p28_s1", "sentA": "Research and development expense also includes certain overhead allocations consisting of support and facilities-related costs.", "sentB": "The study design also includes a single interim analysis for sample size reassessment which will be conducted by an independent data monitoring committee.", "type": 1, "words": ["<tag1>", "Research", "and", "development", "expense", "also", "includes", "certain", "overhead", "allocations", "consisting", "of", "support", "and", "facilities-related", "costs.", "<tag2>", "The", "study", "design", "also", "includes", "a", "single", "interim", "analysis", "for", "sample", "size", "reassessment", "which", "will", "be", "conducted", "by", "an", "independent", "data", "monitoring", "committee.", "<tag3>"], "wordsA": ["Research", "and", "development", "expense", "also", "includes", "certain", "overhead", "allocations", "consisting", "of", "support", "and", "facilities-related", "costs."], "wordsB": ["The", "study", "design", "also", "includes", "a", "single", "interim", "analysis", "for", "sample", "size", "reassessment", "which", "will", "be", "conducted", "by", "an", "independent", "data", "monitoring", "committee."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p11_s5", "idA": "906709_14_item7_p31_s0", "sentA": "(3) We partnered this program with Bayer Healthcare LLC in August 2007.", "sentB": "The second is our significant royalty rights in Cipro DPI (Cipro Dry Powder Inhaler, previously called Cipro Inhale) program with Bayer that we transferred to Novartis as part of a 2008 asset divestiture transaction.", "type": 1, "words": ["<tag1>", "(3)", "We", "partnered", "this", "program", "with", "Bayer", "Healthcare", "LLC", "in", "August", "2007.", "<tag2>", "The", "second", "is", "our", "significant", "royalty", "rights", "in", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "a", "2008", "asset", "divestiture", "transaction.", "<tag3>"], "wordsA": ["(3)", "We", "partnered", "this", "program", "with", "Bayer", "Healthcare", "LLC", "in", "August", "2007."], "wordsB": ["The", "second", "is", "our", "significant", "royalty", "rights", "in", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "a", "2008", "asset", "divestiture", "transaction."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p59_s1", "idA": "906709_14_item7_p31_s2", "sentA": "We expect research and development expense to decrease in 2014 as compared to 2013 and to continue at or above the 2012 level.", "sentB": "ASU 2014-15 requires management to evaluate whether there is substantial doubt about an entity s ability to continue as a going concern and to provide related footnote disclosures.", "type": 1, "words": ["<tag1>", "We", "expect", "research", "and", "development", "expense", "to", "decrease", "in", "2014", "as", "compared", "to", "2013", "and", "to", "continue", "at", "or", "above", "the", "2012", "level.", "<tag2>", "ASU", "2014-15", "requires", "management", "to", "evaluate", "whether", "there", "is", "substantial", "doubt", "about", "an", "entity", "s", "ability", "to", "continue", "as", "a", "going", "concern", "and", "to", "provide", "related", "footnote", "disclosures.", "<tag3>"], "wordsA": ["We", "expect", "research", "and", "development", "expense", "to", "decrease", "in", "2014", "as", "compared", "to", "2013", "and", "to", "continue", "at", "or", "above", "the", "2012", "level."], "wordsB": ["ASU", "2014-15", "requires", "management", "to", "evaluate", "whether", "there", "is", "substantial", "doubt", "about", "an", "entity", "s", "ability", "to", "continue", "as", "a", "going", "concern", "and", "to", "provide", "related", "footnote", "disclosures."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p17_s0", "idA": "906709_14_item7_p31_s3", "sentA": "We plan to continue to advance etirinotecan pegol in the Phase 3 BEACON study for metastatic breast cancer for which we expect the clinical study to continue through early 2015.", "sentB": "AstraZeneca is planning the commercial launch of MOVANTIK in the U.S. late in the first quarter of 2015 and MOVENTIG in the EU in the second half of 2015.", "type": 1, "words": ["<tag1>", "We", "plan", "to", "continue", "to", "advance", "etirinotecan", "pegol", "in", "the", "Phase", "3", "BEACON", "study", "for", "metastatic", "breast", "cancer", "for", "which", "we", "expect", "the", "clinical", "study", "to", "continue", "through", "early", "2015.", "<tag2>", "AstraZeneca", "is", "planning", "the", "commercial", "launch", "of", "MOVANTIK", "in", "the", "U.S.", "late", "in", "the", "first", "quarter", "of", "2015", "and", "MOVENTIG", "in", "the", "EU", "in", "the", "second", "half", "of", "2015.", "<tag3>"], "wordsA": ["We", "plan", "to", "continue", "to", "advance", "etirinotecan", "pegol", "in", "the", "Phase", "3", "BEACON", "study", "for", "metastatic", "breast", "cancer", "for", "which", "we", "expect", "the", "clinical", "study", "to", "continue", "through", "early", "2015."], "wordsB": ["AstraZeneca", "is", "planning", "the", "commercial", "launch", "of", "MOVANTIK", "in", "the", "U.S.", "late", "in", "the", "first", "quarter", "of", "2015", "and", "MOVENTIG", "in", "the", "EU", "in", "the", "second", "half", "of", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p8_s9", "idA": "906709_14_item7_p31_s9", "sentA": "In addition, we plan to continue to make substantial investments to support the clinical and commercial manufacturing preparation and scale-up for the nebulizer devices to supply Bayer for the Amikacin Inhale program.", "sentB": "In this first efficacy study, we plan to enroll approximately 416 patients in an enriched enrollment randomized withdrawal design which will include a qualifying screening period, an open-label titration period where NKTR-181 is given to all patients, followed by a 12 week double-blind randomized period where subjects will be randomized on a 1:1 basis to receive either NKTR-181 or placebo.", "type": 1, "words": ["<tag1>", "In", "addition,", "we", "plan", "to", "continue", "to", "make", "substantial", "investments", "to", "support", "the", "clinical", "and", "commercial", "manufacturing", "preparation", "and", "scale-up", "for", "the", "nebulizer", "devices", "to", "supply", "Bayer", "for", "the", "Amikacin", "Inhale", "program.", "<tag2>", "In", "this", "first", "efficacy", "study,", "we", "plan", "to", "enroll", "approximately", "416", "patients", "in", "an", "enriched", "enrollment", "randomized", "withdrawal", "design", "which", "will", "include", "a", "qualifying", "screening", "period,", "an", "open-label", "titration", "period", "where", "NKTR-181", "is", "given", "to", "all", "patients,", "followed", "by", "a", "12", "week", "double-blind", "randomized", "period", "where", "subjects", "will", "be", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "NKTR-181", "or", "placebo.", "<tag3>"], "wordsA": ["In", "addition,", "we", "plan", "to", "continue", "to", "make", "substantial", "investments", "to", "support", "the", "clinical", "and", "commercial", "manufacturing", "preparation", "and", "scale-up", "for", "the", "nebulizer", "devices", "to", "supply", "Bayer", "for", "the", "Amikacin", "Inhale", "program."], "wordsB": ["In", "this", "first", "efficacy", "study,", "we", "plan", "to", "enroll", "approximately", "416", "patients", "in", "an", "enriched", "enrollment", "randomized", "withdrawal", "design", "which", "will", "include", "a", "qualifying", "screening", "period,", "an", "open-label", "titration", "period", "where", "NKTR-181", "is", "given", "to", "all", "patients,", "followed", "by", "a", "12", "week", "double-blind", "randomized", "period", "where", "subjects", "will", "be", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "NKTR-181", "or", "placebo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p60_s1", "idA": "906709_14_item7_p40_s10", "sentA": "Due to the potential for continued uncertainty in the credit markets in 2014 and thereafter, we may experience reduced liquidity with respect to some of our investments in marketable securities.", "sentB": "To achieve this objective, we invest in liquid, high quality debt securities.", "type": 1, "words": ["<tag1>", "Due", "to", "the", "potential", "for", "continued", "uncertainty", "in", "the", "credit", "markets", "in", "2014", "and", "thereafter,", "we", "may", "experience", "reduced", "liquidity", "with", "respect", "to", "some", "of", "our", "investments", "in", "marketable", "securities.", "<tag2>", "To", "achieve", "this", "objective,", "we", "invest", "in", "liquid,", "high", "quality", "debt", "securities.", "<tag3>"], "wordsA": ["Due", "to", "the", "potential", "for", "continued", "uncertainty", "in", "the", "credit", "markets", "in", "2014", "and", "thereafter,", "we", "may", "experience", "reduced", "liquidity", "with", "respect", "to", "some", "of", "our", "investments", "in", "marketable", "securities."], "wordsB": ["To", "achieve", "this", "objective,", "we", "invest", "in", "liquid,", "high", "quality", "debt", "securities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p61_s0", "idA": "906709_14_item7_p40_s13", "sentA": "At December 31, 2013, the average time to maturity of the investments held in our portfolio was approximately five months and the maturity of any single investment did not exceed one year.", "sentB": "exposure due to an adverse shift in interest rates, we invest in short-term securities and maintain a weighted average maturity of one year or less.", "type": 1, "words": ["<tag1>", "At", "December", "31,", "2013,", "the", "average", "time", "to", "maturity", "of", "the", "investments", "held", "in", "our", "portfolio", "was", "approximately", "five", "months", "and", "the", "maturity", "of", "any", "single", "investment", "did", "not", "exceed", "one", "year.", "<tag2>", "exposure", "due", "to", "an", "adverse", "shift", "in", "interest", "rates,", "we", "invest", "in", "short-term", "securities", "and", "maintain", "a", "weighted", "average", "maturity", "of", "one", "year", "or", "less.", "<tag3>"], "wordsA": ["At", "December", "31,", "2013,", "the", "average", "time", "to", "maturity", "of", "the", "investments", "held", "in", "our", "portfolio", "was", "approximately", "five", "months", "and", "the", "maturity", "of", "any", "single", "investment", "did", "not", "exceed", "one", "year."], "wordsB": ["exposure", "due", "to", "an", "adverse", "shift", "in", "interest", "rates,", "we", "invest", "in", "short-term", "securities", "and", "maintain", "a", "weighted", "average", "maturity", "of", "one", "year", "or", "less."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p61_s7", "idA": "906709_14_item7_p40_s14", "sentA": "To date we have not experienced any liquidity issues with respect to these securities, but if such issues arise, we may be required to hold some, or all, of these securities until maturity.", "sentB": "Based on our available cash and our expected operating cash requirements, we currently do not intend to sell these securities prior to maturity and it is more likely than not that we will not be required to sell these securities before we recover the amortized cost basis.", "type": 1, "words": ["<tag1>", "To", "date", "we", "have", "not", "experienced", "any", "liquidity", "issues", "with", "respect", "to", "these", "securities,", "but", "if", "such", "issues", "arise,", "we", "may", "be", "required", "to", "hold", "some,", "or", "all,", "of", "these", "securities", "until", "maturity.", "<tag2>", "Based", "on", "our", "available", "cash", "and", "our", "expected", "operating", "cash", "requirements,", "we", "currently", "do", "not", "intend", "to", "sell", "these", "securities", "prior", "to", "maturity", "and", "it", "is", "more", "likely", "than", "not", "that", "we", "will", "not", "be", "required", "to", "sell", "these", "securities", "before", "we", "recover", "the", "amortized", "cost", "basis.", "<tag3>"], "wordsA": ["To", "date", "we", "have", "not", "experienced", "any", "liquidity", "issues", "with", "respect", "to", "these", "securities,", "but", "if", "such", "issues", "arise,", "we", "may", "be", "required", "to", "hold", "some,", "or", "all,", "of", "these", "securities", "until", "maturity."], "wordsB": ["Based", "on", "our", "available", "cash", "and", "our", "expected", "operating", "cash", "requirements,", "we", "currently", "do", "not", "intend", "to", "sell", "these", "securities", "prior", "to", "maturity", "and", "it", "is", "more", "likely", "than", "not", "that", "we", "will", "not", "be", "required", "to", "sell", "these", "securities", "before", "we", "recover", "the", "amortized", "cost", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p61_s8", "idA": "906709_14_item7_p40_s14", "sentA": "To date we have not experienced any liquidity issues with respect to these securities, but if such issues arise, we may be required to hold some, or all, of these securities until maturity.", "sentB": "Accordingly, we believe there are no other-than-temporary impairments on these securities and have not recorded any provisions for impairment.", "type": 1, "words": ["<tag1>", "To", "date", "we", "have", "not", "experienced", "any", "liquidity", "issues", "with", "respect", "to", "these", "securities,", "but", "if", "such", "issues", "arise,", "we", "may", "be", "required", "to", "hold", "some,", "or", "all,", "of", "these", "securities", "until", "maturity.", "<tag2>", "Accordingly,", "we", "believe", "there", "are", "no", "other-than-temporary", "impairments", "on", "these", "securities", "and", "have", "not", "recorded", "any", "provisions", "for", "impairment.", "<tag3>"], "wordsA": ["To", "date", "we", "have", "not", "experienced", "any", "liquidity", "issues", "with", "respect", "to", "these", "securities,", "but", "if", "such", "issues", "arise,", "we", "may", "be", "required", "to", "hold", "some,", "or", "all,", "of", "these", "securities", "until", "maturity."], "wordsB": ["Accordingly,", "we", "believe", "there", "are", "no", "other-than-temporary", "impairments", "on", "these", "securities", "and", "have", "not", "recorded", "any", "provisions", "for", "impairment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p6_s5", "idA": "906709_14_item7_p42_s9", "sentA": "In addition, $25.0 million of the proceeds from the senior secured notes issuance is required to be maintained in a restricted account until July 1, 2015.", "sentB": "We are now conducting blinded data verification activities and currently plan to unblind and announce the top-line data from the BEACON Study in March 2015.", "type": 1, "words": ["<tag1>", "In", "addition,", "$25.0", "million", "of", "the", "proceeds", "from", "the", "senior", "secured", "notes", "issuance", "is", "required", "to", "be", "maintained", "in", "a", "restricted", "account", "until", "July", "1,", "2015.", "<tag2>", "We", "are", "now", "conducting", "blinded", "data", "verification", "activities", "and", "currently", "plan", "to", "unblind", "and", "announce", "the", "top-line", "data", "from", "the", "BEACON", "Study", "in", "March", "2015.", "<tag3>"], "wordsA": ["In", "addition,", "$25.0", "million", "of", "the", "proceeds", "from", "the", "senior", "secured", "notes", "issuance", "is", "required", "to", "be", "maintained", "in", "a", "restricted", "account", "until", "July", "1,", "2015."], "wordsB": ["We", "are", "now", "conducting", "blinded", "data", "verification", "activities", "and", "currently", "plan", "to", "unblind", "and", "announce", "the", "top-line", "data", "from", "the", "BEACON", "Study", "in", "March", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p7_s2", "idA": "906709_14_item7_p48_s0", "sentA": "We do not utilize off-balance sheet financing arrangements as a source of liquidity or financing.", "sentB": "Its potential differentiating properties are inherent to its molecular design and, as a new molecular structure, NKTR-181 s potential abuse deterrent properties do not rely on a formulation approach, a common method used with opioid drugs to reduce their ease of conversion into abusable forms of an opioid.", "type": 1, "words": ["<tag1>", "We", "do", "not", "utilize", "off-balance", "sheet", "financing", "arrangements", "as", "a", "source", "of", "liquidity", "or", "financing.", "<tag2>", "Its", "potential", "differentiating", "properties", "are", "inherent", "to", "its", "molecular", "design", "and,", "as", "a", "new", "molecular", "structure,", "NKTR-181", "s", "potential", "abuse", "deterrent", "properties", "do", "not", "rely", "on", "a", "formulation", "approach,", "a", "common", "method", "used", "with", "opioid", "drugs", "to", "reduce", "their", "ease", "of", "conversion", "into", "abusable", "forms", "of", "an", "opioid.", "<tag3>"], "wordsA": ["We", "do", "not", "utilize", "off-balance", "sheet", "financing", "arrangements", "as", "a", "source", "of", "liquidity", "or", "financing."], "wordsB": ["Its", "potential", "differentiating", "properties", "are", "inherent", "to", "its", "molecular", "design", "and,", "as", "a", "new", "molecular", "structure,", "NKTR-181", "s", "potential", "abuse", "deterrent", "properties", "do", "not", "rely", "on", "a", "formulation", "approach,", "a", "common", "method", "used", "with", "opioid", "drugs", "to", "reduce", "their", "ease", "of", "conversion", "into", "abusable", "forms", "of", "an", "opioid."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p2_s4", "idA": "906709_14_item7_p52_s1", "sentA": "Management makes its best estimate of the period over which we expect to fulfill our performance obligations, which may include technology transfer assistance, clinical development activities, or manufacturing activities through the completion of clinical development or the termination or expiration of the collaboration agreement.", "sentB": "MOVANTIK was developed using our oral small molecule polymer conjugate technology and we advanced this drug through the completion of Phase 2 clinical studies prior to licensing it to AstraZeneca.", "type": 1, "words": ["<tag1>", "Management", "makes", "its", "best", "estimate", "of", "the", "period", "over", "which", "we", "expect", "to", "fulfill", "our", "performance", "obligations,", "which", "may", "include", "technology", "transfer", "assistance,", "clinical", "development", "activities,", "or", "manufacturing", "activities", "through", "the", "completion", "of", "clinical", "development", "or", "the", "termination", "or", "expiration", "of", "the", "collaboration", "agreement.", "<tag2>", "MOVANTIK", "was", "developed", "using", "our", "oral", "small", "molecule", "polymer", "conjugate", "technology", "and", "we", "advanced", "this", "drug", "through", "the", "completion", "of", "Phase", "2", "clinical", "studies", "prior", "to", "licensing", "it", "to", "AstraZeneca.", "<tag3>"], "wordsA": ["Management", "makes", "its", "best", "estimate", "of", "the", "period", "over", "which", "we", "expect", "to", "fulfill", "our", "performance", "obligations,", "which", "may", "include", "technology", "transfer", "assistance,", "clinical", "development", "activities,", "or", "manufacturing", "activities", "through", "the", "completion", "of", "clinical", "development", "or", "the", "termination", "or", "expiration", "of", "the", "collaboration", "agreement."], "wordsB": ["MOVANTIK", "was", "developed", "using", "our", "oral", "small", "molecule", "polymer", "conjugate", "technology", "and", "we", "advanced", "this", "drug", "through", "the", "completion", "of", "Phase", "2", "clinical", "studies", "prior", "to", "licensing", "it", "to", "AstraZeneca."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p3_s2", "idA": "906709_14_item7_p55_s6", "sentA": "In addition, at the inception of each new multiple-element arrangement or the material modification of an existing multiple-element arrangement, we allocate arrangement consideration to all units of accounting based on the relative selling price method, generally based on our best estimate of selling price (ESP).", "sentB": "The EC s approval applies to all 28 European Union member countries plus Iceland and Norway.", "type": 1, "words": ["<tag1>", "In", "addition,", "at", "the", "inception", "of", "each", "new", "multiple-element", "arrangement", "or", "the", "material", "modification", "of", "an", "existing", "multiple-element", "arrangement,", "we", "allocate", "arrangement", "consideration", "to", "all", "units", "of", "accounting", "based", "on", "the", "relative", "selling", "price", "method,", "generally", "based", "on", "our", "best", "estimate", "of", "selling", "price", "(ESP).", "<tag2>", "The", "EC", "s", "approval", "applies", "to", "all", "28", "European", "Union", "member", "countries", "plus", "Iceland", "and", "Norway.", "<tag3>"], "wordsA": ["In", "addition,", "at", "the", "inception", "of", "each", "new", "multiple-element", "arrangement", "or", "the", "material", "modification", "of", "an", "existing", "multiple-element", "arrangement,", "we", "allocate", "arrangement", "consideration", "to", "all", "units", "of", "accounting", "based", "on", "the", "relative", "selling", "price", "method,", "generally", "based", "on", "our", "best", "estimate", "of", "selling", "price", "(ESP)."], "wordsB": ["The", "EC", "s", "approval", "applies", "to", "all", "28", "European", "Union", "member", "countries", "plus", "Iceland", "and", "Norway."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p60_s0", "idA": "906709_14_item7_p55_s7", "sentA": "The objective of ESP is to determine the price at which we would transact a sale if the product or service was sold on a stand-alone basis.", "sentB": "The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk.", "type": 1, "words": ["<tag1>", "The", "objective", "of", "ESP", "is", "to", "determine", "the", "price", "at", "which", "we", "would", "transact", "a", "sale", "if", "the", "product", "or", "service", "was", "sold", "on", "a", "stand-alone", "basis.", "<tag2>", "The", "primary", "objective", "of", "our", "investment", "activities", "is", "to", "preserve", "principal", "while", "at", "the", "same", "time", "maximizing", "yields", "without", "significantly", "increasing", "risk.", "<tag3>"], "wordsA": ["The", "objective", "of", "ESP", "is", "to", "determine", "the", "price", "at", "which", "we", "would", "transact", "a", "sale", "if", "the", "product", "or", "service", "was", "sold", "on", "a", "stand-alone", "basis."], "wordsB": ["The", "primary", "objective", "of", "our", "investment", "activities", "is", "to", "preserve", "principal", "while", "at", "the", "same", "time", "maximizing", "yields", "without", "significantly", "increasing", "risk."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p4_s0", "idA": "906709_14_item7_p57_s0", "sentA": "We generally accrue costs associated with the treatment phase of clinical studies based on the total estimated cost of the treatment phase on a per patient basis and we expense the per patient cost ratably based on patient enrollment in the studies.", "sentB": "On January 23, 2015, the DEA published the final rule in the Federal Register, effective immediately on the date it was published, removing naloxegol and its salts from the schedules of the Controlled Substances Act.", "type": 1, "words": ["<tag1>", "We", "generally", "accrue", "costs", "associated", "with", "the", "treatment", "phase", "of", "clinical", "studies", "based", "on", "the", "total", "estimated", "cost", "of", "the", "treatment", "phase", "on", "a", "per", "patient", "basis", "and", "we", "expense", "the", "per", "patient", "cost", "ratably", "based", "on", "patient", "enrollment", "in", "the", "studies.", "<tag2>", "On", "January", "23,", "2015,", "the", "DEA", "published", "the", "final", "rule", "in", "the", "Federal", "Register,", "effective", "immediately", "on", "the", "date", "it", "was", "published,", "removing", "naloxegol", "and", "its", "salts", "from", "the", "schedules", "of", "the", "Controlled", "Substances", "Act.", "<tag3>"], "wordsA": ["We", "generally", "accrue", "costs", "associated", "with", "the", "treatment", "phase", "of", "clinical", "studies", "based", "on", "the", "total", "estimated", "cost", "of", "the", "treatment", "phase", "on", "a", "per", "patient", "basis", "and", "we", "expense", "the", "per", "patient", "cost", "ratably", "based", "on", "patient", "enrollment", "in", "the", "studies."], "wordsB": ["On", "January", "23,", "2015,", "the", "DEA", "published", "the", "final", "rule", "in", "the", "Federal", "Register,", "effective", "immediately", "on", "the", "date", "it", "was", "published,", "removing", "naloxegol", "and", "its", "salts", "from", "the", "schedules", "of", "the", "Controlled", "Substances", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p58_s0", "idA": "906709_14_item7_p64_s0", "sentA": "In July 2013, the Financial Accounting Standards Board issued a new accounting standard that will require the presentation of certain unrecognized tax benefits as a reduction to deferred tax assets rather than as a liability when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists.", "sentB": "In May 2014, the Financial Accounting Standards Board (FASB) issued guidance codified in ASC 606, Revenue Recognition Revenue from Contracts with Customers , which amends the guidance in former ASC 605, Revenue Recognition, and is effective for public companies for fiscal years beginning after December 15, 2016.", "type": 1, "words": ["<tag1>", "In", "July", "2013,", "the", "Financial", "Accounting", "Standards", "Board", "issued", "a", "new", "accounting", "standard", "that", "will", "require", "the", "presentation", "of", "certain", "unrecognized", "tax", "benefits", "as", "a", "reduction", "to", "deferred", "tax", "assets", "rather", "than", "as", "a", "liability", "when", "a", "net", "operating", "loss", "carryforward,", "a", "similar", "tax", "loss,", "or", "a", "tax", "credit", "carryforward", "exists.", "<tag2>", "In", "May", "2014,", "the", "Financial", "Accounting", "Standards", "Board", "(FASB)", "issued", "guidance", "codified", "in", "ASC", "606,", "Revenue", "Recognition", "Revenue", "from", "Contracts", "with", "Customers", ",", "which", "amends", "the", "guidance", "in", "former", "ASC", "605,", "Revenue", "Recognition,", "and", "is", "effective", "for", "public", "companies", "for", "fiscal", "years", "beginning", "after", "December", "15,", "2016.", "<tag3>"], "wordsA": ["In", "July", "2013,", "the", "Financial", "Accounting", "Standards", "Board", "issued", "a", "new", "accounting", "standard", "that", "will", "require", "the", "presentation", "of", "certain", "unrecognized", "tax", "benefits", "as", "a", "reduction", "to", "deferred", "tax", "assets", "rather", "than", "as", "a", "liability", "when", "a", "net", "operating", "loss", "carryforward,", "a", "similar", "tax", "loss,", "or", "a", "tax", "credit", "carryforward", "exists."], "wordsB": ["In", "May", "2014,", "the", "Financial", "Accounting", "Standards", "Board", "(FASB)", "issued", "guidance", "codified", "in", "ASC", "606,", "Revenue", "Recognition", "Revenue", "from", "Contracts", "with", "Customers", ",", "which", "amends", "the", "guidance", "in", "former", "ASC", "605,", "Revenue", "Recognition,", "and", "is", "effective", "for", "public", "companies", "for", "fiscal", "years", "beginning", "after", "December", "15,", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p59_s0", "idA": "906709_14_item7_p64_s0", "sentA": "In July 2013, the Financial Accounting Standards Board issued a new accounting standard that will require the presentation of certain unrecognized tax benefits as a reduction to deferred tax assets rather than as a liability when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists.", "sentB": "In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity s Ability to Continue as a Going Concern (ASU 2014-15).", "type": 1, "words": ["<tag1>", "In", "July", "2013,", "the", "Financial", "Accounting", "Standards", "Board", "issued", "a", "new", "accounting", "standard", "that", "will", "require", "the", "presentation", "of", "certain", "unrecognized", "tax", "benefits", "as", "a", "reduction", "to", "deferred", "tax", "assets", "rather", "than", "as", "a", "liability", "when", "a", "net", "operating", "loss", "carryforward,", "a", "similar", "tax", "loss,", "or", "a", "tax", "credit", "carryforward", "exists.", "<tag2>", "In", "August", "2014,", "the", "FASB", "issued", "Accounting", "Standards", "Update", "No.", "2014-15,", "Disclosure", "of", "Uncertainties", "about", "an", "Entity", "s", "Ability", "to", "Continue", "as", "a", "Going", "Concern", "(ASU", "2014-15).", "<tag3>"], "wordsA": ["In", "July", "2013,", "the", "Financial", "Accounting", "Standards", "Board", "issued", "a", "new", "accounting", "standard", "that", "will", "require", "the", "presentation", "of", "certain", "unrecognized", "tax", "benefits", "as", "a", "reduction", "to", "deferred", "tax", "assets", "rather", "than", "as", "a", "liability", "when", "a", "net", "operating", "loss", "carryforward,", "a", "similar", "tax", "loss,", "or", "a", "tax", "credit", "carryforward", "exists."], "wordsB": ["In", "August", "2014,", "the", "FASB", "issued", "Accounting", "Standards", "Update", "No.", "2014-15,", "Disclosure", "of", "Uncertainties", "about", "an", "Entity", "s", "Ability", "to", "Continue", "as", "a", "Going", "Concern", "(ASU", "2014-15)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item7_p59_s2", "idA": "906709_14_item7_p64_s1", "sentA": "This guidance is effective for our interim and annual periods beginning January 1, 2014.", "sentB": "ASU 2014-15 is effective in 2016 with early adoption permitted.", "type": 1, "words": ["<tag1>", "This", "guidance", "is", "effective", "for", "our", "interim", "and", "annual", "periods", "beginning", "January", "1,", "2014.", "<tag2>", "ASU", "2014-15", "is", "effective", "in", "2016", "with", "early", "adoption", "permitted.", "<tag3>"], "wordsA": ["This", "guidance", "is", "effective", "for", "our", "interim", "and", "annual", "periods", "beginning", "January", "1,", "2014."], "wordsB": ["ASU", "2014-15", "is", "effective", "in", "2016", "with", "early", "adoption", "permitted."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item7_p8_s2", "idA": "906709_15_item7_p0_s2", "sentA": "Our research and development activities involve small molecule drugs, peptides and other biologic drug candidates.", "sentB": "The immunologic effect of NKTR-214 on tumor-infiltrati ng lymphocytes and other immune infiltrating cells in both blood and tumor tissue will also be assessed.", "type": 1, "words": ["<tag1>", "Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "biologic", "drug", "candidates.", "<tag2>", "The", "immunologic", "effect", "of", "NKTR-214", "on", "tumor-infiltrati", "ng", "lymphocytes", "and", "other", "immune", "infiltrating", "cells", "in", "both", "blood", "and", "tumor", "tissue", "will", "also", "be", "assessed.", "<tag3>"], "wordsA": ["Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "biologic", "drug", "candidates."], "wordsB": ["The", "immunologic", "effect", "of", "NKTR-214", "on", "tumor-infiltrati", "ng", "lymphocytes", "and", "other", "immune", "infiltrating", "cells", "in", "both", "blood", "and", "tumor", "tissue", "will", "also", "be", "assessed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item7_p3_s2", "idA": "906709_15_item7_p10_s1", "sentA": "In December 2014, Baxter announced that it filed a biologic license application with the FDA for BAX 855.", "sentB": "In November 2015, ADYNOVATE TM was approved by the FDA for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. Baxalta announced the launch and first shipments of ADYNOVATE TM on November 30, 2015.", "type": 1, "words": ["<tag1>", "In", "December", "2014,", "Baxter", "announced", "that", "it", "filed", "a", "biologic", "license", "application", "with", "the", "FDA", "for", "BAX", "855.", "<tag2>", "In", "November", "2015,", "ADYNOVATE", "TM", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "Baxalta", "announced", "the", "launch", "and", "first", "shipments", "of", "ADYNOVATE", "TM", "on", "November", "30,", "2015.", "<tag3>"], "wordsA": ["In", "December", "2014,", "Baxter", "announced", "that", "it", "filed", "a", "biologic", "license", "application", "with", "the", "FDA", "for", "BAX", "855."], "wordsB": ["In", "November", "2015,", "ADYNOVATE", "TM", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "Baxalta", "announced", "the", "launch", "and", "first", "shipments", "of", "ADYNOVATE", "TM", "on", "November", "30,", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item7_p4_s0", "idA": "906709_15_item7_p11_s3", "sentA": "Bayer is currently enrolling patients in a Phase 3 clinical study for Amikacin Inhale.", "sentB": "ADYNOVATE TM is currently under regulatory review in Japan, Canada and Switzerland.", "type": 1, "words": ["<tag1>", "Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "study", "for", "Amikacin", "Inhale.", "<tag2>", "ADYNOVATE", "TM", "is", "currently", "under", "regulatory", "review", "in", "Japan,", "Canada", "and", "Switzerland.", "<tag3>"], "wordsA": ["Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "study", "for", "Amikacin", "Inhale."], "wordsB": ["ADYNOVATE", "TM", "is", "currently", "under", "regulatory", "review", "in", "Japan,", "Canada", "and", "Switzerland."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item7_p16_s7", "idA": "906709_15_item7_p17_s11", "sentA": "In addition, in April 2013, we recognized a $10.0 million milestone achieved upon the start of the Amikacin Inhale Phase 3 clinical trial by Bayer.", "sentB": "We determined that this $10.0 million obligation should be recorded as a reduction of revenue, which we recorded in 2015.", "type": 1, "words": ["<tag1>", "In", "addition,", "in", "April", "2013,", "we", "recognized", "a", "$10.0", "million", "milestone", "achieved", "upon", "the", "start", "of", "the", "Amikacin", "Inhale", "Phase", "3", "clinical", "trial", "by", "Bayer.", "<tag2>", "We", "determined", "that", "this", "$10.0", "million", "obligation", "should", "be", "recorded", "as", "a", "reduction", "of", "revenue,", "which", "we", "recorded", "in", "2015.", "<tag3>"], "wordsA": ["In", "addition,", "in", "April", "2013,", "we", "recognized", "a", "$10.0", "million", "milestone", "achieved", "upon", "the", "start", "of", "the", "Amikacin", "Inhale", "Phase", "3", "clinical", "trial", "by", "Bayer."], "wordsB": ["We", "determined", "that", "this", "$10.0", "million", "obligation", "should", "be", "recorded", "as", "a", "reduction", "of", "revenue,", "which", "we", "recorded", "in", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item7_p39_s2", "idA": "906709_15_item7_p19_s0", "sentA": "Revenue by geography Revenue by geographic area is based on locations of our partners.", "sentB": "Interest is calculated based on actual days outstanding over a 360 day year.", "type": 1, "words": ["<tag1>", "Revenue", "by", "geography", "Revenue", "by", "geographic", "area", "is", "based", "on", "locations", "of", "our", "partners.", "<tag2>", "Interest", "is", "calculated", "based", "on", "actual", "days", "outstanding", "over", "a", "360", "day", "year.", "<tag3>"], "wordsA": ["Revenue", "by", "geography", "Revenue", "by", "geographic", "area", "is", "based", "on", "locations", "of", "our", "partners."], "wordsB": ["Interest", "is", "calculated", "based", "on", "actual", "days", "outstanding", "over", "a", "360", "day", "year."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item7_p6_s3", "idA": "906709_15_item7_p32_s2", "sentA": "We expect interest expense to increase slightly in 2015 compared to 2014.", "sentB": "On February 29, 2016, the IAC instructed Nektar to increase the sample size by about 200 patients.", "type": 1, "words": ["<tag1>", "We", "expect", "interest", "expense", "to", "increase", "slightly", "in", "2015", "compared", "to", "2014.", "<tag2>", "On", "February", "29,", "2016,", "the", "IAC", "instructed", "Nektar", "to", "increase", "the", "sample", "size", "by", "about", "200", "patients.", "<tag3>"], "wordsA": ["We", "expect", "interest", "expense", "to", "increase", "slightly", "in", "2015", "compared", "to", "2014."], "wordsB": ["On", "February", "29,", "2016,", "the", "IAC", "instructed", "Nektar", "to", "increase", "the", "sample", "size", "by", "about", "200", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item7_p9_s3", "idA": "906709_15_item7_p32_s2", "sentA": "We expect interest expense to increase slightly in 2015 compared to 2014.", "sentB": "In a topline analysis of 852 patients from the trial, NKTR-102 provided a 2.1 month improvement in median overall survival (OS) over TPC (12.4 months for patients receiving NKTR-102 compared to 10.3 months for patients receiving TPC).", "type": 1, "words": ["<tag1>", "We", "expect", "interest", "expense", "to", "increase", "slightly", "in", "2015", "compared", "to", "2014.", "<tag2>", "In", "a", "topline", "analysis", "of", "852", "patients", "from", "the", "trial,", "NKTR-102", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "(OS)", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "NKTR-102", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC).", "<tag3>"], "wordsA": ["We", "expect", "interest", "expense", "to", "increase", "slightly", "in", "2015", "compared", "to", "2014."], "wordsB": ["In", "a", "topline", "analysis", "of", "852", "patients", "from", "the", "trial,", "NKTR-102", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "(OS)", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "NKTR-102", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item7_p6_s1", "idA": "906709_15_item7_p32_s7", "sentA": "We impute interest on the transaction and record interest expense at the effective interest rate, which we currently estimate to be approximately 17%.", "sentB": "The protocol of the NKTR-181 study defined only two possible outcomes for this pre-planned blinded interim sample size assessment: (1) if the conditional powering at the midpoint of the trial fell between 50-85%, the sample size was to be increased by about 200 patients; or (2) if the conditional powering fell below 50%, or above 85%, the sample size was not to be changed.", "type": 1, "words": ["<tag1>", "We", "impute", "interest", "on", "the", "transaction", "and", "record", "interest", "expense", "at", "the", "effective", "interest", "rate,", "which", "we", "currently", "estimate", "to", "be", "approximately", "17%.", "<tag2>", "The", "protocol", "of", "the", "NKTR-181", "study", "defined", "only", "two", "possible", "outcomes", "for", "this", "pre-planned", "blinded", "interim", "sample", "size", "assessment:", "(1)", "if", "the", "conditional", "powering", "at", "the", "midpoint", "of", "the", "trial", "fell", "between", "50-85%,", "the", "sample", "size", "was", "to", "be", "increased", "by", "about", "200", "patients;", "or", "(2)", "if", "the", "conditional", "powering", "fell", "below", "50%,", "or", "above", "85%,", "the", "sample", "size", "was", "not", "to", "be", "changed.", "<tag3>"], "wordsA": ["We", "impute", "interest", "on", "the", "transaction", "and", "record", "interest", "expense", "at", "the", "effective", "interest", "rate,", "which", "we", "currently", "estimate", "to", "be", "approximately", "17%."], "wordsB": ["The", "protocol", "of", "the", "NKTR-181", "study", "defined", "only", "two", "possible", "outcomes", "for", "this", "pre-planned", "blinded", "interim", "sample", "size", "assessment:", "(1)", "if", "the", "conditional", "powering", "at", "the", "midpoint", "of", "the", "trial", "fell", "between", "50-85%,", "the", "sample", "size", "was", "to", "be", "increased", "by", "about", "200", "patients;", "or", "(2)", "if", "the", "conditional", "powering", "fell", "below", "50%,", "or", "above", "85%,", "the", "sample", "size", "was", "not", "to", "be", "changed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item7_p39_s6", "idA": "906709_15_item7_p35_s4", "sentA": "Cash flows used in operating activities for the year ended December 31, 2012 totaled $129.8 million, which includes $148.3 million of net operating cash uses, partially offset by the receipt of $18.5 million from collaboration agreements.", "sentB": "In addition, on October 5, 2015, we paid accrued interest of $3.3 million and made a $12.5 million redemption payment, which includes $1.2 million additional interest paid to the 12% note holders at redemption.", "type": 1, "words": ["<tag1>", "Cash", "flows", "used", "in", "operating", "activities", "for", "the", "year", "ended", "December", "31,", "2012", "totaled", "$129.8", "million,", "which", "includes", "$148.3", "million", "of", "net", "operating", "cash", "uses,", "partially", "offset", "by", "the", "receipt", "of", "$18.5", "million", "from", "collaboration", "agreements.", "<tag2>", "In", "addition,", "on", "October", "5,", "2015,", "we", "paid", "accrued", "interest", "of", "$3.3", "million", "and", "made", "a", "$12.5", "million", "redemption", "payment,", "which", "includes", "$1.2", "million", "additional", "interest", "paid", "to", "the", "12%", "note", "holders", "at", "redemption.", "<tag3>"], "wordsA": ["Cash", "flows", "used", "in", "operating", "activities", "for", "the", "year", "ended", "December", "31,", "2012", "totaled", "$129.8", "million,", "which", "includes", "$148.3", "million", "of", "net", "operating", "cash", "uses,", "partially", "offset", "by", "the", "receipt", "of", "$18.5", "million", "from", "collaboration", "agreements."], "wordsB": ["In", "addition,", "on", "October", "5,", "2015,", "we", "paid", "accrued", "interest", "of", "$3.3", "million", "and", "made", "a", "$12.5", "million", "redemption", "payment,", "which", "includes", "$1.2", "million", "additional", "interest", "paid", "to", "the", "12%", "note", "holders", "at", "redemption."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item7_p62_s2", "idA": "906709_15_item7_p3_s2", "sentA": "The EC s approval applies to all 28 European Union member countries plus Iceland and Norway.", "sentB": "Upon adoption, the new guidance must be applied retrospectively to all periods presented.", "type": 1, "words": ["<tag1>", "The", "EC", "s", "approval", "applies", "to", "all", "28", "European", "Union", "member", "countries", "plus", "Iceland", "and", "Norway.", "<tag2>", "Upon", "adoption,", "the", "new", "guidance", "must", "be", "applied", "retrospectively", "to", "all", "periods", "presented.", "<tag3>"], "wordsA": ["The", "EC", "s", "approval", "applies", "to", "all", "28", "European", "Union", "member", "countries", "plus", "Iceland", "and", "Norway."], "wordsB": ["Upon", "adoption,", "the", "new", "guidance", "must", "be", "applied", "retrospectively", "to", "all", "periods", "presented."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item7_p9_s11", "idA": "906709_15_item7_p52_s2", "sentA": "In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain.", "sentB": "In connection with any MAA filing, we would be required to start a confirmatory trial in conjunction with the MAA review.", "type": 1, "words": ["<tag1>", "In", "this", "event,", "we", "may", "be", "required", "to", "record", "adjustments", "to", "research", "and", "development", "expenses", "in", "future", "periods", "when", "the", "actual", "level", "of", "activity", "becomes", "more", "certain.", "<tag2>", "In", "connection", "with", "any", "MAA", "filing,", "we", "would", "be", "required", "to", "start", "a", "confirmatory", "trial", "in", "conjunction", "with", "the", "MAA", "review.", "<tag3>"], "wordsA": ["In", "this", "event,", "we", "may", "be", "required", "to", "record", "adjustments", "to", "research", "and", "development", "expenses", "in", "future", "periods", "when", "the", "actual", "level", "of", "activity", "becomes", "more", "certain."], "wordsB": ["In", "connection", "with", "any", "MAA", "filing,", "we", "would", "be", "required", "to", "start", "a", "confirmatory", "trial", "in", "conjunction", "with", "the", "MAA", "review."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item7_p9_s12", "idA": "906709_15_item7_p62_s1", "sentA": "However, since a portion of our operations consists of research and development activities outside the United States, we have entered into transactions in other currencies, primarily the Indian Rupee, and we therefore are subject to foreign exchange risk.", "sentB": "In the United States, we met with the FDA and the Oncology Division indicated that we would not be able to use the BEACON data to support an accelerated approval for an NDA.", "type": 1, "words": ["<tag1>", "However,", "since", "a", "portion", "of", "our", "operations", "consists", "of", "research", "and", "development", "activities", "outside", "the", "United", "States,", "we", "have", "entered", "into", "transactions", "in", "other", "currencies,", "primarily", "the", "Indian", "Rupee,", "and", "we", "therefore", "are", "subject", "to", "foreign", "exchange", "risk.", "<tag2>", "In", "the", "United", "States,", "we", "met", "with", "the", "FDA", "and", "the", "Oncology", "Division", "indicated", "that", "we", "would", "not", "be", "able", "to", "use", "the", "BEACON", "data", "to", "support", "an", "accelerated", "approval", "for", "an", "NDA.", "<tag3>"], "wordsA": ["However,", "since", "a", "portion", "of", "our", "operations", "consists", "of", "research", "and", "development", "activities", "outside", "the", "United", "States,", "we", "have", "entered", "into", "transactions", "in", "other", "currencies,", "primarily", "the", "Indian", "Rupee,", "and", "we", "therefore", "are", "subject", "to", "foreign", "exchange", "risk."], "wordsB": ["In", "the", "United", "States,", "we", "met", "with", "the", "FDA", "and", "the", "Oncology", "Division", "indicated", "that", "we", "would", "not", "be", "able", "to", "use", "the", "BEACON", "data", "to", "support", "an", "accelerated", "approval", "for", "an", "NDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item7_p60_s1", "idA": "906709_15_item7_p6_s2", "sentA": "Patients in the BEACON study were randomized on a 1:1 basis to receive either single-agent etirinotecan pegol or a single agent of physician s choice.", "sentB": "Entities have the option of using either a full retrospective or a modified retrospective approach to adopt this new guidance.", "type": 1, "words": ["<tag1>", "Patients", "in", "the", "BEACON", "study", "were", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice.", "<tag2>", "Entities", "have", "the", "option", "of", "using", "either", "a", "full", "retrospective", "or", "a", "modified", "retrospective", "approach", "to", "adopt", "this", "new", "guidance.", "<tag3>"], "wordsA": ["Patients", "in", "the", "BEACON", "study", "were", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice."], "wordsB": ["Entities", "have", "the", "option", "of", "using", "either", "a", "full", "retrospective", "or", "a", "modified", "retrospective", "approach", "to", "adopt", "this", "new", "guidance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item7_p7_s1", "idA": "906709_15_item7_p6_s3", "sentA": "The primary endpoint of the BEACON study is overall survival, and secondary endpoints include progression-free survival and objective tumor response rate.", "sentB": "The study is being conducted initially at two primary investigator sites: the University of Texa s MD Anderson Cancer Center and Yale Cancer Center.", "type": 1, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate.", "<tag2>", "The", "study", "is", "being", "conducted", "initially", "at", "two", "primary", "investigator", "sites:", "the", "University", "of", "Texa", "s", "MD", "Anderson", "Cancer", "Center", "and", "Yale", "Cancer", "Center.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate."], "wordsB": ["The", "study", "is", "being", "conducted", "initially", "at", "two", "primary", "investigator", "sites:", "the", "University", "of", "Texa", "s", "MD", "Anderson", "Cancer", "Center", "and", "Yale", "Cancer", "Center."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item7_p9_s8", "idA": "906709_15_item7_p6_s4", "sentA": "We have now achieved the necessary number of events in the BEACON study to assess the overall survival endpoint and certain other topline data.", "sentB": "In Europe, we have met with the National Authorities in Sweden (MPA) and the United Kingdom (MHRA) to discuss the BEACON data.", "type": 1, "words": ["<tag1>", "We", "have", "now", "achieved", "the", "necessary", "number", "of", "events", "in", "the", "BEACON", "study", "to", "assess", "the", "overall", "survival", "endpoint", "and", "certain", "other", "topline", "data.", "<tag2>", "In", "Europe,", "we", "have", "met", "with", "the", "National", "Authorities", "in", "Sweden", "(MPA)", "and", "the", "United", "Kingdom", "(MHRA)", "to", "discuss", "the", "BEACON", "data.", "<tag3>"], "wordsA": ["We", "have", "now", "achieved", "the", "necessary", "number", "of", "events", "in", "the", "BEACON", "study", "to", "assess", "the", "overall", "survival", "endpoint", "and", "certain", "other", "topline", "data."], "wordsB": ["In", "Europe,", "we", "have", "met", "with", "the", "National", "Authorities", "in", "Sweden", "(MPA)", "and", "the", "United", "Kingdom", "(MHRA)", "to", "discuss", "the", "BEACON", "data."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item7_p9_s6", "idA": "906709_15_item7_p6_s7", "sentA": "As a result, the outcome of the BEACON study will have a significant impact on whether or not we invest significant capital in building and maintaining a sales and market organization for the U.S. that we currently do not have in place.", "sentB": "We also announced that we observed a significant overall survival benefit in two pre-specified subgroups patients with a history of brain metastases and patients with baseline liver metastases at study entry.", "type": 1, "words": ["<tag1>", "As", "a", "result,", "the", "outcome", "of", "the", "BEACON", "study", "will", "have", "a", "significant", "impact", "on", "whether", "or", "not", "we", "invest", "significant", "capital", "in", "building", "and", "maintaining", "a", "sales", "and", "market", "organization", "for", "the", "U.S.", "that", "we", "currently", "do", "not", "have", "in", "place.", "<tag2>", "We", "also", "announced", "that", "we", "observed", "a", "significant", "overall", "survival", "benefit", "in", "two", "pre-specified", "subgroups", "patients", "with", "a", "history", "of", "brain", "metastases", "and", "patients", "with", "baseline", "liver", "metastases", "at", "study", "entry.", "<tag3>"], "wordsA": ["As", "a", "result,", "the", "outcome", "of", "the", "BEACON", "study", "will", "have", "a", "significant", "impact", "on", "whether", "or", "not", "we", "invest", "significant", "capital", "in", "building", "and", "maintaining", "a", "sales", "and", "market", "organization", "for", "the", "U.S.", "that", "we", "currently", "do", "not", "have", "in", "place."], "wordsB": ["We", "also", "announced", "that", "we", "observed", "a", "significant", "overall", "survival", "benefit", "in", "two", "pre-specified", "subgroups", "patients", "with", "a", "history", "of", "brain", "metastases", "and", "patients", "with", "baseline", "liver", "metastases", "at", "study", "entry."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item7_p6_s2", "idA": "906709_15_item7_p8_s5", "sentA": "This lack of a placebo rebound in the maintenance phase of the trial caused the Phase 2 study to miss the primary endpoint.", "sentB": "The IAC s determination is nondiscretionary and was based upon our determination of pre-defined acceptable power to detect a statistically significant difference between NKTR-181 and placebo based on the primary efficacy endpoint.", "type": 1, "words": ["<tag1>", "This", "lack", "of", "a", "placebo", "rebound", "in", "the", "maintenance", "phase", "of", "the", "trial", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint.", "<tag2>", "The", "IAC", "s", "determination", "is", "nondiscretionary", "and", "was", "based", "upon", "our", "determination", "of", "pre-defined", "acceptable", "power", "to", "detect", "a", "statistically", "significant", "difference", "between", "NKTR-181", "and", "placebo", "based", "on", "the", "primary", "efficacy", "endpoint.", "<tag3>"], "wordsA": ["This", "lack", "of", "a", "placebo", "rebound", "in", "the", "maintenance", "phase", "of", "the", "trial", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint."], "wordsB": ["The", "IAC", "s", "determination", "is", "nondiscretionary", "and", "was", "based", "upon", "our", "determination", "of", "pre-defined", "acceptable", "power", "to", "detect", "a", "statistically", "significant", "difference", "between", "NKTR-181", "and", "placebo", "based", "on", "the", "primary", "efficacy", "endpoint."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item7_p39_s1", "idA": "906709_15_item7_p8_s8", "sentA": "We enrolled the first patient in this first Phase 3 study on February 24, 2015.", "sentB": "The Notes bear interest at a rate of 7.75% per annum payable in cash quarterly in arrears on January 15, April 15, July 15, and October 15 of each year, beginning on October 15, 2015.", "type": 1, "words": ["<tag1>", "We", "enrolled", "the", "first", "patient", "in", "this", "first", "Phase", "3", "study", "on", "February", "24,", "2015.", "<tag2>", "The", "Notes", "bear", "interest", "at", "a", "rate", "of", "7.75%", "per", "annum", "payable", "in", "cash", "quarterly", "in", "arrears", "on", "January", "15,", "April", "15,", "July", "15,", "and", "October", "15", "of", "each", "year,", "beginning", "on", "October", "15,", "2015.", "<tag3>"], "wordsA": ["We", "enrolled", "the", "first", "patient", "in", "this", "first", "Phase", "3", "study", "on", "February", "24,", "2015."], "wordsB": ["The", "Notes", "bear", "interest", "at", "a", "rate", "of", "7.75%", "per", "annum", "payable", "in", "cash", "quarterly", "in", "arrears", "on", "January", "15,", "April", "15,", "July", "15,", "and", "October", "15", "of", "each", "year,", "beginning", "on", "October", "15,", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item7_p0_s5", "idA": "906709_16_item7_p25_s4", "sentA": "In addition to our NKTR-181 development activities, in 2016, we plan to continue to advance the development of NKTR-214, which entered Phase 1/2 clinical development in December 2015.", "sentB": "In 2017, our plan is to execute a broad clinical development program for NKTR-214 in combination with other immuno-oncology agents including Opdivo (nivolumab) as part of our broad Phase 1/2 clinical collaboration with BMS in five tumor types and eight potential indications, a dose-escalation study with atezolizumab, and numerous preclinical collaboration programs.", "type": 1, "words": ["<tag1>", "In", "addition", "to", "our", "NKTR-181", "development", "activities,", "in", "2016,", "we", "plan", "to", "continue", "to", "advance", "the", "development", "of", "NKTR-214,", "which", "entered", "Phase", "1/2", "clinical", "development", "in", "December", "2015.", "<tag2>", "In", "2017,", "our", "plan", "is", "to", "execute", "a", "broad", "clinical", "development", "program", "for", "NKTR-214", "in", "combination", "with", "other", "immuno-oncology", "agents", "including", "Opdivo", "(nivolumab)", "as", "part", "of", "our", "broad", "Phase", "1/2", "clinical", "collaboration", "with", "BMS", "in", "five", "tumor", "types", "and", "eight", "potential", "indications,", "a", "dose-escalation", "study", "with", "atezolizumab,", "and", "numerous", "preclinical", "collaboration", "programs.", "<tag3>"], "wordsA": ["In", "addition", "to", "our", "NKTR-181", "development", "activities,", "in", "2016,", "we", "plan", "to", "continue", "to", "advance", "the", "development", "of", "NKTR-214,", "which", "entered", "Phase", "1/2", "clinical", "development", "in", "December", "2015."], "wordsB": ["In", "2017,", "our", "plan", "is", "to", "execute", "a", "broad", "clinical", "development", "program", "for", "NKTR-214", "in", "combination", "with", "other", "immuno-oncology", "agents", "including", "Opdivo", "(nivolumab)", "as", "part", "of", "our", "broad", "Phase", "1/2", "clinical", "collaboration", "with", "BMS", "in", "five", "tumor", "types", "and", "eight", "potential", "indications,", "a", "dose-escalation", "study", "with", "atezolizumab,", "and", "numerous", "preclinical", "collaboration", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item7_p6_s1", "idA": "906709_16_item7_p36_s5", "sentA": "As a result, we received $100.3 million in net proceeds in connection with these transactions.", "sentB": "As a result, other than approximately $10.4 million of product sales to Ophthotech related to their binding purchase commitments, we currently do not expect any further sales to Ophthotech in 2017.", "type": 1, "words": ["<tag1>", "As", "a", "result,", "we", "received", "$100.3", "million", "in", "net", "proceeds", "in", "connection", "with", "these", "transactions.", "<tag2>", "As", "a", "result,", "other", "than", "approximately", "$10.4", "million", "of", "product", "sales", "to", "Ophthotech", "related", "to", "their", "binding", "purchase", "commitments,", "we", "currently", "do", "not", "expect", "any", "further", "sales", "to", "Ophthotech", "in", "2017.", "<tag3>"], "wordsA": ["As", "a", "result,", "we", "received", "$100.3", "million", "in", "net", "proceeds", "in", "connection", "with", "these", "transactions."], "wordsB": ["As", "a", "result,", "other", "than", "approximately", "$10.4", "million", "of", "product", "sales", "to", "Ophthotech", "related", "to", "their", "binding", "purchase", "commitments,", "we", "currently", "do", "not", "expect", "any", "further", "sales", "to", "Ophthotech", "in", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item7_p54_s1", "idA": "906709_16_item7_p52_s4", "sentA": "We generally accrue costs associated with the treatment phase of clinical studies based on the total estimated cost of the treatment phase on a per patient basis and we expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the studies.", "sentB": "The new revenue standard, however, may require us to recognize these payments before the payment-triggering event is completely achieved, subject to management s assessment of whether it is probable that the triggering event will be achieved and that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.", "type": 1, "words": ["<tag1>", "We", "generally", "accrue", "costs", "associated", "with", "the", "treatment", "phase", "of", "clinical", "studies", "based", "on", "the", "total", "estimated", "cost", "of", "the", "treatment", "phase", "on", "a", "per", "patient", "basis", "and", "we", "expense", "the", "per", "patient", "cost", "ratably", "over", "the", "estimated", "patient", "treatment", "period", "based", "on", "patient", "enrollment", "in", "the", "studies.", "<tag2>", "The", "new", "revenue", "standard,", "however,", "may", "require", "us", "to", "recognize", "these", "payments", "before", "the", "payment-triggering", "event", "is", "completely", "achieved,", "subject", "to", "management", "s", "assessment", "of", "whether", "it", "is", "probable", "that", "the", "triggering", "event", "will", "be", "achieved", "and", "that", "a", "significant", "reversal", "in", "the", "amount", "of", "cumulative", "revenue", "recognized", "will", "not", "occur", "when", "the", "uncertainty", "associated", "with", "the", "variable", "consideration", "is", "subsequently", "resolved.", "<tag3>"], "wordsA": ["We", "generally", "accrue", "costs", "associated", "with", "the", "treatment", "phase", "of", "clinical", "studies", "based", "on", "the", "total", "estimated", "cost", "of", "the", "treatment", "phase", "on", "a", "per", "patient", "basis", "and", "we", "expense", "the", "per", "patient", "cost", "ratably", "over", "the", "estimated", "patient", "treatment", "period", "based", "on", "patient", "enrollment", "in", "the", "studies."], "wordsB": ["The", "new", "revenue", "standard,", "however,", "may", "require", "us", "to", "recognize", "these", "payments", "before", "the", "payment-triggering", "event", "is", "completely", "achieved,", "subject", "to", "management", "s", "assessment", "of", "whether", "it", "is", "probable", "that", "the", "triggering", "event", "will", "be", "achieved", "and", "that", "a", "significant", "reversal", "in", "the", "amount", "of", "cumulative", "revenue", "recognized", "will", "not", "occur", "when", "the", "uncertainty", "associated", "with", "the", "variable", "consideration", "is", "subsequently", "resolved."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item7_p0_s0", "idA": "906709_16_item7_p5_s0", "sentA": "NKTR-181 is a novel mu-opioid analgesic drug candidate for chronic pain conditions and is currently in Phase 3 clinical development.", "sentB": "Overview Strategic Direction of Our Business Nektar Therapeutics is a research-based biopharmaceutical company that discovers and develops innovative new medicines in areas of high unmet medical need.", "type": 1, "words": ["<tag1>", "NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions", "and", "is", "currently", "in", "Phase", "3", "clinical", "development.", "<tag2>", "Overview", "Strategic", "Direction", "of", "Our", "Business", "Nektar", "Therapeutics", "is", "a", "research-based", "biopharmaceutical", "company", "that", "discovers", "and", "develops", "innovative", "new", "medicines", "in", "areas", "of", "high", "unmet", "medical", "need.", "<tag3>"], "wordsA": ["NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions", "and", "is", "currently", "in", "Phase", "3", "clinical", "development."], "wordsB": ["Overview", "Strategic", "Direction", "of", "Our", "Business", "Nektar", "Therapeutics", "is", "a", "research-based", "biopharmaceutical", "company", "that", "discovers", "and", "develops", "innovative", "new", "medicines", "in", "areas", "of", "high", "unmet", "medical", "need."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item7_p0_s21", "idA": "906709_16_item7_p9_s16", "sentA": "We also have two significant drug development programs with Bayer.", "sentB": "We also have milestone and royalty interests in other collaboration partner programs including PEGPH20 with Halozyme that is in Phase 3 development and dapirolizumab pegol with UCB Pharma that is in Phase 2 development for systemic lupus erythematosus (SLE).", "type": 1, "words": ["<tag1>", "We", "also", "have", "two", "significant", "drug", "development", "programs", "with", "Bayer.", "<tag2>", "We", "also", "have", "milestone", "and", "royalty", "interests", "in", "other", "collaboration", "partner", "programs", "including", "PEGPH20", "with", "Halozyme", "that", "is", "in", "Phase", "3", "development", "and", "dapirolizumab", "pegol", "with", "UCB", "Pharma", "that", "is", "in", "Phase", "2", "development", "for", "systemic", "lupus", "erythematosus", "(SLE).", "<tag3>"], "wordsA": ["We", "also", "have", "two", "significant", "drug", "development", "programs", "with", "Bayer."], "wordsB": ["We", "also", "have", "milestone", "and", "royalty", "interests", "in", "other", "collaboration", "partner", "programs", "including", "PEGPH20", "with", "Halozyme", "that", "is", "in", "Phase", "3", "development", "and", "dapirolizumab", "pegol", "with", "UCB", "Pharma", "that", "is", "in", "Phase", "2", "development", "for", "systemic", "lupus", "erythematosus", "(SLE)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item7_p0_s6", "idA": "906709_16_item7_p9_s26", "sentA": "We are also advancing several other drug candidates in preclinical development in the areas of cancer immunotherapy, pain and other therapeutic indications.", "sentB": "In February 2017, we filed an IND for NKTR-358, our auto-immune disease drug candidate, and plan to start the Phase 1 study for this program in healthy volunteers and then advance the program into Phase 1b in patients with systemic lupus erythematous (SLE), and other potential immune disease indications.", "type": 1, "words": ["<tag1>", "We", "are", "also", "advancing", "several", "other", "drug", "candidates", "in", "preclinical", "development", "in", "the", "areas", "of", "cancer", "immunotherapy,", "pain", "and", "other", "therapeutic", "indications.", "<tag2>", "In", "February", "2017,", "we", "filed", "an", "IND", "for", "NKTR-358,", "our", "auto-immune", "disease", "drug", "candidate,", "and", "plan", "to", "start", "the", "Phase", "1", "study", "for", "this", "program", "in", "healthy", "volunteers", "and", "then", "advance", "the", "program", "into", "Phase", "1b", "in", "patients", "with", "systemic", "lupus", "erythematous", "(SLE),", "and", "other", "potential", "immune", "disease", "indications.", "<tag3>"], "wordsA": ["We", "are", "also", "advancing", "several", "other", "drug", "candidates", "in", "preclinical", "development", "in", "the", "areas", "of", "cancer", "immunotherapy,", "pain", "and", "other", "therapeutic", "indications."], "wordsB": ["In", "February", "2017,", "we", "filed", "an", "IND", "for", "NKTR-358,", "our", "auto-immune", "disease", "drug", "candidate,", "and", "plan", "to", "start", "the", "Phase", "1", "study", "for", "this", "program", "in", "healthy", "volunteers", "and", "then", "advance", "the", "program", "into", "Phase", "1b", "in", "patients", "with", "systemic", "lupus", "erythematous", "(SLE),", "and", "other", "potential", "immune", "disease", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item7_p6_s2", "idA": "906709_17_item7_p0_s3", "sentA": "These drug candidates utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.", "sentB": "This study is designed to establish a range of dose levels and evaluate pharmacokinetics and safety.", "type": 1, "words": ["<tag1>", "These", "drug", "candidates", "utilize", "our", "advanced", "polymer", "conjugate", "technology", "platforms,", "which", "are", "designed", "to", "enable", "the", "development", "of", "new", "molecular", "entities", "that", "target", "known", "mechanisms", "of", "action.", "<tag2>", "This", "study", "is", "designed", "to", "establish", "a", "range", "of", "dose", "levels", "and", "evaluate", "pharmacokinetics", "and", "safety.", "<tag3>"], "wordsA": ["These", "drug", "candidates", "utilize", "our", "advanced", "polymer", "conjugate", "technology", "platforms,", "which", "are", "designed", "to", "enable", "the", "development", "of", "new", "molecular", "entities", "that", "target", "known", "mechanisms", "of", "action."], "wordsB": ["This", "study", "is", "designed", "to", "establish", "a", "range", "of", "dose", "levels", "and", "evaluate", "pharmacokinetics", "and", "safety."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item7_p1_s0", "idA": "906709_17_item7_p0_s5", "sentA": "In 2017, our plan is to execute a broad clinical development program for NKTR-214 in combination with other immuno-oncology agents including Opdivo (nivolumab) as part of our broad Phase 1/2 clinical collaboration with BMS in five tumor types and eight potential indications, a dose-escalation study with atezolizumab, and numerous preclinical collaboration programs.", "sentB": "On February 13, 2018, we entered into a Strategic Collaboration Agreement (BMS Collaboration Agreement) with Bristol-Myers Squibb Company (BMS), pursuant to which we and BMS will jointly develop NKTR-214, our lead immuno-oncology drug candidate, in combination with BMS s Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab), in more than 20 indications across nine tumor types, as well as potential combinations with other anti-cancer agents from BMS, us and third parties.", "type": 1, "words": ["<tag1>", "In", "2017,", "our", "plan", "is", "to", "execute", "a", "broad", "clinical", "development", "program", "for", "NKTR-214", "in", "combination", "with", "other", "immuno-oncology", "agents", "including", "Opdivo", "(nivolumab)", "as", "part", "of", "our", "broad", "Phase", "1/2", "clinical", "collaboration", "with", "BMS", "in", "five", "tumor", "types", "and", "eight", "potential", "indications,", "a", "dose-escalation", "study", "with", "atezolizumab,", "and", "numerous", "preclinical", "collaboration", "programs.", "<tag2>", "On", "February", "13,", "2018,", "we", "entered", "into", "a", "Strategic", "Collaboration", "Agreement", "(BMS", "Collaboration", "Agreement)", "with", "Bristol-Myers", "Squibb", "Company", "(BMS),", "pursuant", "to", "which", "we", "and", "BMS", "will", "jointly", "develop", "NKTR-214,", "our", "lead", "immuno-oncology", "drug", "candidate,", "in", "combination", "with", "BMS", "s", "Opdivo", "(nivolumab)", "and", "Opdivo", "plus", "Yervoy", "(ipilimumab),", "in", "more", "than", "20", "indications", "across", "nine", "tumor", "types,", "as", "well", "as", "potential", "combinations", "with", "other", "anti-cancer", "agents", "from", "BMS,", "us", "and", "third", "parties.", "<tag3>"], "wordsA": ["In", "2017,", "our", "plan", "is", "to", "execute", "a", "broad", "clinical", "development", "program", "for", "NKTR-214", "in", "combination", "with", "other", "immuno-oncology", "agents", "including", "Opdivo", "(nivolumab)", "as", "part", "of", "our", "broad", "Phase", "1/2", "clinical", "collaboration", "with", "BMS", "in", "five", "tumor", "types", "and", "eight", "potential", "indications,", "a", "dose-escalation", "study", "with", "atezolizumab,", "and", "numerous", "preclinical", "collaboration", "programs."], "wordsB": ["On", "February", "13,", "2018,", "we", "entered", "into", "a", "Strategic", "Collaboration", "Agreement", "(BMS", "Collaboration", "Agreement)", "with", "Bristol-Myers", "Squibb", "Company", "(BMS),", "pursuant", "to", "which", "we", "and", "BMS", "will", "jointly", "develop", "NKTR-214,", "our", "lead", "immuno-oncology", "drug", "candidate,", "in", "combination", "with", "BMS", "s", "Opdivo", "(nivolumab)", "and", "Opdivo", "plus", "Yervoy", "(ipilimumab),", "in", "more", "than", "20", "indications", "across", "nine", "tumor", "types,", "as", "well", "as", "potential", "combinations", "with", "other", "anti-cancer", "agents", "from", "BMS,", "us", "and", "third", "parties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item7_p7_s2", "idA": "906709_17_item7_p15_s2", "sentA": "Research and development expense increased during the year ended December 31, 2016 compared to the year ended December 31, 2015 primarily due to costs incurred in our NKTR-214 clinical and NKTR-358 pre-clinical programs as well as increased headcount costs, partially offset by a decrease to our ONZEALD TM program costs.", "sentB": "The HAP study was designed to assess the relative oral abuse potential of NKTR-181 at its highest tested therapeutic dose as well as at the highest dose to which patients have been exposed in our long-term safety study and at a supratherapeutic dose compared to common therapeutic doses of oxycodone, a Schedule II opioid.", "type": 1, "words": ["<tag1>", "Research", "and", "development", "expense", "increased", "during", "the", "year", "ended", "December", "31,", "2016", "compared", "to", "the", "year", "ended", "December", "31,", "2015", "primarily", "due", "to", "costs", "incurred", "in", "our", "NKTR-214", "clinical", "and", "NKTR-358", "pre-clinical", "programs", "as", "well", "as", "increased", "headcount", "costs,", "partially", "offset", "by", "a", "decrease", "to", "our", "ONZEALD", "TM", "program", "costs.", "<tag2>", "The", "HAP", "study", "was", "designed", "to", "assess", "the", "relative", "oral", "abuse", "potential", "of", "NKTR-181", "at", "its", "highest", "tested", "therapeutic", "dose", "as", "well", "as", "at", "the", "highest", "dose", "to", "which", "patients", "have", "been", "exposed", "in", "our", "long-term", "safety", "study", "and", "at", "a", "supratherapeutic", "dose", "compared", "to", "common", "therapeutic", "doses", "of", "oxycodone,", "a", "Schedule", "II", "opioid.", "<tag3>"], "wordsA": ["Research", "and", "development", "expense", "increased", "during", "the", "year", "ended", "December", "31,", "2016", "compared", "to", "the", "year", "ended", "December", "31,", "2015", "primarily", "due", "to", "costs", "incurred", "in", "our", "NKTR-214", "clinical", "and", "NKTR-358", "pre-clinical", "programs", "as", "well", "as", "increased", "headcount", "costs,", "partially", "offset", "by", "a", "decrease", "to", "our", "ONZEALD", "TM", "program", "costs."], "wordsB": ["The", "HAP", "study", "was", "designed", "to", "assess", "the", "relative", "oral", "abuse", "potential", "of", "NKTR-181", "at", "its", "highest", "tested", "therapeutic", "dose", "as", "well", "as", "at", "the", "highest", "dose", "to", "which", "patients", "have", "been", "exposed", "in", "our", "long-term", "safety", "study", "and", "at", "a", "supratherapeutic", "dose", "compared", "to", "common", "therapeutic", "doses", "of", "oxycodone,", "a", "Schedule", "II", "opioid."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item7_p4_s0", "idA": "906709_17_item7_p24_s3", "sentA": "In 2017, we expect general and administrative expenses to increase compared to 2016.", "sentB": "On May 22, 2017, we announced a research collaboration that will allow Nektar and Takeda Pharmaceutical Company Limited (Takeda) to evaluate NKTR-214 with five compounds from Takeda s cancer portfolio.", "type": 1, "words": ["<tag1>", "In", "2017,", "we", "expect", "general", "and", "administrative", "expenses", "to", "increase", "compared", "to", "2016.", "<tag2>", "On", "May", "22,", "2017,", "we", "announced", "a", "research", "collaboration", "that", "will", "allow", "Nektar", "and", "Takeda", "Pharmaceutical", "Company", "Limited", "(Takeda)", "to", "evaluate", "NKTR-214", "with", "five", "compounds", "from", "Takeda", "s", "cancer", "portfolio.", "<tag3>"], "wordsA": ["In", "2017,", "we", "expect", "general", "and", "administrative", "expenses", "to", "increase", "compared", "to", "2016."], "wordsB": ["On", "May", "22,", "2017,", "we", "announced", "a", "research", "collaboration", "that", "will", "allow", "Nektar", "and", "Takeda", "Pharmaceutical", "Company", "Limited", "(Takeda)", "to", "evaluate", "NKTR-214", "with", "five", "compounds", "from", "Takeda", "s", "cancer", "portfolio."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item7_p3_s1", "idA": "906709_17_item7_p41_s2", "sentA": "For these, the shortest reasonable period is the end of the development period (estimated to be 4 to 8 years) and the longest period is the contractual life of the agreement, which is generally 10-12 years from the first commercial sale.", "sentB": "On November 11, 2017 we announced interim data from the dose-escalation phase of the PIVOT-02 Phase 1/2 study.", "type": 1, "words": ["<tag1>", "For", "these,", "the", "shortest", "reasonable", "period", "is", "the", "end", "of", "the", "development", "period", "(estimated", "to", "be", "4", "to", "8", "years)", "and", "the", "longest", "period", "is", "the", "contractual", "life", "of", "the", "agreement,", "which", "is", "generally", "10-12", "years", "from", "the", "first", "commercial", "sale.", "<tag2>", "On", "November", "11,", "2017", "we", "announced", "interim", "data", "from", "the", "dose-escalation", "phase", "of", "the", "PIVOT-02", "Phase", "1/2", "study.", "<tag3>"], "wordsA": ["For", "these,", "the", "shortest", "reasonable", "period", "is", "the", "end", "of", "the", "development", "period", "(estimated", "to", "be", "4", "to", "8", "years)", "and", "the", "longest", "period", "is", "the", "contractual", "life", "of", "the", "agreement,", "which", "is", "generally", "10-12", "years", "from", "the", "first", "commercial", "sale."], "wordsB": ["On", "November", "11,", "2017", "we", "announced", "interim", "data", "from", "the", "dose-escalation", "phase", "of", "the", "PIVOT-02", "Phase", "1/2", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item7_p17_s4", "idA": "906709_17_item7_p46_s1", "sentA": "However, additional information may become available to us which may allow us to make a more accurate estimate in future periods.", "sentB": "In no case can amounts be recovered by the reduction of a contingent payment due from AstraZeneca to us or through a payment from us to AstraZeneca.", "type": 1, "words": ["<tag1>", "However,", "additional", "information", "may", "become", "available", "to", "us", "which", "may", "allow", "us", "to", "make", "a", "more", "accurate", "estimate", "in", "future", "periods.", "<tag2>", "In", "no", "case", "can", "amounts", "be", "recovered", "by", "the", "reduction", "of", "a", "contingent", "payment", "due", "from", "AstraZeneca", "to", "us", "or", "through", "a", "payment", "from", "us", "to", "AstraZeneca.", "<tag3>"], "wordsA": ["However,", "additional", "information", "may", "become", "available", "to", "us", "which", "may", "allow", "us", "to", "make", "a", "more", "accurate", "estimate", "in", "future", "periods."], "wordsB": ["In", "no", "case", "can", "amounts", "be", "recovered", "by", "the", "reduction", "of", "a", "contingent", "payment", "due", "from", "AstraZeneca", "to", "us", "or", "through", "a", "payment", "from", "us", "to", "AstraZeneca."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item7_p62_s3", "idA": "906709_17_item7_p4_s4", "sentA": "Given the uncertainties in research and development collaborations, significant judgment is required by us to determine the performance periods.", "sentB": "To achieve this core principle, the guidance provides the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.", "type": 1, "words": ["<tag1>", "Given", "the", "uncertainties", "in", "research", "and", "development", "collaborations,", "significant", "judgment", "is", "required", "by", "us", "to", "determine", "the", "performance", "periods.", "<tag2>", "To", "achieve", "this", "core", "principle,", "the", "guidance", "provides", "the", "following", "steps:", "(1)", "identify", "the", "contract(s)", "with", "a", "customer;", "(2)", "identify", "the", "performance", "obligations", "in", "the", "contract;", "(3)", "determine", "the", "transaction", "price;", "(4)", "allocate", "the", "transaction", "price", "to", "the", "performance", "obligations", "in", "the", "contract;", "and", "(5)", "recognize", "revenue", "when", "(or", "as)", "the", "entity", "satisfies", "a", "performance", "obligation.", "<tag3>"], "wordsA": ["Given", "the", "uncertainties", "in", "research", "and", "development", "collaborations,", "significant", "judgment", "is", "required", "by", "us", "to", "determine", "the", "performance", "periods."], "wordsB": ["To", "achieve", "this", "core", "principle,", "the", "guidance", "provides", "the", "following", "steps:", "(1)", "identify", "the", "contract(s)", "with", "a", "customer;", "(2)", "identify", "the", "performance", "obligations", "in", "the", "contract;", "(3)", "determine", "the", "transaction", "price;", "(4)", "allocate", "the", "transaction", "price", "to", "the", "performance", "obligations", "in", "the", "contract;", "and", "(5)", "recognize", "revenue", "when", "(or", "as)", "the", "entity", "satisfies", "a", "performance", "obligation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item7_p62_s9", "idA": "906709_17_item7_p56_s0", "sentA": "In February 2016, the FASB issued guidance to amend a number of aspects of lease accounting, including requiring lessees to recognize almost all leases with a term greater than one year as a right-of-use asset and corresponding liability, measured at the present value of the lease payments.", "sentB": "For certain other arrangements, under current ASC 605 guidance, we identified the value of the license as a separate unit of accounting and recognize revenue upon issuance of the license.", "type": 1, "words": ["<tag1>", "In", "February", "2016,", "the", "FASB", "issued", "guidance", "to", "amend", "a", "number", "of", "aspects", "of", "lease", "accounting,", "including", "requiring", "lessees", "to", "recognize", "almost", "all", "leases", "with", "a", "term", "greater", "than", "one", "year", "as", "a", "right-of-use", "asset", "and", "corresponding", "liability,", "measured", "at", "the", "present", "value", "of", "the", "lease", "payments.", "<tag2>", "For", "certain", "other", "arrangements,", "under", "current", "ASC", "605", "guidance,", "we", "identified", "the", "value", "of", "the", "license", "as", "a", "separate", "unit", "of", "accounting", "and", "recognize", "revenue", "upon", "issuance", "of", "the", "license.", "<tag3>"], "wordsA": ["In", "February", "2016,", "the", "FASB", "issued", "guidance", "to", "amend", "a", "number", "of", "aspects", "of", "lease", "accounting,", "including", "requiring", "lessees", "to", "recognize", "almost", "all", "leases", "with", "a", "term", "greater", "than", "one", "year", "as", "a", "right-of-use", "asset", "and", "corresponding", "liability,", "measured", "at", "the", "present", "value", "of", "the", "lease", "payments."], "wordsB": ["For", "certain", "other", "arrangements,", "under", "current", "ASC", "605", "guidance,", "we", "identified", "the", "value", "of", "the", "license", "as", "a", "separate", "unit", "of", "accounting", "and", "recognize", "revenue", "upon", "issuance", "of", "the", "license."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item7_p62_s4", "idA": "906709_17_item7_p56_s2", "sentA": "We are currently evaluating the impact of the adoption of this standard.", "sentB": "Under ASC 606, companies may need to use more judgment and make more estimates than under ASC 605 in the application of this five-step process.", "type": 1, "words": ["<tag1>", "We", "are", "currently", "evaluating", "the", "impact", "of", "the", "adoption", "of", "this", "standard.", "<tag2>", "Under", "ASC", "606,", "companies", "may", "need", "to", "use", "more", "judgment", "and", "make", "more", "estimates", "than", "under", "ASC", "605", "in", "the", "application", "of", "this", "five-step", "process.", "<tag3>"], "wordsA": ["We", "are", "currently", "evaluating", "the", "impact", "of", "the", "adoption", "of", "this", "standard."], "wordsB": ["Under", "ASC", "606,", "companies", "may", "need", "to", "use", "more", "judgment", "and", "make", "more", "estimates", "than", "under", "ASC", "605", "in", "the", "application", "of", "this", "five-step", "process."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item7_p62_s10", "idA": "906709_17_item7_p7_s5", "sentA": "As a result of this liability accounting, even though the royalties from UCB and Roche are remitted directly to the purchaser of these royalty interests, we will continue to record revenue for these royalties.", "sentB": "Under ASC 606, we may continue to recognize revenue for such licenses upon delivery of the license.", "type": 1, "words": ["<tag1>", "As", "a", "result", "of", "this", "liability", "accounting,", "even", "though", "the", "royalties", "from", "UCB", "and", "Roche", "are", "remitted", "directly", "to", "the", "purchaser", "of", "these", "royalty", "interests,", "we", "will", "continue", "to", "record", "revenue", "for", "these", "royalties.", "<tag2>", "Under", "ASC", "606,", "we", "may", "continue", "to", "recognize", "revenue", "for", "such", "licenses", "upon", "delivery", "of", "the", "license.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "this", "liability", "accounting,", "even", "though", "the", "royalties", "from", "UCB", "and", "Roche", "are", "remitted", "directly", "to", "the", "purchaser", "of", "these", "royalty", "interests,", "we", "will", "continue", "to", "record", "revenue", "for", "these", "royalties."], "wordsB": ["Under", "ASC", "606,", "we", "may", "continue", "to", "recognize", "revenue", "for", "such", "licenses", "upon", "delivery", "of", "the", "license."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item7_p23_s1", "idA": "906709_17_item7_p9_s1", "sentA": "See Part I, Item 1A Risk Factors for discussion of the risks associated with the complex nature of our collaboration agreements.", "sentB": "We have elected to only enter into and maintain those manufacturing relationships associated with long-term collaboration agreements which include multiple sources of revenue, which we view holistically and in aggregate.", "type": 1, "words": ["<tag1>", "See", "Part", "I,", "Item", "1A", "Risk", "Factors", "for", "discussion", "of", "the", "risks", "associated", "with", "the", "complex", "nature", "of", "our", "collaboration", "agreements.", "<tag2>", "We", "have", "elected", "to", "only", "enter", "into", "and", "maintain", "those", "manufacturing", "relationships", "associated", "with", "long-term", "collaboration", "agreements", "which", "include", "multiple", "sources", "of", "revenue,", "which", "we", "view", "holistically", "and", "in", "aggregate.", "<tag3>"], "wordsA": ["See", "Part", "I,", "Item", "1A", "Risk", "Factors", "for", "discussion", "of", "the", "risks", "associated", "with", "the", "complex", "nature", "of", "our", "collaboration", "agreements."], "wordsB": ["We", "have", "elected", "to", "only", "enter", "into", "and", "maintain", "those", "manufacturing", "relationships", "associated", "with", "long-term", "collaboration", "agreements", "which", "include", "multiple", "sources", "of", "revenue,", "which", "we", "view", "holistically", "and", "in", "aggregate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item7_p62_s6", "idA": "906709_17_item7_p9_s1", "sentA": "See Part I, Item 1A Risk Factors for discussion of the risks associated with the complex nature of our collaboration agreements.", "sentB": "Since each collaboration agreement is unique, we will separately assess each agreement (see Note 10 for a discussion of our existing collaboration agreements) under the new standard.", "type": 1, "words": ["<tag1>", "See", "Part", "I,", "Item", "1A", "Risk", "Factors", "for", "discussion", "of", "the", "risks", "associated", "with", "the", "complex", "nature", "of", "our", "collaboration", "agreements.", "<tag2>", "Since", "each", "collaboration", "agreement", "is", "unique,", "we", "will", "separately", "assess", "each", "agreement", "(see", "Note", "10", "for", "a", "discussion", "of", "our", "existing", "collaboration", "agreements)", "under", "the", "new", "standard.", "<tag3>"], "wordsA": ["See", "Part", "I,", "Item", "1A", "Risk", "Factors", "for", "discussion", "of", "the", "risks", "associated", "with", "the", "complex", "nature", "of", "our", "collaboration", "agreements."], "wordsB": ["Since", "each", "collaboration", "agreement", "is", "unique,", "we", "will", "separately", "assess", "each", "agreement", "(see", "Note", "10", "for", "a", "discussion", "of", "our", "existing", "collaboration", "agreements)", "under", "the", "new", "standard."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item7_p62_s8", "idA": "906709_17_item7_p9_s1", "sentA": "See Part I, Item 1A Risk Factors for discussion of the risks associated with the complex nature of our collaboration agreements.", "sentB": "For certain of our arrangements, the value associated with the licenses and certain other deliverables have been assessed as one unit of accounting and recognized over a period of time in which services are rendered or made available to our customer pursuant to revenue recognition guidance in effect for such arrangements at the time such arrangements commenced.", "type": 1, "words": ["<tag1>", "See", "Part", "I,", "Item", "1A", "Risk", "Factors", "for", "discussion", "of", "the", "risks", "associated", "with", "the", "complex", "nature", "of", "our", "collaboration", "agreements.", "<tag2>", "For", "certain", "of", "our", "arrangements,", "the", "value", "associated", "with", "the", "licenses", "and", "certain", "other", "deliverables", "have", "been", "assessed", "as", "one", "unit", "of", "accounting", "and", "recognized", "over", "a", "period", "of", "time", "in", "which", "services", "are", "rendered", "or", "made", "available", "to", "our", "customer", "pursuant", "to", "revenue", "recognition", "guidance", "in", "effect", "for", "such", "arrangements", "at", "the", "time", "such", "arrangements", "commenced.", "<tag3>"], "wordsA": ["See", "Part", "I,", "Item", "1A", "Risk", "Factors", "for", "discussion", "of", "the", "risks", "associated", "with", "the", "complex", "nature", "of", "our", "collaboration", "agreements."], "wordsB": ["For", "certain", "of", "our", "arrangements,", "the", "value", "associated", "with", "the", "licenses", "and", "certain", "other", "deliverables", "have", "been", "assessed", "as", "one", "unit", "of", "accounting", "and", "recognized", "over", "a", "period", "of", "time", "in", "which", "services", "are", "rendered", "or", "made", "available", "to", "our", "customer", "pursuant", "to", "revenue", "recognition", "guidance", "in", "effect", "for", "such", "arrangements", "at", "the", "time", "such", "arrangements", "commenced."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
